Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1-[2-[4-(trifluoromethyl)phenyl]ethyl]-1H-1,2,3-triazol-4-yl)methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
compound forms pi-pi interactions with residues Phe177, His367 and coordinates iron
-
(1E)-1-(2,5-dihydroxyphenyl)-5-phenylpent-1-en-3-one
inhibits leukotriene biosynthesis in isolated human neutrophils and in whole blood
-
(1E)-1-(3,4-dihydroxyphenyl)-6-phenylhex-1-en-3-one
inhibits leukotriene biosynthesis in isolated human neutrophils and in whole blood
-
(1E)-1-(4-hydroxy-3,5-dimethoxyphenyl)-5-phenylpent-1-en-3-one
inhibits leukotriene biosynthesis in isolated human neutrophils and in whole blood, retains 50% of inhibitory activity after up to one hour of incubation
-
(2,4-dihydroxyphenyl)[3-(1-[hydroxy[(3,4,5-trihydroxyphenyl)methyl]amino]ethyl)phenyl]methanone
-
(2,4-dihydroxyphenyl)[3-(1-[hydroxy[(4-hydroxyphenyl)methyl]amino]ethyl)phenyl]methanone
-
(2E)-3-[4-[(1E)-3-[[(2E)-3-(2,3-dihydroxyphenyl)prop-2-enoyl]oxy]prop-1-en-1-yl]phenyl]prop-2-en-1-yl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
caffeic acid phenylethyl ester analogue, IC50 value for inhibition of 5-Lox product synthesis in transfected HEK-293 cells is 0.00061 mM. Compound is a good radical scavenger
-
(2E,6E,10E)-13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)-N-(4-methoxybenzyl)-2,6,10-trimethyltrideca-2,6,10-trienamide
significant inhibitory activity in both cell-free and cell-based assays, inhibits leukotriene biosynthesis by human primary polymorphonuclear leukocytes, IC50 value 250 nM
-
(2E,6E,10E)-13-((R)-6-hydroxy-2,8-dimethylchroman-2-yl)-N-(4-methoxybenzyl)-2,6,10-trimethyltrideca-2,6,10-trienamide
significant inhibitory activity in both cell-free and cell-based assays, inhibits leukotriene biosynthesis by human primary polymorphonuclear leukocytes, IC50 value 184 nM
-
(2E,6E,10E)-13-(6-hydroxy-2,8-dimethylchroman-2-yl)-2,6,10-trimethyl-N-(pyridin-3-ylmethyl)trideca-2,6,10-trienamide
inhibits leukotriene biosynthesis by human primary polymorphonuclear leukocytes, IC50 value 415 nM
-
(2E,6E,10E)-N-benzyl-13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)-2,6,10-trimethyltrideca-2,6,10-trienamide
significant inhibitory activity in both cell-free and cell-based assays, inhibits leukotriene biosynthesis by human primary polymorphonuclear leukocytes, IC50 value 173 nM
-
(2E,6E,10E)-N-benzyl-13-((R)-6-hydroxy-2,8-dimethylchroman-2-yl)-2,6,10-trimethyltrideca-2,6,10-trienamide
inhibits leukotriene biosynthesis by human primary polymorphonuclear leukocytes, IC50 value 303 nM
-
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate
product inhibition
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl) methyl)-N-hydroxyheptanamide
-
-
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl) methyl)-N-hydroxyoctanamide
-
-
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)-N-hydroxypentanamide
-
-
(R)-N-(2-(diphenylamino)ethyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
(R)-N-(3,3-bis(4-fluorophenyl)propyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
1-(3-[5-(hydroxyureido)methyl-2-methoxyphenoxy]propyl)-3-[4-(trifluoromethoxy)phenyl]urea
KM55, a multitarget ligand and dual 5-lipoxygenase (5-LO)/soluble epoxide hydrolase (sEH) inhibitor. KM55 potently inhibits both enzymes in vitro and attenuates the formation of leukotrienes in human whole blood. It significantly inhibits the LPS-induced adhesion of leukocytes to endothelial cells by blocking leukocyte activation. Compound synthesis and evaluation, overview. KM55 inhibits the formation of leukotriene B4 and 5-hydroxyeicosatrienoic acid, while the formation of 12-hydroperoxyicosatetraenoate and 15-hydroperoxyicosatetraenoate are unaffected. KM55 blocks leukocyte-endothelial cell interaction by impairing leukocyte activation, whereas endothelial cells are not affected
10-nitro-oleic acid
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0015 mM
-
2,3-dichlorophenyl 3,5-dinitrobenzoate
-
2,5-dimethoxy-3-tridecylbenzene-1,4-diol
-
2-(3-acetylphenyl)propanoic acid
-
2-(3-benzoylphenyl)propanoic acid
-
2-(3-phenoxyphenyl)propanoic acid
-
2-methyl-3-[(morpholine-4-carbonyl)amino]-3-oxopropanoic acid
-
2-phenylethyl (2E)-3-(2,5-dihydroxyphenyl)prop-2-enoate
-
2-phenylethyl (2E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoate
inhibits leukotriene biosynthesis in isolated human neutrophils and in whole blood
-
2-[2-[(2-methyl-1H-benzimidazol-1-yl)methyl]phenoxy]acetamide
a BRP-7 derivative
2-[2-[(2-[1-[4-(2-methylpropyl)phenyl]ethyl]-1H-benzimidazol-1-yl)methyl]phenoxy]acetamide
a BRP-7 derivative
2-[3-(2-methylpropanoyl)phenyl]propanoic acid
-
2-[3-(morpholine-4-carbonyl)phenyl]propanoic acid
-
2-[3-[(4-hydroxyphenyl)carbamoyl]phenyl]propanoic acid
-
2-[3-[hydroxy(phenyl)amino]phenyl]propanoic acid
-
2-[4'-[(morpholin-4-yl)sulfanyl][1,1'-biphenyl]-3-yl]propanoic acid
-
2-[4-(morpholine-4-carbonyl)phenyl]propanoic acid
-
3,4,6-trimethoxy-5-undecylcyclohexa-2,4-dien-1-one
-
3-((naphthalene-1-yloxy)carbonyl)benzoic acid
-
3-(1,10-dihydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
3-(1-acetoxy-10-hydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
3-(1-carboxyethyl)benzoic acid
-
3-(10-hydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
3-(10-hydroxydecyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
-
3-(11-hydroxyundecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
3-(11-hydroxyundecyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
-
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(3-phenyl-3-(4-(trifluoromethoxy)phenyl)propyl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(4-methoxy-2-(trifluoromethyl)benzyl)-benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
3-(3-(1-hydroxyureido)hex-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
3-(8-hydroxyoctyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
3-(8-hydroxyoctyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
-
3-(benzyloxycarbonyl)benzoic acid
-
3-(naphhthalen-1-ylcarbmoyl)benzoic acid
-
3-(phenylcarbamoyl)benzoic acid
-
3-acetyl-11-keto-beta-boswellic acid
allosteric inhibitor from frankincense, wedges between the membrane-binding and catalytic domains of 5-LOX, some 30 A from the catalytic iron. Binding promotes a shift in the regiospecificity, i.e. a significant increase in the formation of 12-hydroxyeicosatetraenoic acid with the most prominent effect at 10 microM
3-dodecyl-4,5-dimethoxybenzene-1,2-diol
-
3-dodecyl-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
-
3-n-pentadecylcatechol
-
-
3-propylphenyl 3,5-dinitrobenzoate
-
3-tolyl 3,5-dinitrobenzoate
-
3-tridecyl-4,5-dimethoxybenzene-1,2-diol
shows anti-inflammatory effectiveness
3-undecyl-4,5-dimethoxybenzene-1,2-diol
-
3-[(10E)-pentadec-10'-en-1-yl]-catechol
-
-
3-[(10Z)-pentadec-10'-en-1-yl]-catechol
-
-
3-[4-(3-[[(2E)-3-(2,3-dihydroxyphenyl)prop-2-enoyl]oxy]prop-1-yn-1-yl)phenyl]prop-2-yn-1-yl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
caffeic acid phenylethyl ester analogue, IC50 value for inhibition of 5-Lox product synthesis in transfected HEK-293 cells is 0.00036 mM. Compound is a good radical scavenger
-
4,5-dimethoxy-3-tridecylcyclohexa-3,5-diene-1,2-dione
shows anti-inflammatory effectiveness
4,5-dimethoxy-3-undecylcyclohexa-3,5-diene-1,2-dione
-
4-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor, displays cellular activity in human polymorphonuclear leukocytes, oral bioavailability, and target engagement in vivo and demonstrates anti-inflammatory and anti-fibrotic efficiency in a kidney injury model caused by unilateral ureteral obstruction in mice
-
4-(4-(4-chlorophenyl)thiazol-2-ylimino)cyclohexa-2,5-dienone
ST-1905
4-[(1E)-3-(3-phenylpropoxy)prop-1-en-1-yl]benzene-1,2-diol
caffeic acid phenylethyl ester analogue, IC50 value for inhibition of 5-Lox product synthesis in transfected HEK-293 cells is 0.00018 mM. Compound is a good radical scavenger
-
4-[(1E)-3-(benzyloxy)prop-1-en-1-yl]benzene-1,2-diol
caffeic acid phenylethyl ester analogue, IC50 value for inhibition of 5-Lox product synthesis in transfected HEK-293 cells is 0.00043 mM. Compound is a good radical scavenger
-
4-[(4-cyclohexyl-5-methyl-1,3-thiazol-2-yl)amino]-2,6-dimethylphenol
lead compound, in vitro pharmacokinetic profile, shows no cytotoxicity, overview
4-[(hydroxy[1-[3'-(morpholin-4-yl)[1,1'-biphenyl]-3-yl]ethyl]amino)methyl]phenol
-
4-[[4-(2,4-dichlorophenyl)-5-methyl-1,3-thiazol-2-yl]amino]-2,6-dimethylphenol
lead compound, in vitro pharmacokinetic profile, shows no cytotoxicity, overview
4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol
-
4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]imino]cyclohexa-2,5-dien-1-one
-
4-[[hydroxy(2-methyl-1-[3-[(morpholin-4-yl)oxy]phenyl]propyl)amino]methyl]phenol
-
5-methoxy-3-tridecylbenzene-1,2,4-triol
-
5-[[hydroxy(2-methyl-1-[3-[(morpholin-4-yl)oxy]phenyl]propyl)amino]methyl]benzene-1,2,3-triol
-
6-hydroxy-3,4-dimethoxy-5-undecylcyclohexa-2,4-dien-1-one
-
AA-861
compound reacts with catalytically relevant cysteine residues 416 and 418, inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0082 mM
arachidonate
substrate inhibition
baicalein
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0014 mM
biphenyl-3-yl 3,5-dinitrobenzoate
-
biphenyl-4-yl 3,5-dinitrobenzoate
-
BRP-7
benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP). BRP-7 blocks 5-LOX co-localization with FLAP at the nuclear envelope in neutrophils. No complete inhibition up to 0.01 mM
caffeic acid phenethyl ester
chalcone
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.006 mM
curcumin
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0016 mM
cyrhetrenyl carboxylic acid
the compound is a good ROS generator
-
delta-garcinoic acid
i.e. an omega-oxidized tocotrienol, inhibits leukotriene biosynthesis by human primary polymorphonuclear leukocytes, IC50 value 345 nM
-
delta-tocopherol-13'-carboxychromanol
competitive, compound decreases leukotriene B4 from stimulated neutrophil-like cells without affecting translocation of 5-Lox from cytosol to the nucleus. Compound additionally inhibits cyclooxygenases Cox-1 and Cox-2
-
delta-tocotrienol
competitive, compound decreases leukotriene B4 from stimulated neutrophil-like cells without affecting translocation of 5-Lox from cytosol to the nucleus. Compound additionally inhibits cyclooxygenases Cox-1 and Cox-2
delta-tocotrienol-13'-carboxychromanol
competitive, compound decreases leukotriene B4 from stimulated neutrophil-like cells without affecting translocation of 5-Lox from cytosol to the nucleus. Compound additionally inhibits cyclooxygenases Cox-1 and Cox-2
-
Diamide
in 5-LO/FLAP-transfected HeLa cells, treatment with the thiol-oxidizing agent diamide which promotes glutathionylation at surface Cys residues leads to a decreased leukotriene synthesis by wild-type 5-LO
ethyl 2-((2,4-difluorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
ethyl 2-((2,6-dichlorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
ethyl 2-((2,6-dimethylphenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
ethyl 2-((3,5-dimethylphenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
ethyl 2-((3-chlorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
ethyl 2-((4-fluorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-1-methyl-2-((2-(trifluoromethyl)phenylthio)methyl)-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-1-methyl-2-((4-(trifluoromethoxy)phenylthio)methyl)-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-1-methyl-2-((4-(trifluoromethyl)phenylthio)methyl)-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-1-methyl-2-(phenylthiomethyl)-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-2-((2-methoxyphenylthio)methyl)-1-methyl-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-2-((4-methoxyphenylthio)methyl)-1-methyl-1H-indole-3-carboxylate
-
ethyl 5-hydroxy-2-(mesitylthiomethyl)-1-methyl-1H-indole-3-carboxylate
-
ethyl [2-[(2-[1-[4-(2-methylpropyl)phenyl]ethyl]-1H-benzimidazol-1-yl)methyl]phenoxy]acetate
a BRP-7 derivative
ferrocenyl carboxylic acid
mixed type inhibitor. The compound shows better antioxidant activity than the antioxidant Trolox
-
glutathione
efficiency of non-redox-type 5-LO inhibitors depends on the presence of glutathione peroxidase activity leading to low hydroperoxide concentration
luteolin
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0006 mM
myxochelin A
isolated from extracts of the predatory myxobacterium Pyxidicoccus fallax HKI 727, IC50 values for inhibition of proliferative cells K-562 and HeLa are 0.3052 mM and 0.0039 mM, respectively
myxochelin C
isolated from extracts of the predatory myxobacterium Pyxidicoccus fallax HKI 727, IC50 values for inhibition of proliferative cells K-562 and HeLa are 0.424 mM and 0.0535 mM, respectively
myxochelin D
isolated from extracts of the predatory myxobacterium Pyxidicoccus fallax HKI 727, IC50 values for inhibition of proliferative cells K-562 and HeLa are above 0.5 mM
N-(3,4-dimethoxyphenyl)-3,5-dinitrobenzamide
-
N-(3-(4-chlorophenyl)-3-phenylpropyl)-3-(3-(1-hydroxyureido)-but-1-yn-1-yl)benzamide
dual 5-LOX/soluble epoxide hydrolase inhibitor
-
N-(3-bromobenzyl)-3,5-dinitrobenzamide
-
N-(3-bromophenyl)-3,5-dinitrobenzamide
-
N-(3-chlorophenyl)-3,5-dinitrobenzamide
-
N-(4-methoxyphenyl)-3,5-dinitrobenzamide
-
N-(biphenyl-3-yl)-3,5-dinitrobenzamide
-
N-(naphthalene-1-yl)-3,5-dinitrobenzamide
-
N-([(5R)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)-N-hydroxy-2-methylpropanamide
-
-
N-([(5R)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)-N-hydroxycyclopropanecarboxamide
-
-
N-3-tolyl-3,5-dinitrobenzamide
-
N-phenyl-3,5-dinitrobenzamide
-
naphthalen-1-yl 3,5-dinitrobenzoate
JMC-4, identified from virtual inhibitor screening
naphthalene-1-yl 3-nitrobenzoate
-
NAPQI
compound reacts with catalytically relevant cysteine residues 416 and 418
-
nordihydroguaiaretic acid
redox-type inhibitor, is lodged in the 5-LOX active site, fully exposed by disordering of the helix that caps it in the apo-enzyme
phenyl 3,5-dinitrobenzoate
-
Plumbagin
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.007 mM
primin
compound reacts with catalytically relevant cysteine residues 416 and 418, inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0028 mM
-
shikonin
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0015 mM
shogaol
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.005 mM
thymoquinone
compound reacts with catalytically relevant cysteine residues 416 and 418, inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0015 mM
[1-(2-cyclohexylethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
compound is equipotent to zileuton. It forms pi-pi interactions with residues His367, Phe421 and coordinates iron
-
[2-[(2-methyl-1H-benzimidazol-1-yl)methyl]phenoxy]acetyl chloride
a BRP-7 derivative
[3-(1-[hydroxy[(3,4,5-trihydroxyphenyl)methyl]amino]ethyl)phenyl](morpholin-4-yl)methanone
-
[3-(1-[hydroxy[(4-hydroxyphenyl)methyl]amino]ethyl)phenyl](morpholin-4-yl)methanone
-
[3-(bromocarbonyl)phenyl](morpholin-4-yl)acetic acid
-
(2E,2'E)-(1,1'-(2,2-bis((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
-
potent inhibition by 92%
(2E,2'E)-(1,1'-(2,2-bis((4-(cinnamoyloxymethyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-phenylacrylate)
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
(2E,2'E)-(1,1'-(2-((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
-
potent inhibition by 91%
(2E,2'E)-(1,1'-(2-((4-(cinnamoyloxymethyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-phenylacrylate)
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
(2E,2'E)-2,2'-(4,4'-(2,2-bis(((1-(2-((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)methyl)propane-1,3-diyl)bis(oxy)bis(methylene)bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl) bis(3-(3,4-dihydroxyphenyl)acrylate)
-
-
(2E,2'E)-2,2'-(4,4'-(2,2-bis(((1-(2-(cinnamoyloxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)methyl)propane-1,3-diyl)bis(oxy)bis(methylene)bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl) bis(3-phenylacrylate)
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
(2E,5E)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-3-phenyl-2-(phenylimino)-1,3-thiazolidin-4-one
-
-
(5E)-2-(3-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(3-fluorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-aminophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-chlorophenyl)-5-(4-hydroxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-chlorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-hydroxyphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-methylphenyl)-5-(3,4,5-trimethoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(2,4-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3,5-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3-chlorobenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-hydroxy-3-methoxy-5-nitrobenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-methoxybenzylidene)-2-(4-methoxyphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-tert-butylbenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-[(methylperoxy)acetyl]benzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(5-chloro-2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(anthracen-9-ylmethylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-4-[(methylperoxy)acetyl]benzylidene
-
-
(5E)-5-benzylidene-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-[4-(dimethylamino)benzylidene]-2-(piperidin-1-yl)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-(cyclohexylamino)-5-(4-propoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-5-(4-methoxybenzylidene)-2-(pyrrolidin-1-yl)-1,3-thiazol-4(5H)-one
-
-
(5Z)-5-(4-methylbenzylidene)-2-(naphthalen-2-ylamino)-1,3-thiazol-4(5H)-one
-
-
(5Z)-5-benzylidene-2-(phenylamino)-1,3-thiazol-4(5H)-one
-
-
(E)-N-hydroxy-N-(3-(3-phenoxyphenyl)-allyl)acetamide
-
BWA4C
([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)(naphthalen-1-yl)acetic acid
-
-
1-(2,4-difluorophenyl)-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
-
-
1-(2,4-dihydroxyphenyl)-2-(naphthalen-2-yl)ethanone
-
-
1-benzyl-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
-
-
1-O-dodecyl 2,3-O-isopropylidene-5,6-dideoxy-5-N-[4-(2-hydroxy-2-oxoethyl) phenylaminocarbonyl] amino-beta-L-gulofuranoside sodium salt
-
competitive inhibitor, IC50: 0.0035 mM with recombinant enzyme, IC50: 0.005 mM with native enzyme
1-[3-(methylsulfanyl)phenyl]-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
-
-
10,17(S)-dihydroxydocosahexaenoic acid
-
IC50: 0.017 mM
11alpha,13-dihydrohelenalin acetate
-
enzyme from polymorphonuclear leukocyte
15-hydroperoxy-6,8,11,13-eicosatetraenoic acid
-
IC50: 0.0048 mM
2-(2,2-dimethyl-6-(4-nitrophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
-
-
2-(2,2-dimethyl-7-phenyl-6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
-
-
2-(2-methoxyphenyl)-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)acetamide
-
-
2-(4-(biphenyl-4-ylamino)-6-chloropyrimidine-2-ylthio)octanoic acid
-
-
2-(4-(biphenyl-4-ylmethylamino)-6-chloropyrimidin-2-ylthio)octanoic acid
-
-
2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)acetic acid
-
-
2-(4-chloro-6-(4'-cyanobiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
-
-
2-(4-chloro-6-(5-methoxy-2-methylbiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
-
-
2-(4-methylphenyl)-5-(2-phenylethenylidene)-1,3-thiazol-4(5H)-one
-
-
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(5-methyl-1,3-thiazol-2-yl)propanamide
-
-
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
-
-
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
-
-
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-thiophen-3-ylpropanamide
-
-
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-(methylsulfonyl)acetamide
-
-
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-(phenylsulfonyl)acetamide
-
-
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-tosylacetamide
-
-
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1Hpyrrolizin-5-yl)-N-tosylpropanamide
-
-
2-(6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
-
-
2-(6-(4-tert-butylphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
-
-
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(thiophen-2-ylmethyl)propanamide
-
-
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
-
-
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
-
-
2-(dibenzo[b,d]furan-3-yl)-5-hydroxycyclohexa-2,5-diene-1,4-dione
-
-
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)octanoic acid
-
-
2-benzyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
-
-
2-hexyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
-
-
2-hydroxy-5-(3-nitrophenyl)cyclohexa-2,5-diene-1,4-dione
-
-
2-hydroxy-5-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
-
-
2-hydroxy-5-methoxy-3-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
-
-
2-methoxy-5-(naphthalen-2-yloxy)cyclohexa-2,5-diene-1,4-dione
-
-
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
-
-
2-[4'-(iso-propylphenyl)-amino]-5,6-dimethyl-1,4-benzoquinone
-
potent inhibitor, IC50: 0.006 mM
2-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
-
2-[5,8-dimethyl-7-(2-morpholin-4-ylethoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
-
-
2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl]acetic acid
-
-
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
-
-
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-pyridin-2-ylpropanamide
-
-
3'-nitrobiphenyl-2,4-diol
-
-
3,4,5-trimethoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
-
-
3-(6-(4-chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)propionic acid
-
-
3-(cyclohexylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
-
-
3-(decahydronaphthalen-2-ylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
-
-
3-benzyl-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione
-
-
4-(1-benzothiophen-3-yl)benzene-1,3-diol
-
-
4-(4-chlorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-2H-chromen-2-one
-
IC50: 180 nM
4-(4-fluorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenoxy]methyl)-2H-chromen-2-one
-
IC50: 55 nM
4-(4-fluorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-2H-chromen-2-one
-
IC50: 27 nM
4-(dibenzo[b,d]furan-3-yl)benzene-1,3-diol
-
-
4-(naphthalen-2-ylmethyl)benzene-1,3-diol
-
-
4-(thianthren-2-yl)benzene-1,3-diol
-
-
4-benzylbenzene-1,3-diol
-
-
4-chloro-N-([4-[(2E)-3-(2,4-dichlorophenyl)prop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
-
IC50: 0.00042 mM
4-chloro-N-([4-[(2E)-3-phenylprop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
-
IC50: 0.00083 mM
4-hexylbenzene-1,3-diol
-
-
4-methoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
-
-
4-methyl-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,2,3-thiadiazole-5-carboxamide
-
-
4-methyl-N-([4-[(2E)-3-(2,3,4-trimethylphenyl)prop-2 enoyl]phenyl]carbamoyl)benzenesulfonamide
-
IC50: 0.00045 mM
4-methyl-N-([4-[(2E)-3-phenylprop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
-
IC50: 0.00089 mM
4-[5-(1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
-
0.01 mM inhibits LOX-5 by 41%
4-[5-(6-chloro-1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
-
0.01 mM inhibits LOX-5 by 51%
4-[5-(7-chloro-1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
-
0.01 mM inhibits LOX-5 by 94%
6-[(4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)methyl]naphthalene-2-carboxylic acid
-
-
7,17(S)-dihydroxydocosahexaenoic acid
-
IC50: 0.007 mM
7-([3-fluoro-5-[(1R)-1-hydroxy-1-pyridin-2-ylpropyl]phenoxy]methyl)-4-furan-3-yl-2H-chromen-2-one
-
IC50: 175 nM
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-(4-fluorophenyl)-2H-chromen-2-one
-
-
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-furan-3-yl-2H-chromen-2-one
-
IC50: 200 nM
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-phenyl-2H-chromen-2-one
-
IC50: 300 nM
7-([3-fluoro-5-[(1S)-1-hydroxy-1-(1,3-thiazol-2-yl)propyl]phenoxy]methyl)-4-(4-fluorophenyl)-2H-chromen-2-one
-
IC50: 175 nM
7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-4-furan-3-yl-2H-chromen-2-one
-
IC50: 9 nM
7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-4-phenyl-2H-chromen-2-one
-
IC50: 26 nM
7-[[3-(1-ethyl-1-hydroxypropyl)-5-fluorophenoxy]methyl]-4-furan-3-yl-2H-chromen-2-one
-
IC50: 15 nM
AA-861
-
competitive 5-LO inhibitor
AA861
-
specific inhibition
benzyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
benzyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
beta-hydroxyacteoside
-
enzyme from polymorphonuclear leukocyte
capsaicin
-
enzyme from polymorphonuclear leukocyte
cholesterol
-
addition to a membrane preperation in vitro reduces 5-lipoxygenase activity by half. Cholesterol sulfate can inhibit 5-lipoxygenase in intact cells
daidzein
-
noncompetitive
delphinidin 3-O-galactoside
-
from Vaccinium myrtillus berries, strong inhibitor, in a concentration-dependent manner
delphinidin 3-O-glucoside
-
from Vaccinium myrtillus berries, strong inhibitor, in a concentration-dependent manner
ethyl 1-benzyl-2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(3-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-pyrrolo[2,3-f]quinoline-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-hydroxy-6-phenyl-1H-indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-methoxy-1-methyl-1H-benzo[g]-indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-phenyl-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-7,8-dimethoxy-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(3-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(4-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-trifluoromethylbenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]octanoate
-
-
ethyl 5-benzoyloxy-2-(3-chlorobenzyl)-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 5-hydroxy-2-phenylethyl-1H-indole-3-carboxylate
-
-
ethyl 5-hydroxy-2-phenylpropyl-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 6-biphenyl-4-yl-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
eugenol
-
non-competitive, reversible inhibitor, IC50: 0.026 mM
forsythiaside
-
enzyme from polymorphonuclear leukocyte
genistein
-
noncompetitive
gingerdione
-
enzyme from polymorphonuclear leukocyte
glutathione
-
inhibition is increased in presence of glutathione peroxidase
helenalin
-
enzyme from polymorphonuclear leukocyte
L-656,224
-
i.e. 7-chloro-2-[(4-methoxyphenyl)-methyl]-3-methyl-5-propyl-4-benzofuranol, IC50: 0.0008 mM
L-670,630
-
IC50: 0.0004 mM
L-689,065
-
IC50: 0.0003 mM
L-697,198
-
IC50: 0.00002 mM
L-702,701
-
IC50: 0.0015 mM
L705,302
-
IC50: 0.00002 mM
methanol
-
complete inhibition at 50% v/v
methyl (4-[(5E)-5-(4-methoxybenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]phenoxy)acetate
-
-
methyl 2-(allylamino)-1H-indole-3-carboxylate
-
-
methyl 2-(benzylamino)-1H-indole-3-carboxylate
-
-
methyl 2-(diallylamino)-1H-indole-3-carboxylate
-
-
methyl 2-[(2-chlorophenyl)amino]-1H-indole-3-carboxylate
-
-
methyl 2-[(3-bromophenyl)amino]-1H-indole-3-carboxylate
-
-
methyl 2-[(3-chlorophenyl)amino]-1H-indole-3-carboxylate
-
-
methyl 2-[(3-chlorophenyl)amino]-5-chloro-1H-indole-3-carboxylate
-
-
methyl 2-[(3-fluorophenyl)amino]-1H-indole-3-carboxylate
-
-
methyl 2-[(4-chlorophenyl)amino]-1H-indole-3-carboxylate
-
-
miogadial
-
potent inhibitor, IC50: 0.004 mM
miogatrial
-
potent inhibitor, IC50: 0.0075 mM
mithramycin
-
reduces endogenous 5-lipoxygenase in Mono Mac 6 cell, which blocks GC-boxes in the proximal part of the 5-lipoxygenase gene promoter
MK 886
-
i.e. CAS: 118414-82-7, inhibition of 5-lipoxygenase in prostate cancer cells blocks production of 5-hydroxyeicosatetraenoic acid and induces massive apoptosisin both hormone-responsive and hormone-nonresponsive prostate cancer cells
ML-3000
-
i.e. licofelone, ML-3000 has no effect on 5-LOX product synthesis in whole-blood assay, inhibition of COX pathways does not increase the transformation of arachidonic acid by the 5-LOX pathway
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,3-benzodioxole-5-carboxamide
-
-
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)cyclopentanecarboxamide
-
-
N-(3-phenoxycinnamyl)-acetohydroxamic acid
-
-
N-(4-chlorophenyl)-N-hydroxy-N'-(3-chlorophenyl)urea
-
IC50: 0.0001 mM
N-(furan-2-ylmethyl)-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
-
-
N-([4-[(2E)-3-(2,4-dichlorophenyl)prop-2-enoyl]phenyl]carbamoyl)-4-methylbenzenesulfonamide
-
IC50: 0.00045 mM
N-cyclopentyl-2-[7-(2-methoxyethoxy)-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]propanamide
-
-
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
-
-
N-tert-butyl-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
-
-
nordihydroguaiaretic acid
polygodial
-
strong inhibitory activity, IC50: 0.0086 mM
Rev-5901
-
competitive 5-LO inhibitor
shogaol
-
enzyme from polymorphonuclear leukocyte
suspensaside
-
enzyme from polymorphonuclear leukocyte
verbascoside
-
enzyme from polymorphonuclear leukocyte
ZM 230,486
-
IC50: 0.00009 mM
[1-(2-[[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
-
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
-
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-phenylprop-2-enoate
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
[1-(3-[4-([[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-2-[(3-[4-([[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-2,2-bis[[4-([[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]methyl]propoxy)methyl]-2-[[4-([[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]methyl]propyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
incorporation of additional caffeoyl units in hexamer results in less potent inhibition
[1-(3-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-2-[(3-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-2,2-bis[[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]methyl]propoxy)methyl]-2-[[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]methyl]propyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-phenylprop-2-enoate
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
2-phenylethyl (2E)-3-(2,5-dihydroxyphenyl)prop-2-enoate
compound reduces the cell viability of renal cancer cells and is more selective toward RCC4 and 786.0 cells deficient for the Von Hippel-Lindau tumor suppressor gene. Compound induces apoptosis in Von Hippel-Lindau-deficient RCC4 cells and may block the autophagic flux in renal cancer cells
-
2-phenylethyl (2E)-3-(2,5-dihydroxyphenyl)prop-2-enoate
inhibits leukotriene biosynthesis in isolated human neutrophils and in whole blood
-
BWA4C
a direct inhibitor of 5-LO, treatment results not only in a suppression of leukotriene production, but in an almost complete inhibition of enzymatic
BWA4C
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.00015 mM
caffeic acid phenethyl ester
IC50 value for inhibition of 5-Lox product synthesis in transfected HEK-293 cells is 0.00099 mM. Compound is a good radical scavenger
caffeic acid phenethyl ester
inhibits leukotriene biosynthesis in isolated human neutrophils and in whole blood
embelin
-
embelin
compound reacts with catalytically relevant cysteine residues 416 and 418, inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0035 mM
U73122
-
U73122
inhibition of the 5-LO product formation of intact human polymorphonuclear leukocytes, IC50 value 0.0069 mM
zileuton
-
zileuton
IC50 value for inhibition of 5-Lox product synthesis in transfected HEK-293 cells is 0.003 mM. Compound is a good radical scavenger
BW755C
-
CAS: 66000-40-6
BW755C
-
i.e. 3-amino-1-[3-(trifluoromethyl)phenyl]-2-pyrazoline, IC50: 0.013 mM
celecoxib
-
-
celecoxib
-
0.01 mM inhibits LOX-5 by 89%
licofelone
-
formerly termed ML-3000
licofelone
-
dual COX-2?5-LO inhibitor
MK-886
-
-
MK-886
-
competitive 5-LO inhibitor
MK886
-
a specific FLAP inhibitor
MK886
-
specific inhibitor of 5-hydroperoxyeicosatetraenoic acid synthesis by the enzyme
MK886
-
5-LOX activating protein inhibitor
nordihydroguaiaretic acid
-
-
nordihydroguaiaretic acid
-
IC50: 5 ppm
nordihydroguaiaretic acid
-
NDGA
rofecoxib
-
-
rofecoxib
-
0.01 mM inhibits LOX-5 by 11%
sulindac sulfide
-
-
sulindac sulfide
-
5-LO-selective inhibitor
ZD 2138
-
-
ZD 2138
-
i.e. CAS: 140841-32-3, IC50: 0.0003 mM
zileuton
-
-
zileuton
-
IC50: 0.0038 mM with recombinant enzyme, IC50: 0.0011 mM with native enzyme
additional information
design, synthesis, and evaluation of 2-phenylthiomethyl-indole derivatives from an ethyl 5-hydroxy-indole-3-carboxylate scaffold as efficient inhibitors of human 5-lipoxygenase, structure-activity relationships, overview. The potency of compounds is closely related to the positioning of the substituents at the phenylthiomethyl ring. The introduction of methyl or chlorine groups in ortho- and ortho/para-position of thiophenol represent the most favorable modifications. Among all tested compounds, ethyl 5-hydroxy-2-(mesitylthiomethyl)-1-methyl-1H-indole-3-carboxylate is the most potent derivative which blocks 5-LO activity in cell-free assays and suppresses 5-LO product synthesis in polymorphonuclear leukocytes. The compounds are not active against 12-LO and 15-LO, EC 1.13.11.31 and EC 1.13.11.33
-
additional information
-
design, synthesis, and evaluation of 2-phenylthiomethyl-indole derivatives from an ethyl 5-hydroxy-indole-3-carboxylate scaffold as efficient inhibitors of human 5-lipoxygenase, structure-activity relationships, overview. The potency of compounds is closely related to the positioning of the substituents at the phenylthiomethyl ring. The introduction of methyl or chlorine groups in ortho- and ortho/para-position of thiophenol represent the most favorable modifications. Among all tested compounds, ethyl 5-hydroxy-2-(mesitylthiomethyl)-1-methyl-1H-indole-3-carboxylate is the most potent derivative which blocks 5-LO activity in cell-free assays and suppresses 5-LO product synthesis in polymorphonuclear leukocytes. The compounds are not active against 12-LO and 15-LO, EC 1.13.11.31 and EC 1.13.11.33
-
additional information
development of 3,5-dinitrobenzoate-based 5-lipoxygenase inhibitors, structure-activity relationship study, overview
-
additional information
-
development of 3,5-dinitrobenzoate-based 5-lipoxygenase inhibitors, structure-activity relationship study, overview
-
additional information
high potency of 4,5-dimethoxy-3-alkyl-1,2-benzoquinones on 5-lipoxygenase inhibition is used for systematic structural optimization through accurate structure-based design of the compounds, improvement of the inhibitory potential in vitro and in vivo, overview. Binding patterns of the quinone- and hydroquinone-based 5-LO inhibitors are analyzed by molecular docking, and determination of the optimal alkyl chain pattern of quinones and corresponding hydroquinones
-
additional information
-
high potency of 4,5-dimethoxy-3-alkyl-1,2-benzoquinones on 5-lipoxygenase inhibition is used for systematic structural optimization through accurate structure-based design of the compounds, improvement of the inhibitory potential in vitro and in vivo, overview. Binding patterns of the quinone- and hydroquinone-based 5-LO inhibitors are analyzed by molecular docking, and determination of the optimal alkyl chain pattern of quinones and corresponding hydroquinones
-
additional information
human 5-lipoxygenase (5-LO) is a molecular target of the myxochelins that have antiproliferative effects on K-562 and HeLa cancer cells
-
additional information
-
human 5-lipoxygenase (5-LO) is a molecular target of the myxochelins that have antiproliferative effects on K-562 and HeLa cancer cells
-
additional information
immobilization of BRP-7 derivatives and pull-down assays, overview
-
additional information
molecular mechanism of 5-lipoxygenase inhibition by 2-aminothiazoles, overview. ST-1083 and ST-1905, but not the lead compounds, show covalent binding to 5-LO and the potency of ST-1083 and ST-1905, but not of the lead compounds is impaired for 5-LO cysteine mutants. Especially the cysteines 159, 300, 416, and 418, located in the substrate entry channel of 5-LO, are prone to be potential targets for inhibition. The lead compounds show no dependency on thiol level
-
additional information
-
molecular mechanism of 5-lipoxygenase inhibition by 2-aminothiazoles, overview. ST-1083 and ST-1905, but not the lead compounds, show covalent binding to 5-LO and the potency of ST-1083 and ST-1905, but not of the lead compounds is impaired for 5-LO cysteine mutants. Especially the cysteines 159, 300, 416, and 418, located in the substrate entry channel of 5-LO, are prone to be potential targets for inhibition. The lead compounds show no dependency on thiol level
-
additional information
outstanding anti-inflammatory potential of selected Asteraceae species through the potent dual inhibition of cyclooxygenase-1 and 5-lipoxygenase, evaluation of 57 Asteraceae extracts (EtOH:H2O - 7:3 v/v) for in vitro enzyme inhibition activity, e.g. from known anti-inflammatory herbs such as Solidago microglossa, Tithonia diversifolia, Vernonia polyanthes and Viguiera robusta, or food plants or previously uninvestigated species, such a Minasia scapigera, Piptolepis monticola, Prestelia eriopus, Sphagneticola trilobata, Vernonia herbacea, Vernonia platensis, Vernonia rubriramea, and Viguiera trichophylla, chemical profiles, detailed overview
-
additional information
synthesis and evaluation of inhibitors of 5-lipoxygenase catalytic activity based on 2-(3-methylphenyl)propanoic acid and 4-substituted morpholine derivatives, inhibitor molecular docking in the active site of 5-LOX, overview. 2-(3-benzoylphenyl)propanoic acid is an active component of the nonsteroidal antiinflammatory drug ketoprofen
-
additional information
treatement with FLAP inhibitor MK886 does not affect 5-H(p)ETE formation
-
additional information
-
treatement with FLAP inhibitor MK886 does not affect 5-H(p)ETE formation
-
additional information
naturally occurring or synthetic anti-inflammatory compounds carrying a Michael acceptor, such as thymoquinone, the paracetamol metabolite NAPQI, the 5-Lox inhibitor AA-861, and bardoxolone methyl (i.e. RTA 402 or CDDO-methyl ester) are direct covalent 5-Lox enzyme inhibitors that target the catalytically relevant cysteines 416 and 418
-
additional information
-
naturally occurring or synthetic anti-inflammatory compounds carrying a Michael acceptor, such as thymoquinone, the paracetamol metabolite NAPQI, the 5-Lox inhibitor AA-861, and bardoxolone methyl (i.e. RTA 402 or CDDO-methyl ester) are direct covalent 5-Lox enzyme inhibitors that target the catalytically relevant cysteines 416 and 418
-
additional information
synthesis of 5-(hydroxamic acid)methyl oxazolidinone derivatives as inhibitors. Increasing alkyl chain length on the hydroxamic acid moiety enhances activity and morpholinyl-containing derivatives are more active than N-acetyl-piperizinyl derivatives. The inhibitory effect of the compounds paralleles their effects in cell-based assays
-
additional information
-
synthesis of 5-(hydroxamic acid)methyl oxazolidinone derivatives as inhibitors. Increasing alkyl chain length on the hydroxamic acid moiety enhances activity and morpholinyl-containing derivatives are more active than N-acetyl-piperizinyl derivatives. The inhibitory effect of the compounds paralleles their effects in cell-based assays
-
additional information
-
classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198
-
additional information
-
overview: inhibitors and perspectives for future drug development
-
additional information
-
zinc inhibits leukotriene B4 formation due to a direct or indirect inhibitory effect on 5-lipoxygenase
-
additional information
-
selenium-induced apoptosis in prostate cancer cells may be mediated through inhibition of the activity of arachidonate 5-lipoxygenase. The anti-cancer effects of selenium may be substantially compromised by consumption of high-fat diets rich in arachidonic acid or its precursor fatty acids
-
additional information
-
enzyme activity is inhibited by essential oil from Ballota africana (IC50: 29.99 ppm), methanol extract from Croton sylvaticus (IC50: 25.64 ppm), aqueous extract from Croton sylvaticus (IC50: 60.9 ppm), methanol extract from Melianthus comosus (IC50: 55.05 ppm), aqueous extract from Melianthus comosus (IC50: 13.84 ppm), methanol extract from Pentanisia prunelloides (IC50: 32.7 ppm), and methanol extract from Warburgia salutaris (IC50: 32.11 ppm)
-
additional information
-
no inhibition by galanal A, galanal B and 8beta(17)-epoxy-15-hydroxy-12(E)-labden-16-al
-
additional information
-
isoflavones reduce active state iron to ferrous state and prevent the activation of the resting enzyme, model for the inhibition of lipoxygenase by isoflavones, overview
-
additional information
-
virtual inhibitor screening, structure-function relationship analysis, overview
-
additional information
-
5-lipoxygenase may be inhibited either by the direct interaction with an inhibitor or by the binding of an inhibitor to the 5-lipoxygenase activating protein (FLAP), e.g., the clinically effective MK-0591. Highly potent FLAP inhibitors are 2,2-bisaryl-bicycloheptanes
-
additional information
-
class of dual microsomal PGE2 synthase-1/5-lipoxygenase inhibitors based on the structure of pirinixic acid. Target oriented structural modification of pirinixic acid, particularly R substitution with extended n-alkyl or bulky aryl substituents and concomitant replacement of the 2,3-dimethylaniline by a biphenyl-4-yl-methane-amino residue, results in potent suppression of mPGES-1 and 5-lipoxygenase activity. Is not inhibited by 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid
-
additional information
-
sulindac sulfone and sulindac do not inhibit 5-LO
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Aberrant Crypt Foci
Effects of green tea and high-fat diet on arachidonic acid metabolism and aberrant crypt foci formation in an azoxymethane-induced colon carcinogenesis mouse model.
Acne Vulgaris
A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor.
Acne Vulgaris
Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis.
Acne Vulgaris
Zileuton, a new efficient and safe systemic anti-acne drug.
Acne Vulgaris
Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production.
Acquired Immunodeficiency Syndrome
Granulocyte-macrophage colony-stimulating factor upregulates reduced 5-lipoxygenase metabolism in peripheral blood monocytes and neutrophils in acquired immunodeficiency syndrome.
Acute Chest Syndrome
Eicosanoids in sickle cell disease: potential relevance of neutrophil leukotriene B4 to disease pathophysiology.
Acute Coronary Syndrome
A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome.
Acute Coronary Syndrome
Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future.
Acute Coronary Syndrome
Candidate genes of the 5-lipoxygenase pathway in acute coronary syndrome: a pilot study.
Acute Coronary Syndrome
Effect of 5-lipoxygenase inhibitor, VIA-2291 (Atreleuton), on epicardial fat volume in patients with recent acute coronary syndrome.
Acute Coronary Syndrome
Treatment with 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients with Recent Acute Coronary Syndrome.
Acute Kidney Injury
Post-treatment effects of erythropoietin and nordihydroguaiaretic acid on recovery from cisplatin-induced acute renal failure in the rat.
Acute Kidney Injury
Zileuton alleviates acute cisplatin nephrotoxicity: Inhibition of lipoxygenase pathway favorably modulates the renal oxidative/inflammatory/caspase-3 axis.
Acute Lung Injury
Analysis of mRNA?lncRNA and mRNA?lncRNA-pathway co?expression networks based on WGCNA in developing pediatric sepsis.
Acute Lung Injury
Influence of cyclooxygenase and lipoxygenase inhibitors on oxidative stress-induced lung injury.
Acute Lung Injury
The 5-Lipoxygenase Pathway is Required for Acute Lung Injury Following Hemorrhagic Shock.
Acute Lung Injury
[Protective mechanisms of sevoflurane against one-lung ventilation-induced acute lung injury: role of cyclooxygenase-2 and 5-lipoxygenase pathways].
Adenocarcinoma
5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue.
Adenocarcinoma
5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage.
Adenocarcinoma
Cysteinyl leukotriene 1 receptor influences intestinal polyp incidence in a gender-specific manner in the ApcMin/+ mouse model.
Adenocarcinoma
Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.
Adenocarcinoma
Increased expression of the 5-lipoxygenase pathway and its cellular localization in Barrett's adenocarcinoma.
Adenocarcinoma
Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells.
Adenocarcinoma
Inhibitory activities and attenuated expressions of 5-LOX with red ginseng in Helicobacter pylori-infected gastric epithelial cells.
Adenocarcinoma
Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC).
Adenocarcinoma
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Adenocarcinoma
Prognostic value of eicosanoid pathways in extrahepatic cholangiocarcinoma.
Adenocarcinoma
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Adenocarcinoma
The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis.
Adenocarcinoma, Bronchiolo-Alveolar
A genomic response of H-358 bronchiolar carcinoma cells to MK 886, an inhibitor of 5-lipoxygenase, assessed with a cDNA array.
Adenoma
Chemopreventive Efficacy and Mechanism of Licofelone in a Mouse Lung Tumor Model via Aspiration.
Adenoma
Common polymorphisms in 5-lipoxygenase and 12-lipoxygenase genes and the risk of incident, sporadic colorectal adenoma.
Adenoma
Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking.
Adenoma
Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells.
Adenoma
Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
Adenoma
Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation.
Adenoma
Inhalation of an ethanol-based zileuton formulation provides a reduction of pulmonary adenomas in the A/J mouse model.
Adenoma
Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway.
Adenoma
Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis.
Adenoma
Oxylipin patterns in human colon adenomas.
Adenoma
The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis.
Adenomatous Polyps
Overexpression of 5-Lipoxygenase in Colon Polyps and Cancer and the Effect of 5-LOX Inhibitors In vitro and in a Murine Model.
Adenomatous Polyps
Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis.
Adrenoleukodystrophy
Very long chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy.
Airway Obstruction
Enhanced arachidonic acid metabolism and human neutrophil migration in asthma.
Airway Obstruction
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
Airway Obstruction
The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air.
Altitude Sickness
A new 5-lipoxygenase inhibitor seems to be safe and effective for the treatment of osteoarthritis.
Altitude Sickness
The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude.
Alveolar Bone Loss
The role of 5-lipoxygenase in Aggregatibacter actinomycetemcomitans-induced alveolar bone loss.
Alzheimer Disease
5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer's disease.
Alzheimer Disease
5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease.
Alzheimer Disease
5-lipoxygenase activating protein reduction ameliorates cognitive deficit, synaptic dysfunction, and neuropathology in a mouse model of Alzheimer's disease.
Alzheimer Disease
5-lipoxygenase as an endogenous modulator of amyloid ? formation in vivo.
Alzheimer Disease
5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease.
Alzheimer Disease
5-Lipoxygenase gene polymorphism and onset of Alzheimer's disease.
Alzheimer Disease
5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease.
Alzheimer Disease
5-Lipoxygenase in the Prefrontal Cortex of Suicide Victims.
Alzheimer Disease
5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer's disease.
Alzheimer Disease
5-LOX in Alzheimer's Disease: Potential Serum Marker and In Vitro Evidences for Rescue of Neurotoxicity by Its Inhibitor YWCS.
Alzheimer Disease
Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice.
Alzheimer Disease
Arachidonate 5-lipoxygenase (ALOX5) gene polymorphism is associated with Alzheimer's disease and body mass index.
Alzheimer Disease
Corrigendum to 'Arachidonate 5-Lipoxygenase (ALOX5) gene polymorphism is associated with Alzheimer's disease and body mass index [erý et al., J. Neurol. Sci. 362 (2016) 27-32].
Alzheimer Disease
Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease.
Alzheimer Disease
Cysteinyl Leukotrienes and Their Receptors: Emerging Therapeutic Targets in Central Nervous System Disorders.
Alzheimer Disease
Dissecting the Role of 5-Lipoxygenase in the Homocysteine-Induced Alzheimer's Disease Pathology.
Alzheimer Disease
Evaluation of the neuroprotective and antidiabetic potential of phenol-rich extracts from virgin olive oils by in vitro assays.
Alzheimer Disease
Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease.
Alzheimer Disease
Homocysteine modulates 5-lipoxygenase expression level via DNA methylation.
Alzheimer Disease
Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease.
Alzheimer Disease
Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase pathways.
Alzheimer Disease
Interrelationship between the 5-lipoxygenase pathway and microbial dysbiosis in the progression of Alzheimer's disease.
Alzheimer Disease
Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model.
Alzheimer Disease
Involvement of 5-lipoxygenase in Alzheimer's disease: a role for DNA methylation.
Alzheimer Disease
Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease.
Alzheimer Disease
Modulation of Amyloid-? Production by Leukotriene B4 via the ?-Secretase Pathway.
Alzheimer Disease
Neuroprotection of (+)-2-(1-Hydroxyl-4-Oxocyclohexyl) Ethyl Caffeate Against Hydrogen Peroxide and Lipopolysaccharide Induced Injury via Modulating Arachidonic Acid Network and p38-MAPK Signaling.
Alzheimer Disease
Nutraceutical Potential of Phenolics from 'Brava' and 'Mansa' Extra-Virgin Olive Oils on the Inhibition of Enzymes Associated to Neurodegenerative Disorders in Comparison with Those of 'Picual' and 'Cornicabra'.
Alzheimer Disease
Pharmacologic Blockade of 5-Lipoxygenase Improves the Amyloidotic Phenotype of an Alzheimer's Disease Transgenic Mouse Model Involvement of ?-Secretase.
Alzheimer Disease
Pharmacologic Inhibition of 5-Lipoxygenase Improves Memory, Rescues Synaptic Dysfunction, and Ameliorates Tau Pathology in a Transgenic Model of Tauopathy.
Alzheimer Disease
Role of Cyclooxygenase-2 and 5-Lipoxygenase Polymorphisms in Alzheimer's Disease in a Population from Northern Italy: Implication for Pharmacogenomics.
Alzheimer Disease
Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: implication for pharmacogenomics.
Alzheimer Disease
SAR-studies of ?-secretase modulators with PPAR?-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer's disease.
Alzheimer Disease
The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia.
Alzheimer Disease
The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype.
Alzheimer Disease
The Sp1/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene promoter is not associated with late onset Alzheimer disease.
Alzheimer Disease
Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice.
Amyloidosis
Pharmacologic Inhibition of 5-Lipoxygenase Improves Memory, Rescues Synaptic Dysfunction, and Ameliorates Tau Pathology in a Transgenic Model of Tauopathy.
Anaphylaxis
2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis.
Anaphylaxis
Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure-activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acryl amides.
Anaphylaxis
Acrylamide derivatives as antiallergic agents. III. Synthesis and structure-activity relationships of N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]- and N-[4-(4-diphenylmethylene-1-piperidyl)butyl]-3-heteroarylacry lamides.
Anaphylaxis
Anti-inflammatory activity of the ethanol extract of Chungkukjang, Korean fermented bean: 5-lipoxygenase inhibition.
Anaphylaxis
Characterization and modulation of antigen-induced effects in isolated rat heart.
Anaphylaxis
Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from platelets and their in vivo effects on inflammation and anaphylaxis.
Anaphylaxis
Effect of 5-lipoxygenase inhibitors on the anti-IgE-induced contraction of passively sensitized human bronchus in vitro.
Anaphylaxis
Effect of AA-861, a selective 5-lipoxygenase inhibitor, on models of allergy in several species.
Anaphylaxis
Effect of BW B70C, a novel inhibitor of arachidonic acid 5-lipoxygenase, on allergen-induced bronchoconstriction and late-phase lung eosinophil accumulation in sensitised guinea-pigs.
Anaphylaxis
Effects of 5-lipoxygenase inhibition on cardiac anaphylaxis in isolated guinea pig hearts.
Anaphylaxis
Flavonoids: potent inhibitors of arachidonate 5-lipoxygenase.
Anaphylaxis
Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid.
Anaphylaxis
Inhibition of leukotriene biosynthesis in the rat peritoneal cavity.
Anaphylaxis
Leukotrienes in respiratory disease.
Anaphylaxis
Non steroidal anti-inflammatory and anti-allergy agents.
Anaphylaxis
OKY-046 prevents increases in LTB4 and pulmonary edema in phorbol ester-induced lung injury in dogs.
Anaphylaxis
Predominant synthesis of 5-hydroxyeicosatetraenoic acid by a cloned mastocytoma P-815 line, 2-E-6 cells.
Anaphylaxis
Role of leukotriene B4 in 5-lipoxygenase metabolite- and allergy-induced itch-associated responses in mice.
Anaphylaxis
Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects on bronchial anaphylaxis in anaesthetized guinea-pigs.
Anaphylaxis
Substituted arylmethyl phenyl ethers. 1. A novel series of 5-lipoxygenase inhibitors and leukotriene antagonists.
Anaphylaxis
Synthesis and 5-lipoxygenase inhibitory activities of eicosanoid compounds.
Anaphylaxis
Synthesis and antiallergic activity of N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-1,4-dihydro-4-oxopyridine-3 - carboxamides.
Anaphylaxis
Synthesis of trimethylhydroquinone derivatives as anti-allergic agents with anti-oxidative actions.
Anaphylaxis
The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis.
Anaphylaxis
[Characteristics of the antioxidant system of alveolar surfactant in immediate-type allergies]
Anemia
5-Lipoxygenase plays a role in the control of parasite burden and contributes to oxidative damage of erythrocytes in murine Chagas' disease.
Aneurysm
Inhibition of 5-lipoxygenase suppresses vascular endothelial growth factor-induced angiogenesis in endothelial cells.
Aneurysm
Smoking promotes pathogenesis of aortic aneurysm through the 5-lipoxygenase pathway.
Angina, Unstable
Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.
Angioedema
NSAID-induced urticaria and angioedema: a reappraisal of its clinical management.
Anthrax
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
Aortic Aneurysm
A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine aortic aneurysm model.
Aortic Aneurysm
Is there a role for the macrophage 5-lipoxygenase pathway in aortic aneurysm development in apolipoprotein E-deficient mice?
Aortic Aneurysm
Smoking promotes pathogenesis of aortic aneurysm through the 5-lipoxygenase pathway.
Aortic Aneurysm
The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm.
Aortic Aneurysm, Abdominal
5-Lipoxygenase pathway in experimental abdominal aortic aneurysms.
Aortic Aneurysm, Abdominal
Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice.
Aortic Aneurysm, Abdominal
Increased expression of leukotriene C4 synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysm.
Aortic Aneurysm, Abdominal
The association between the gene encoding 5-lipoxygenase activating protein and abdominal aortic aneurysms.
Aortic Valve Stenosis
Epigenetic regulation of 5-lipoxygenase in the phenotypic plasticity of valvular interstitial cells associated with aortic valve stenosis.
Aortic Valve Stenosis
Role of 5-lipoxygenase pathway in the pathophysiology of the aortic stenosis.
arachidonate 12-lipoxygenase deficiency
Altered arachidonate metabolism by leukocytes and platelets in myeloproliferative disorders.
arachidonate 5-lipoxygenase deficiency
5-Lipoxygenase deficiency impairs innate and adaptive immune responses during fungal infection.
arachidonate 5-lipoxygenase deficiency
5-Lipoxygenase deficiency prevents respiratory failure during ventilator-induced lung injury.
arachidonate 5-lipoxygenase deficiency
5-lipoxygenase deficiency reduces acetaminophen-induced hepatotoxicity and lethality.
arachidonate 5-lipoxygenase deficiency
5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice.
arachidonate 5-lipoxygenase deficiency
Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice.
arachidonate 5-lipoxygenase deficiency
Effects of cocaine in 5-lipoxygenase-deficient mice.
arachidonate 5-lipoxygenase deficiency
Effects of minocycline on cocaine sensitization and phosphorylation of GluR1 receptors in 5-lipoxygenase deficient mice.
arachidonate 5-lipoxygenase deficiency
Effects of MK-886, a 5-lipoxygenase activating protein (FLAP) inhibitor, and 5-lipoxygenase deficiency on the forced swimming behavior of mice.
arachidonate 5-lipoxygenase deficiency
Inhibition of 5-lipoxygenase is associated with downregulation of the leukotriene B4 receptor 1/ Interleukin-12p35 pathway and ameliorates sepsis-induced myocardial injury.
arachidonate 5-lipoxygenase deficiency
Inhibition of 5-lipoxygenase suppresses vascular endothelial growth factor-induced angiogenesis in endothelial cells.
Arteritis
Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis.
Arthritis
5-Lipoxygenase inhibitors attenuate TNF-?-induced inflammation in human synovial fibroblasts.
Arthritis
5-Lipoxygenase-deficient mice infected with Borrelia burgdorferi develop persistent arthritis.
Arthritis
Anti-inflammatory Potential of Alpha-Linolenic Acid Mediated Through Selective COX Inhibition: Computational and Experimental Data.
Arthritis
Computer modeling in predicting the bioactivity of human 5-lipoxygenase inhibitors.
Arthritis
Designing therapeutically effective 5-lipoxygenase inhibitors.
Arthritis
Drug-Mediated Intracellular Donation of Nitric Oxide Potently Inhibits 5-Lipoxygenase: A Possible Key to Future Antileukotriene Therapy.
Arthritis
Fuscoside: an anti-inflammatory marine natural product which selectively inhibits 5-lipoxygenase. Part II: Biochemical studies in the human neutrophil.
Arthritis
Identification of Novel Therapeutic Molecular Targets in Inflammatory Bowel Disease by Using Genetic Databases.
Arthritis
In Vitro Anti-Inflammatory and In Vivo Antiarthritic Activities of Aqueous and Ethanolic Extracts of Dissotis thollonii Cogn. (Melastomataceae) in Rats.
Arthritis
Inhibition by leukotriene inhibitors, and calcium and platelet-activating factor antagonists, of acute gastric and intestinal damage in arthritic rats and in cholinomimetic-treated mice.
Arthritis
Pro-inflammatory enzymes, cyclooxygenase 1, cyclooxygenase 2, and 5-lipooxygenase, inhibited by stabilized rice bran extracts.
Arthritis
Therapeutic effects of standardized Vitex negundo seeds extract on complete Freund's adjuvant induced arthritis in rats.
Arthritis, Experimental
Antiinflammatory 2,6-di-tert-butyl-4-(2-arylethenyl)phenols.
Arthritis, Experimental
Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis.
Arthritis, Experimental
Effects of the second-generation leukotriene B(4) receptor antagonist, LY293111Na, on leukocyte infiltration and collagen-induced arthritis in mice.
Arthritis, Experimental
Inhibitory effects of the root extract of Litsea cubeba (Lour.) Pers. on adjuvant arthritis in rats.
Arthritis, Gouty
Frontline Science: Reprogramming COX-2, 5-LOX, and CYP4A-mediated arachidonic acid metabolism in macrophages by salidroside alleviates gouty arthritis.
Arthritis, Gouty
Metabolic profiling of human plasma reveals the activation of 5-lipoxygenase in the acute attack of gouty arthritis.
Arthritis, Rheumatoid
5-Lipoxygenase inhibitors attenuate TNF-?-induced inflammation in human synovial fibroblasts.
Arthritis, Rheumatoid
A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Arthritis, Rheumatoid
Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate.
Arthritis, Rheumatoid
Altered formation of leukotriene B4 in vitro by synovial fluid neutrophils in rheumatoid arthritis.
Arthritis, Rheumatoid
Differential synthesis of 5-lipoxygenase in peripheral blood and synovial fluid neutrophils in rheumatoid arthritis.
Arthritis, Rheumatoid
Effect of 5-lipoxygenase inhibition on events associated with inflammatory bowel disease in rats.
Arthritis, Rheumatoid
Enhanced capacity for release of leucotriene B4 by neutrophils in rheumatoid arthritis.
Arthritis, Rheumatoid
Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids.
Arthritis, Rheumatoid
Inhibition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells.
Arthritis, Rheumatoid
Mechanistic insights into 5-lipoxygenase inhibition by pyocyanin: a molecular docking and molecular dynamics study.
Arthritis, Rheumatoid
Non steroidal anti-inflammatory and anti-allergy agents.
Arthritis, Rheumatoid
Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Proinflammatory lipoxygenase products from peripheral mononuclear cells in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Synthesis and Biological Evaluation of N-Aryl-4-Aryl-1,3-Thiazole-2-Amine Derivatives as direct 5-Lipoxygenase Inhibitors.
Arthritis, Rheumatoid
Synthesis and Biological Evaluation of N-Aryl-5-aryloxazol-2-amine Derivatives as 5-Lipoxygenase Inhibitors.
Arthritis, Rheumatoid
The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Therapeutic effects of standardized Vitex negundo seeds extract on complete Freund's adjuvant induced arthritis in rats.
Arthritis, Rheumatoid
Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
Arthritis, Rheumatoid
[Leukotrienes. A review of the significance for disease in man and the possibilities for therapeutic intervention]
Aspergillosis
12/15-Lipoxygenase Deficiency Impairs Neutrophil Granulopoiesis and Lung Proinflammatory Responses to Aspergillus fumigatus.
Asthma
2,3-Dihydro-5-benzofuranols as antioxidant-based inhibitors of leukotriene biosynthesis.
Asthma
2-ABT-S-oxide detoxification by glutathione S-transferases A1-1, M1-1 and P1-1: implications for toxicity associated with zileuton.
Asthma
5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.
Asthma
5-Lipoxygenase pathway gene polymorphisms: lack of association with asthma in a Spanish population.
Asthma
5-Lipoxygenase Pathway, Dendritic Cells, and Adaptive Immunity.
Asthma
5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci.
Asthma
5-Lipoxygenase-deficient mice infected with Borrelia burgdorferi develop persistent arthritis.
Asthma
A Cell-based Assay for Screening Lipoxygenase Inhibitors.
Asthma
A new 5-lipoxygenase inhibitor seems to be safe and effective for the treatment of osteoarthritis.
Asthma
A novel polymorphism, E254K, in the 5-lipoxygenase gene associated with bronchial asthma.
Asthma
A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Asthma
A turn on and a turn off: BLT1 and BLT2 mechanisms in the lung.
Asthma
ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents.
Asthma
Activity of a novel hydroquinone inhibitor of leukotriene synthesis (U-66,858) in the rhesus monkey Ascaris reactor.
Asthma
Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.
Asthma
Allergen-stimulated leukotriene B4 and interleukin-8 levels in patients with asthma and allergic rhinitis-modulation by a lipid pathway inhibitor.
Asthma
ALOX5 polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma.
Asthma
An ex vivo model of severe asthma using reconstituted human bronchial epithelium.
Asthma
Analysis of proximal ALOX5 promoter binding proteins by quantitative proteomics.
Asthma
Arachidonate 5-lipoxygenase metabolism in human neutrophils from patients with asthma: in vitro effect of nedocromil sodium.
Asthma
Arachidonic acid metabolites: mediators of inflammation in asthma.
Asthma
Association of 5-lipoxygenase gene polymorphisms with bronchial asthma.
Asthma
Bioguidage search of active compounds from Waltheria indica L. (Malvaceae) used for asthma and inflammation treatment in Burkina Faso.
Asthma
Biosynthesis and actions of 5-oxoeicosatetraenoic acid (5-oxo-ETE) on feline granulocytes.
Asthma
CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.
Asthma
Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
Asthma
Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors
Asthma
Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors.
Asthma
Comprehensive asthma management: guidelines for clinicians.
Asthma
Computer modeling in predicting the bioactivity of human 5-lipoxygenase inhibitors.
Asthma
Cysteinyl Leukotrienes (CysLTs): Role in Obesity-Induced Asthma.
Asthma
Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation.
Asthma
Cysteinyl Leukotrienes Regulate Th2 Cell-Dependent Pulmonary Inflammation.
Asthma
Design, synthesis and identification of novel coumaperine derivatives for inhibition of human 5-LOX: Antioxidant, pseudoperoxidase and docking studies.
Asthma
Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase.
Asthma
Designing therapeutically effective 5-lipoxygenase inhibitors.
Asthma
Development of 3D-QSAR models for 5-lipoxygenase antagonists: chalcones.
Asthma
Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers.
Asthma
Drug-Mediated Intracellular Donation of Nitric Oxide Potently Inhibits 5-Lipoxygenase: A Possible Key to Future Antileukotriene Therapy.
Asthma
Drugs that target lipoxygenases and leukotrienes as emerging therapies for asthma and cancer.
Asthma
Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.
Asthma
Effect of 5-lipoxygenase inhibition on events associated with inflammatory bowel disease in rats.
Asthma
Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.
Asthma
Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air.
Asthma
Effect of AA-861, a selective 5-lipoxygenase inhibitor, on models of allergy in several species.
Asthma
Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects.
Asthma
Effect of physicochemical and formulation variables on the in vivo absorption of ABT-761.
Asthma
Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses.
Asthma
Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma.
Asthma
Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
Asthma
Effect of zileuton on theophylline pharmacokinetics.
Asthma
Effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers.
Asthma
Effects of antirheumatic drugs on leukotriene B4 and prostanoid synthesis in human polymorphonuclear leukocytes in vitro.
Asthma
Effects of glucocorticoids on endogenous and transcellular metabolism of eicosanoids in asthma.
Asthma
Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients.
Asthma
Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study.
Asthma
Eicosanoid mediator expression in mononuclear and polymorphonuclear cells in normal subjects and patients with atopic asthma and cystic fibrosis.
Asthma
Endogenous metabolites of vitamin E limit inflammation by targeting 5-lipoxygenase.
Asthma
Endogenous S-nitrosoglutathione modifies 5-lipoxygenase expression in airway epithelial cells.
Asthma
Experimental treatments for asthma.
Asthma
Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma.
Asthma
Expression of COX-1, COX-2, 5-LOX and
CysLT
2
in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease.
Asthma
From Molecular Docking to 3D-Quantitative Structure-Activity Relationships (3D-QSAR): Insights into the Binding Mode of 5-Lipoxygenase Inhibitors.
Asthma
Functional characterization of human cysteinyl leukotriene 1 receptor gene structure.
Asthma
Functional variants of the human 5-lipoxygenase gene and their genetic diagnosis.
Asthma
Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice.
Asthma
Genetics and pharmacogenetics of the leukotriene pathway.
Asthma
GM-CSF- and M-CSF-primed macrophages present similar resolving but distinct inflammatory lipid mediator signatures.
Asthma
Guinea pig whole blood 5-lipoxygenase assay: utility in the assessment of potential 5-lipoxygenase inhibitors.
Asthma
Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma.
Asthma
In situ amplification of 5-lipoxygenase and 5-lipoxygenase-activating protein in allergic airway inflammation and inhibition by leukotriene blockade.
Asthma
In vitro allergen challenge of peripheral blood induces differential gene expression in mononuclear cells of asthmatic patients: inhibition of cytosolic phospholipase A2alpha overcomes the asthma-associated response.
Asthma
Increased activity of 5-lipoxygenase in polymorphonuclear leukocytes from asthmatic patients.
Asthma
Increased excretion of leukotriene E4 during aspirin-induced asthma.
Asthma
Inhibition of 5-lipoxygenase as anti-inflammatory mode of action of Plectranthus zeylanicus Benth and chemical characterization of ingredients by a mass spectrometric approach.
Asthma
Inhibition of 5-lipoxygenase suppresses vascular endothelial growth factor-induced angiogenesis in endothelial cells.
Asthma
Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells.
Asthma
Inhibition of leukotriene C4 and B4 generation by human eosinophils and neutrophils with the lipoxygenase pathway inhibitors U60257 and BW755C.
Asthma
L-656,224 (7-chloro-2-[(4-methoxyphenyl)methyl]-3- methyl-5-propyl-4-benzofuranol): a novel, selective, orally active 5-lipoxygenase inhibitor.
Asthma
Lack of cytochrome P450 1A2 interaction effect of ABT-761 on the pharmacokinetics of theophylline.
Asthma
Leukotriene and prostanoid pathway enzymes in bronchial biopsies of seasonal allergic asthmatics.
Asthma
Leukotriene inhibitors and antagonists in asthma.
Asthma
Leukotriene inhibitors and non-steroidal therapies in the treatment of asthma.
Asthma
Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease.
Asthma
Leukotriene-receptor antagonists and 5-lipoxygenase inhibitors in asthma.
Asthma
Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase.
Asthma
Leukotrienes in respiratory disease.
Asthma
Leukotrienes in the pathogenesis of asthma.
Asthma
Lipoxygenase inhibitor-provoked acute asthma in a patient with asthma relieved by aspirin.
Asthma
Lipoxygenase inhibitors from natural plant sources. Part 2: medicinal plants with inhibitory activity on arachidonate 12-lipoxygenase, 15-lipoxygenase and leukotriene receptor antagonists.
Asthma
Mechanistic insights into 5-lipoxygenase inhibition by pyocyanin: a molecular docking and molecular dynamics study.
Asthma
MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase.
Asthma
Moderating the inflammation of asthma: inhibiting the production or action of products of the 5-lipoxygenase pathway.
Asthma
Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury.
Asthma
New approaches to anti-inflammatory therapy for asthma.
Asthma
New frontiers in asthma therapy: leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Introduction.
Asthma
Non steroidal anti-inflammatory and anti-allergy agents.
Asthma
Novel Cytochrome P450-mediated Ring Opening of the 1,3,4-oxadiazole in Setileuton, a 5-lipoxygenase inhibitor.
Asthma
Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys.
Asthma
Novel polymorphism of the 5-lipoxygenase activating protein (FLAP) promoter gene associated with asthma.
Asthma
Oral vs inhaled asthma therapy. Pros, cons and combinations.
Asthma
Pharmaceutical analysis combined with in-silico therapeutic and toxicological profiling on zileuton and its impurities to assist in modern drug discovery.
Asthma
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.
Asthma
Pharmacogenetics of the 5-lipoxygenase pathway in asthma.
Asthma
Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma.
Asthma
Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma.
Asthma
Pharmacologically active natural products in the defence secretion of Palembus ocularis (Tenebrionidae, Coleoptera).
Asthma
Pharmacology of 4-(3-(4-(1-methyl-1H-pyrazol-5-yl) phenylthio) phenyl)-tetrahydro-2H-pyran-4-carboxamide (PF-4191834), a Novel Selective, non-redox, 5-Lipoxygenase Inhibitor Effective in Inflammation and Pain.
Asthma
Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma.
Asthma
Pharmacophore modeling and virtual screening for designing potential 5-Lipoxygenase inhibitors.
Asthma
Platelet-activating factor antagonists: current status in asthma.
Asthma
Platelet-activating factor increases leukotriene B4 release in stimulated alveolar macrophages from asthmatic patients.
Asthma
Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness.
Asthma
Polymorphisms in candidate asthma genes.
Asthma
Polymorphisms in the 5-lipoxygenase activating protein (ALOX5AP) gene are not associated with asthma in an Australian population.
Asthma
Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005.
Asthma
Predictive genetic testing -- new possibilities in determination of risk of complex diseases.
Asthma
Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population.
Asthma
Quantitative analysis of 5-oxo-6,8,11,14-eicosatetraenoic acid by electrospray mass spectrometry using a deuterium-labeled internal standard.
Asthma
Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma.
Asthma
Recurrent panniculitis in a man with asthma receiving treatment with leukotriene-modifying agents.
Asthma
Reversed changes of lipoxin A4 and leukotrienes in children with asthma in different severity degree.
Asthma
Role of leukotrienes in asthma.
Asthma
Roles of 5-lipoxygenase and cysteinyl-leukotriene type 1 receptors in the hematological response to allergen challenge and its prevention by diethylcarbamazine in a murine model of asthma.
Asthma
Simulation Study of Interactions Between Two Bioactive Components from Zingiber cassumunar and 5-Lipoxygenase.
Asthma
Structure and Ligand Based Drug Design Strategies in the Development of Novel 5- LOX Inhibitors.
Asthma
Studies on hindered phenols and analogues. 2. 1,3-Benzoxathioles having SRS-A inhibiting activity.
Asthma
Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma.
Asthma
Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
Asthma
Synthesis and Biological Evaluation of N-Aryl-4-Aryl-1,3-Thiazole-2-Amine Derivatives as direct 5-Lipoxygenase Inhibitors.
Asthma
Synthesis and Biological Evaluation of N-Aryl-5-aryloxazol-2-amine Derivatives as 5-Lipoxygenase Inhibitors.
Asthma
Synthesis and evaluation of 5-lipoxygenase translocation inhibitors from acylnitroso hetero-Diels-Alder cycloadducts.
Asthma
Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors.
Asthma
Synthesis, stereochemical assignments, and biological activities of homoisoflavonoids.
Asthma
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma.
Asthma
Targeting leukotriene B4 in inflammation.
Asthma
The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep.
Asthma
The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages.
Asthma
The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease.
Asthma
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
Asthma
The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo.
Asthma
The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma.
Asthma
The effects of a 5-lipoxygenase inhibitor on antigen-induced mediator release, late-phase bronchoconstriction and cellular infiltrates in primates.
Asthma
The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air.
Asthma
The effects of ML 3000 on antigen-induced responses in sheep.
Asthma
The effects of oral Cardax (disodium disuccinate astaxanthin) on multiple independent oxidative stress markers in a mouse peritoneal inflammation model: influence on 5-lipoxygenase in vitro and in vivo.
Asthma
The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma.
Asthma
The N-terminal "beta-barrel" domain of 5-lipoxygenase is essential for nuclear membrane translocation.
Asthma
The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).
Asthma
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
Asthma
The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report.
Asthma
The role of 5-lipoxygenase products in preclinical models of asthma.
Asthma
The role of lipoxygenases in pathophysiology; new insights and future perspectives.
Asthma
The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma.
Asthma
Therapeutic advances: leukotriene antagonists for the treatment of asthma.
Asthma
Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase pathway.
Asthma
Untangling the web of 5-lipoxygenase-derived products from a molecular and structural perspective: The battle between pro- and anti-inflammatory lipid mediators.
Asthma
Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregation in patients with asthma.
Asthma
Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma.
Asthma
[5-lipoxygenase inhibitors in asthma therapy]
Asthma
[Current opinions about asthma: genetic factors]
Asthma
[New developments in asthma therapy: how do individual leukotriene antagonists work?]
Asthma
[Reversed changes of the 15-lipoxygenase product lipoxin A? and the 5-lipoxygenase product leukotriene C? in children with asthma].
Asthma
[The significance of leukotrienes in pathophysiology of bronchial asthma--therapy perspectives]
Asthma
[The use of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in bronchial asthma treatment]
Asthma, Aspirin-Induced
Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma.
Asthma, Aspirin-Induced
Effects of pranlukast on aspirin-induced bronchoconstriction: differences in chemical mediators between aspirin-intolerant and tolerant asthmatic patients.
Asthma, Aspirin-Induced
Over-expression of the LTC(4) synthase gene in mice reproduces human aspirin-induced asthma.
Asthma, Exercise-Induced
Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma.
Asthma, Exercise-Induced
Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor.
Astrocytoma
Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma.
Astrocytoma
Increased expression of 5-lipoxygenase in high-grade astrocytomas.
Atherosclerosis
4-Hydroxynonenal enhances CD36 expression on murine macrophages via p38 MAPK-mediated activation of 5-lipoxygenase.
Atherosclerosis
5-lipoxygenase and atherosclerosis.
Atherosclerosis
5-lipoxygenase as a possible biological link between depressive symptoms and atherosclerosis.
Atherosclerosis
5-Lipoxygenase as a putative link between cardiovascular and psychiatric disorders.
Atherosclerosis
5-Lipoxygenase Gene Variants Are Not Associated With Atherosclerosis or Incident Coronary Heart Disease in the Multi-Ethnic Study of Atherosclerosis Cohort.
Atherosclerosis
5-Lipoxygenase plays a pivotal role in endothelial adhesion of monocytes via an increased expression of Mac-1.
Atherosclerosis
5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation.
Atherosclerosis
5-lipoxygenase: regulation and possible involvement in atherosclerosis.
Atherosclerosis
A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Atherosclerosis
Anti-atherogenic effect of BHB-TZD having inhibitory activities on cyclooxygenase and 5-lipoxygenase in hyperlipidemic mice.
Atherosclerosis
Anti-atherosclerotic molecules targeting oxidative stress and inflammation.
Atherosclerosis
Arachidonate 5-lipoxygenase (5-LO) promoter genotype and risk of myocardial infarction: a case-control study.
Atherosclerosis
Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis.
Atherosclerosis
Arachidonate 5-lipoxygenase variants in atherosclerosis, obesity, and bone traits.
Atherosclerosis
Association between 5-lipoxygenase expression and plaque instability in humans.
Atherosclerosis
Association of ALOX5AP haplotypes with susceptibility to coronary artery disease in a Chinese Han population.
Atherosclerosis
Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
Atherosclerosis
Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway.
Atherosclerosis
Biologic relevance of lipoxygenase isoforms in atherogenesis.
Atherosclerosis
Complex inheritance of the 5-lipoxygenase locus influencing atherosclerosis in mice.
Atherosclerosis
Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis.
Atherosclerosis
Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome.
Atherosclerosis
Design and synthesis of novel 2-amino-5-hydroxyindole derivatives that inhibit human 5-lipoxygenase.
Atherosclerosis
Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice.
Atherosclerosis
Drug-Mediated Intracellular Donation of Nitric Oxide Potently Inhibits 5-Lipoxygenase: A Possible Key to Future Antileukotriene Therapy.
Atherosclerosis
Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice.
Atherosclerosis
Effects of MK-886, a 5-lipoxygenase activating protein (FLAP) inhibitor, and 5-lipoxygenase deficiency on the forced swimming behavior of mice.
Atherosclerosis
Eicosanoids and Docosanoids in Plasma and Aorta of Healthy and Atherosclerotic Rabbits.
Atherosclerosis
Endothelium-dependent vascular responses induced by leukotriene B4.
Atherosclerosis
Evidence for Activation of Inflammatory Lipoxygenase Pathways in Visceral Adipose Tissue of Obese Zucker Rats.
Atherosclerosis
Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis.
Atherosclerosis
Expanding expression of the 5-lipoxygenase/leukotriene B(4) pathway in atherosclerotic lesions of diabetic patients promotes plaque instability.
Atherosclerosis
Functional characterization of human cysteinyl leukotriene 1 receptor gene structure.
Atherosclerosis
Functional variants of the human 5-lipoxygenase gene and their genetic diagnosis.
Atherosclerosis
GC-rich sequences in the 5-lipoxygenase gene promoter are required for expression in Mono Mac 6 cells, characterization of a novel Sp1 binding site.
Atherosclerosis
Human lipoxygenase pathway gene variation and association with markers of subclinical atherosclerosis in the diabetes heart study.
Atherosclerosis
Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice.
Atherosclerosis
Identification of ALOX5 as a gene regulating adiposity and pancreatic function.
Atherosclerosis
Inhibition of 5-lipoxygenase as anti-inflammatory mode of action of Plectranthus zeylanicus Benth and chemical characterization of ingredients by a mass spectrometric approach.
Atherosclerosis
Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells.
Atherosclerosis
Inhibitors of the 5-lipoxygenase pathway in atherosclerosis.
Atherosclerosis
Iron-Dependent Trafficking of 5-Lipoxygenase and Impact on Human Macrophage Activation.
Atherosclerosis
Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes.
Atherosclerosis
Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.
Atherosclerosis
Lipid metabolism: 5-lipoxygenase, 12/15-lipoxygenase, and atherogenesis.
Atherosclerosis
LPS Increases 5-LO Expression on Monocytes via an Activation of Akt-Sp1/NF-?B Pathways.
Atherosclerosis
New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease.
Atherosclerosis
Novel Cytochrome P450-mediated Ring Opening of the 1,3,4-oxadiazole in Setileuton, a 5-lipoxygenase inhibitor.
Atherosclerosis
Nutrigenetic association of the 5-lipoxygenase gene with myocardial infarction.
Atherosclerosis
Platelet-induced growth of human fibroblasts is associated with an increased expression of 5-lipoxygenase.
Atherosclerosis
Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics.
Atherosclerosis
Promoter methylation and functional variants in arachidonate 5-lipoxygenase and forkhead box protein O1 genes associated with coronary artery disease.
Atherosclerosis
Response to arachidonate 5-lipoxygenase variants in atherosclerosis, obesity, and bone traits.
Atherosclerosis
Role of inflammatory responses in initiation of atherosclerosis: effects of anti-inflammatory drugs on cuff-induced leukocyte accumulation and intimal thickening of rabbit carotid artery.
Atherosclerosis
Selective inhibition of leukotriene receptor BLT-2 reduces vascular oxidative stress and improves endothelial function in ApoE-/- mice.
Atherosclerosis
Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
Atherosclerosis
The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis.
Atherosclerosis
The current view on the role of leukotrienes in atherogenesis.
Atherosclerosis
The effects of oral Cardax (disodium disuccinate astaxanthin) on multiple independent oxidative stress markers in a mouse peritoneal inflammation model: influence on 5-lipoxygenase in vitro and in vivo.
Atherosclerosis
The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field.
Atherosclerosis
The potential role of antileukotriene drugs in atherosclerosis.
Atherosclerosis
The putative role of leukotrienes in experimental atherogenesis.
Atherosclerosis
[Leukotriene-lipoxygenase pathway and drug discovery]
Autoimmune Diseases
In vivo sex differences in leukotriene biosynthesis in zymosan-induced peritonitis.
Bacterial Infections
Exotoxins from Staphylococcus aureus activate 5-lipoxygenase and induce leukotriene biosynthesis.
Blister
Increased levels of immunoreactive leukotriene B4 in blister fluids of bullous pemphigoid patients and effects of a selective 5-lipoxygenase inhibitor on experimental skin lesions.
Bone Resorption
Amino derivatives of phenyl alkyl thiophene as inhibitors of bone resorption. Structure-activity relationship.
Bone Resorption
Avian osteoclast cells are stimulated to resorb calcified matrices by and possess receptors for leukotriene B4.
Bone Resorption
Cytokines and growth factors in the regulation of bone remodeling.
Bone Resorption
Effects of 5-lipoxygenase gene disruption on inflammation, osteoclastogenesis and bone resorption in polymicrobial apical periodontitis.
Bone Resorption
Inhibition of 5-Lipoxygenase (5-Lo) Attenuates Inflammation and Bone Resorption in Lipopolysaccharide (Lps)-Induced Periodontal Disease.
Bone Resorption
Inhibition of 5-lipoxygenase attenuates inflammation and BONE resorption in lipopolysaccharide-induced periodontal disease.
Bone Resorption
Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo.
Bone Resorption
LTB4 can directly stimulate human osteoclast formation from PBMC independent of RANKL.
Bone Resorption
Staphylococcus epidermidis produces a cell-associated proteinaceous fraction which causes bone resorption by a prostanoid-independent mechanism: relevance to the treatment of infected orthopaedic implants.
Bone Resorption
The 5-lipoxygenase inhibitor BWA4C impairs osteoclastic resorption in a synchronized model of bone remodeling.
Brain Diseases
5-Lipoxygenase as an emerging target against age-related brain disorders.
Brain Diseases
Antidepressant-like effect of zileuton is accompanied by hippocampal neuroinflammation reduction and CREB/BDNF upregulation in lipopolysaccharide-challenged mice.
Brain Diseases
Exploring the molecular approach of COX and LOX in Alzheimer's and Parkinson's disorder.
Brain Edema
Cerebral edema induced by arachidonic acid: role of leukocytes and 5-lipoxygenase products.
Brain Edema
Protective effect of the 5-lipoxygenase inhibitor AA-861 on cerebral edema after transient ischemia.
Brain Edema
Role of leukocytes and 5-lipoxygenase products in induction of cerebral edema.
Brain Infarction
Inhibition of NF-kappaB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia.
Brain Injuries
A dual inhibitor of cyclooxygenase and 5-lipoxygenase protects against kainic acid-induced brain injury.
Brain Injuries
Cysteinyl Leukotrienes and Their Receptors: Emerging Therapeutic Targets in Central Nervous System Disorders.
Brain Injuries
Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma.
Brain Injuries
Integrating Network Pharmacology and Experimental Models to Investigate the Mechanism of Huanglian Jiedu Decoction on Inflammatory Injury Induced by Cerebral Ischemia.
Brain Injuries
Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats.
Brain Injuries
Minocycline inhibits 5-lipoxygenase expression and accelerates functional recovery in chronic phase of focal cerebral ischemia in rats.
Brain Injuries
Phosphorylation of 5-LOX: The Potential Set-point of Inflammation.
Brain Injuries
Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats.
Brain Injuries
Transforming growth factor ? 1-induced astrocyte migration is mediated in part by activating 5-lipoxygenase and cysteinyl leukotriene receptor 1.
Brain Injuries, Traumatic
Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma.
Brain Injuries, Traumatic
Impact of 5-lipoxygenase inhibitors on the spatiotemporal distribution of inflammatory cells and neuronal COX-2 expression following experimental traumatic brain injury in rats.
Brain Ischemia
5-Lipoxygenase as an emerging target against age-related brain disorders.
Brain Ischemia
5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9.
Brain Ischemia
5-Lipoxygenase Inhibitor Zileuton Inhibits Neuronal Apoptosis Following Focal Cerebral Ischemia.
Brain Ischemia
A comparative study on the expression of cyclooxygenase and 5-lipoxygenase during cerebral ischemia in humans.
Brain Ischemia
Activation of CysLT receptors induces astrocyte proliferation and death after oxygen-glucose deprivation.
Brain Ischemia
Caffeic acid ameliorates early and delayed brain injuries after focal cerebral ischemia in rats.
Brain Ischemia
Cerebral ischemia in 5-lipoxygenase knockout mice.
Brain Ischemia
Cysteinyl Leukotrienes and Their Receptors: Emerging Therapeutic Targets in Central Nervous System Disorders.
Brain Ischemia
Inhibition of NF-kappaB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia.
Brain Ischemia
MicroRNA-193b-3p alleviates focal cerebral ischemia and reperfusion-induced injury in rats by inhibiting 5-lipoxygenase expression.
Brain Ischemia
Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats.
Brain Ischemia
Minocycline inhibits 5-lipoxygenase expression and accelerates functional recovery in chronic phase of focal cerebral ischemia in rats.
Brain Ischemia
Protection from hypoxic and N-methyl-D-aspartate injury with azelastine, a leukotriene inhibitor.
Brain Ischemia
Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats.
Brain Ischemia
The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia.
Brain Ischemia
The protective effect of caffeic acid on global cerebral ischemia-reperfusion injury in rats.
Brain Ischemia
Zileuton Reduces Inflammatory Reaction and Brain Damage Following Permanent Cerebral Ischemia in Rats.
Brain Ischemia
[Expression of 5-lipoxygenase in hippocampal CA1 neuronal damage following global cerebral ischemia in rats].
Brain Ischemia
[Nordihydroguaiaretic acid partially inhibits inflammatory responses after focal cerebral ischemia in rats.]
Brain Neoplasms
A Hydroquinone-Based Derivative Elicits Apoptosis and Autophagy via Activating a ROS-Dependent Unfolded Protein Response in Human Glioblastoma.
Brain Neoplasms
Cytoplasmic 5-Lipoxygenase Staining Is a Highly Sensitive Marker of Human Tumors of the Choroid Plexus.
Brain Neoplasms
Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family.
Brain Neoplasms
The effect of 5-lipoxygenase inhibition on blood-brain barrier permeability in experimental brain tumors.
Breast Neoplasms
5-lipoxygenase and 5-lipoxygenase-activating protein gene polymorphisms, dietary linoleic Acid, and risk for breast cancer.
Breast Neoplasms
Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer.
Breast Neoplasms
Attenuation of breast tumor cell growth by conjugated linoleic acid via inhibition of 5-lipoxygenase activating protein.
Breast Neoplasms
Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway.
Breast Neoplasms
Cancer-Produced Metabolites of 5-Lipoxygenase Induce Tumor-Evoked Regulatory B Cells via Peroxisome Proliferator-Activated Receptor ?.
Breast Neoplasms
Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer.
Breast Neoplasms
Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions.
Breast Neoplasms
Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer.
Breast Neoplasms
Influence of 5-lipoxygenase on in vitro growth of human mammary carcinoma cell line MCF-7.
Breast Neoplasms
Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition.
Breast Neoplasms
Serum 5-LOX: a progressive protein marker for breast cancer and new approach for therapeutic target.
Breast Neoplasms
Tepoxalin increases chemotherapy efficacy in drug-resistant breast cancer cells overexpressing the multidrug transporter gene ABCB1.
Breast Neoplasms
The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells.
Bronchial Spasm
Effect of a novel 5-lipoxygenase inhibitor, E6080 on bronchospasm, airway cellular infiltration and leukotriene production in guinea pigs.
Bronchial Spasm
Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma.
Bronchial Spasm
Generation of leukotrienes in guinea-pigs in vivo during antigen-induced bronchospasm.
Bronchial Spasm
Guinea pig whole blood 5-lipoxygenase assay: utility in the assessment of potential 5-lipoxygenase inhibitors.
Bronchial Spasm
Substituted arylmethyl phenyl ethers. 1. A novel series of 5-lipoxygenase inhibitors and leukotriene antagonists.
Bronchial Spasm
Synthesis of [[(naphthalenylmethoxy)- and [[(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters. A novel series of leukotriene D4 antagonists and 5-lipoxygenase inhibitors.
Bronchial Spasm
The effect of leukotriene antagonists, lipoxygenase inhibitors and selected standards on leukotriene-mediated allergic bronchospasm in guinea pigs.
Bronchial Spasm
[5-lipoxygenase inhibitors in asthma therapy]
Bronchiectasis
The detection of 5-lipoxygenase and cyclo-oxygenase products in sputum of patients with chronic bronchitis and bronchiectasis.
Bronchitis
Frankincense--therapeutic properties.
Bronchitis, Chronic
15(S)-HETE modulates LTB(4) production and neutrophil chemotaxis in chronic bronchitis.
Bronchitis, Chronic
The detection of 5-lipoxygenase and cyclo-oxygenase products in sputum of patients with chronic bronchitis and bronchiectasis.
Bronchopneumonia
5-lipoxygenase and cyclooxygenase-2 in porcine parasitic bronchopneumonia: immunohistochemical and biochemical investigations.
Burkitt Lymphoma
B-lymphocytic cell line Raji expresses the leukotriene A4 hydrolase gene but not the 5-lipoxygenase gene.
Capillary Leak Syndrome
Production of 5-lipoxygenase pathway metabolites by peripheral leucocytes in capillary leak syndrome (Clarkson disease).
Carcinogenesis
15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth.
Carcinogenesis
5-lipoxygenase and 5-lipoxygenase-activating protein gene polymorphisms, dietary linoleic Acid, and risk for breast cancer.
Carcinogenesis
5-lipoxygenase pathway promotes cell proliferation in human glioma cell lines.
Carcinogenesis
5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis.
Carcinogenesis
Antitumor Activities of Ethyl Acetate Extracts from Selaginella doederleinii Hieron In Vitro and In Vivo and Its Possible Mechanism.
Carcinogenesis
Attenuation of breast tumor cell growth by conjugated linoleic acid via inhibition of 5-lipoxygenase activating protein.
Carcinogenesis
Chebulagic acid, a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO-205 cell line.
Carcinogenesis
Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch carcinogenesis by a 5-lipoxygenase inhibitor, garcinol.
Carcinogenesis
Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis.
Carcinogenesis
Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking.
Carcinogenesis
Correlative study of microvessel density and 5-lipoxygenase expression in human sporadic colorectal cancer.
Carcinogenesis
Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway.
Carcinogenesis
Cysteinyl Leukotriene Receptor Antagonists Inhibit Migration, Invasion, and Expression of MMP-2/9 in Human Glioblastoma.
Carcinogenesis
Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
Carcinogenesis
Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Carcinogenesis
Ethanol promotes chemically induced oral cancer in mice through activation of the 5-lipoxygenase pathway of arachidonic acid metabolism.
Carcinogenesis
Five-lipoxygenase pathway of arachidonic acid metabolism in carcino-genesis and cancer chemoprevention.
Carcinogenesis
Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer.
Carcinogenesis
Identification of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol.
Carcinogenesis
Increased expression of 5-lipoxygenase in high-grade astrocytomas.
Carcinogenesis
Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma.
Carcinogenesis
Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents.
Carcinogenesis
Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors.
Carcinogenesis
Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.
Carcinogenesis
Lipoxygenase metabolism: roles in tumor progression and survival.
Carcinogenesis
Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice.
Carcinogenesis
MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation.
Carcinogenesis
Modulation by Licofelone and Celecoxib of Experimentally Induced Cancer and Preneoplastic Lesions in Mice Exposed to Cigarette Smoke.
Carcinogenesis
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Carcinogenesis
Overexpression of 5-lipoxygenase and its relation with cell proliferation and angiogenesis in 7,12-dimethylbenz(?)anthracene-induced rat mammary carcinogenesis.
Carcinogenesis
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Carcinogenesis
Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis.
Carcinogenesis
Regulation of the eicosanoid pathway by tumour necrosis factor alpha and leukotriene D4 in intestinal epithelial cells.
Carcinogenesis
Role of 5-lipoxygenase in resveratrol mediated suppression of 7,12-dimethylbenz(?)anthracene-induced mammary carcinogenesis in rats.
Carcinogenesis
Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines.
Carcinogenesis
The Co-regulatory Role of 5-Lipoxygenase and Cyclooxygenase-2 in the Carcinogenesis and their Promotion by Cigarette Smoking in Colons.
Carcinogenesis
The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis.
Carcinogenesis
The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.
Carcinogenesis
The long-term effect of Helicobacter pylori eradication on COX-1/2, 5-LOX and leukotriene receptors in patients with a risk gastritis phenotype--a link to gastric carcinogenesis.
Carcinogenesis
Time-selective chemoprevention of vitamin E and selenium on esophageal carcinogenesis in rats: The possible role of nuclear factor kappaB signaling pathway.
Carcinogenesis
Zileuton, a 5-Lipoxygenase Inhibitor, Exerts Anti-Angiogenic Effect by Inducing Apoptosis of HUVEC via BK Channel Activation.
Carcinogenesis
Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model.
Carcinogenesis
[Protein expression of 5-lipoxygenase and activation and cytotoxicity of benzidine in human bronchial epithelial cells.]
Carcinoma
15-Lipoxygenase-2 is differentially expressed in normal and neoplastic ovary.
Carcinoma
5-lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats.
Carcinoma
5-Lipoxygenase expression in benign and malignant canine prostate tissues.
Carcinoma
5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
Carcinoma
5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells.
Carcinoma
Association between 5-lipoxygenase expression, and malignant behaviors and poor prognosis in esophageal squamous cell carcinoma.
Carcinoma
Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas.
Carcinoma
Dual inhibition of 5-LOX and COX-2 suppresses esophageal squamous cell carcinoma.
Carcinoma
Fatty acid oxidation and signaling in apoptosis.
Carcinoma
Identification of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol.
Carcinoma
Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma.
Carcinoma
Influence of 5-lipoxygenase on in vitro growth of human mammary carcinoma cell line MCF-7.
Carcinoma
Methyl jasmonate induced apoptosis in human prostate carcinoma cells via 5-lipoxygenase dependent pathway.
Carcinoma
Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals.
Carcinoma
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.
Carcinoma
Wedelolactone induces growth of breast cancer cells by stimulation of estrogen receptor signalling.
Carcinoma in Situ
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Carcinoma, Hepatocellular
5-Lipoxygenase contributes to the progression of hepatocellular carcinoma.
Carcinoma, Hepatocellular
A mutant of HBx (HBxDelta127) promotes hepatoma cell growth via sterol regulatory element binding protein 1c involving 5-lipoxygenase.
Carcinoma, Hepatocellular
A mutant of hepatitis B virus X protein (HBx Delta 127) enhances hepatoma cell migration via osteopontin involving 5-lipoxygenase.
Carcinoma, Hepatocellular
Lipid metabolism enzyme 5-LOX and its metabolite LTB4 are capable of activating transcription factor NF-?B in hepatoma cells.
Carcinoma, Renal Cell
5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
Carcinoma, Renal Cell
Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
5-lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats.
Carcinoma, Squamous Cell
5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells.
Cardiomyopathies
Inhibition of 5-lipoxygenase is associated with downregulation of the leukotriene B4 receptor 1/ Interleukin-12p35 pathway and ameliorates sepsis-induced myocardial injury.
Cardiovascular Diseases
A Cell-based Assay for Screening Lipoxygenase Inhibitors.
Cardiovascular Diseases
ALOX5 gene variants affect eicosanoid production and response to fish oil supplementation.
Cardiovascular Diseases
ALOX5AP expression, but not gene haplotypes, is associated with obesity and insulin resistance.
Cardiovascular Diseases
Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice.
Cardiovascular Diseases
Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy african americans.
Cardiovascular Diseases
Common Polymorphisms in the 5-Lipoxygenase Pathway and Risk of Incident Myocardial Infarction: A Danish Case-Cohort Study.
Cardiovascular Diseases
Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein.
Cardiovascular Diseases
Depression, inflammation, and cardiovascular disease: is 5-lipoxygenase the missing link?
Cardiovascular Diseases
Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Cardiovascular Diseases
Functional Analysis of 5-Lipoxygenase Promoter Repeat Variants.
Cardiovascular Diseases
Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice.
Cardiovascular Diseases
Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: a replication study in two independent populations.
Cardiovascular Diseases
Grape seed and red wine polyphenol extracts inhibit cellular cholesterol uptake, cell proliferation, and 5-lipoxygenase activity.
Cardiovascular Diseases
Hemolytic and sphingomyelinase activities of Clostridium perfringens alpha-toxin are dependent on a domain homologous to that of an enzyme from the human arachidonic acid pathway.
Cardiovascular Diseases
Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP).
Cardiovascular Diseases
Inhibitors of the 5-lipoxygenase pathway in atherosclerosis.
Cardiovascular Diseases
Metabolism of 5-hydroxy-6,8,11,14-eicosatetraenoic acid by human endothelial cells.
Cardiovascular Diseases
MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation.
Cardiovascular Diseases
Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury.
Cardiovascular Diseases
Oxidative enzymopathies and vascular disease.
Cardiovascular Diseases
Oxidized but not native cardiolipin has pro-inflammatory effects, which are inhibited by Annexin A5.
Cardiovascular Diseases
Polymorphism of SG13S114T/A in the ALOX5AP gene and the risk for stroke in a large Chinese cohort.
Cardiovascular Diseases
Predictive genetic testing -- new possibilities in determination of risk of complex diseases.
Cardiovascular Diseases
Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7.
Cardiovascular Diseases
The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).
Carotid Artery Diseases
Association of Sp1 tandem repeat polymorphism of ALOX5 with coronary artery disease in Indian subjects.
Carotid Artery Diseases
Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis.
Cataract
Lens cholesterol biosynthesis inhibition: A common mechanism of cataract formation in laboratory animals by pharmaceutical products.
Central Nervous System Diseases
5-Lipoxygenase inhibition reduces inflammation and neuronal apoptosis via AKT signaling after subarachnoid hemorrhage in rats.
Central Nervous System Diseases
Cysteinyl Leukotrienes and Their Receptors: Emerging Therapeutic Targets in Central Nervous System Disorders.
Cerebral Infarction
5-LOX Inhibitor Zileuton Reduces Inflammatory Reaction and Ischemic Brain Damage Through the Activation of PI3K/Akt Signaling Pathway.
Cerebrovascular Disorders
PDE4D and ALOX5AP genetic variants and risk for Ischemic Cerebrovascular Disease in Sweden.
Chagas Cardiomyopathy
Simvastatin Attenuates Endothelial Activation through 15-Epi-Lipoxin A4 Production in Murine Chronic Chagas Cardiomyopathy.
Chagas Disease
5-Lipoxygenase is a key determinant of acute myocardial inflammation and mortality during Trypanosoma cruzi infection.
Chagas Disease
5-Lipoxygenase plays a role in the control of parasite burden and contributes to oxidative damage of erythrocytes in murine Chagas' disease.
Chagas Disease
Differences in cNOS/iNOS Activity during Resistance to Trypanosoma cruzi Infection in 5-Lipoxygenase Knockout Mice.
Chagas Disease
Trypanosoma cruzi: Effect of the absence of 5-lipoxygenase (5-LO)-derived leukotrienes on levels of cytokines, nitric oxide and iNOS expression in cardiac tissue in the acute phase of infection in mice.
Cholangiocarcinoma
CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
Cholangiocarcinoma
Oxidative stress-mediated mouse liver lesions caused by Clonorchis sinensis infection.
Cholangiocarcinoma
Prognostic value of eicosanoid pathways in extrahepatic cholangiocarcinoma.
Cholangiocarcinoma
Zileuton suppresses cholangiocarcinoma cell proliferation and migration through inhibition of the Akt signaling pathway.
Chronic Urticaria
Is there a role for antileukotrienes in urticaria?
Chronic Urticaria
Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review.
Coccidiosis
Dietary fish oil or lofrin, a 5-lipoxygenase inhibitor, decrease the growth-suppressing effects of coccidiosis in broiler chicks.
Coinfection
Coupling of recombinant 5-lipoxygenase and leukotriene A4 hydrolase activities and transcellular metabolism of leukotriene A4 in Sf9 insect cells.
Colitis
5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration.
Colitis
5-lipoxygenase modulates the alteration of paracellular barrier function in mice ileum during experimental colitis.
Colitis
Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats.
Colitis
Bioactive indanes: insight into the bioactivity of indane dimers related to the lead anti-inflammatory molecule PH46A.
Colitis
Effect of 5-lipoxygenase inhibition on events associated with inflammatory bowel disease in rats.
Colitis
Effects of cyclooxygenase and lipoxygenase inhibition on eicosanoids and healing of acetic acid colitis in rats.
Colitis
Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats.
Colitis
Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis.
Colitis
Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease.
Colitis
Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis.
Colitis
The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis.
Colitis, Ulcerative
4-Aminosalicylic acid, in contrast to 5-aminosalicylic acid, has no effect on arachidonic acid metabolism in human neutrophils, or on the free radical 1,1-diphenyl-2-picrylhydrazyl.
Colitis, Ulcerative
A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.
Colitis, Ulcerative
Altered leukotriene B4 metabolism in colonic mucosa with inflammatory bowel disease.
Colitis, Ulcerative
Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis.
Colitis, Ulcerative
Colonic expression of leukotriene-pathway enzymes in inflammatory bowel diseases.
Colitis, Ulcerative
Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C.
Colitis, Ulcerative
Effects of ropivacaine on eicosanoid release from human granulocytes and endothelial cells in vitro.
Colitis, Ulcerative
Frankincense--therapeutic properties.
Colitis, Ulcerative
Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis.
Colitis, Ulcerative
Role of nitric oxide-synthase and cyclooxygenase/lipooxygenase systems in development of experimental ulcerative colitis.
Colitis, Ulcerative
Selective 5-lipoxygenase inhibition in ulcerative colitis.
Colitis, Ulcerative
Selective blockade of leukotriene production by a single dose of the FPL 64170XX 0.5% enema in active ulcerative colitis.
Colitis, Ulcerative
Verapamil inhibits in-vitro leucotriene B4 release by rectal mucosa in active ulcerative colitis.
Colonic Neoplasms
A mechanistic study of colon cancer growth promoted by cigarette smoke extract.
Colonic Neoplasms
Altered eicosanoid levels in human colon cancer.
Colonic Neoplasms
Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.
Colonic Neoplasms
Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking.
Colonic Neoplasms
Cyclooxygenase-2 and 5-lipoxygenase pathways in diosgenin-induced apoptosis in HT-29 and HCT-116 colon cancer cells.
Colonic Neoplasms
Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
Colonic Neoplasms
Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro.
Colonic Neoplasms
Genetic deletion of 5-lipoxygenase increases tumor-infiltrating macrophages in Apc(?468) mice.
Colonic Neoplasms
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells.
Colonic Neoplasms
Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice.
Colonic Neoplasms
Mechanisms involved in the cell cycle and apoptosis of HT-29 cells pre-treated with MK-886 prior to photodynamic therapy with hypericin.
Colonic Neoplasms
Modulation of hypericin photodynamic therapy by pretreatment with 12 various inhibitors of arachidonic acid metabolism in colon adenocarcinoma HT-29 cells.
Colonic Neoplasms
Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities.
Colonic Neoplasms
Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells.
Colonic Neoplasms
Overexpression of 5-Lipoxygenase in Colon Polyps and Cancer and the Effect of 5-LOX Inhibitors In vitro and in a Murine Model.
Colonic Neoplasms
Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps.
Colonic Neoplasms
Smoking promotes pathogenesis of aortic aneurysm through the 5-lipoxygenase pathway.
Colonic Neoplasms
The Co-regulatory Role of 5-Lipoxygenase and Cyclooxygenase-2 in the Carcinogenesis and their Promotion by Cigarette Smoking in Colons.
Colonic Neoplasms
The leukotriene receptor CysLT1 and 5-lipoxygenase are upregulated in colon cancer.
Colonic Neoplasms
The modulating role of nuclear factor-kappaB in the action of alpha7-nicotinic acetylcholine receptor and cross-talk between 5-lipoxygenase and cyclooxygenase-2 in colon cancer growth induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone.
Colonic Neoplasms
Vitamin E metabolite 13'-carboxychromanols inhibit pro-inflammatory enzymes, induce apoptosis and autophagy in human cancer cells by modulating sphingolipids and suppress colon tumor development in mice.
Colonic Neoplasms
Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation.
Colorectal Neoplasms
5-Lipoxygenase Antagonist therapy: a new approach towards targeted cancer chemotherapy.
Colorectal Neoplasms
5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage.
Colorectal Neoplasms
Correlative study of microvessel density and 5-lipoxygenase expression in human sporadic colorectal cancer.
Colorectal Neoplasms
Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells.
Colorectal Neoplasms
Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes.
Colorectal Neoplasms
Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro.
Colorectal Neoplasms
Expression of 5-lipoxygenase by human colorectal carcinoma Caco-2 cells during butyrate-induced cell differentiation.
Colorectal Neoplasms
Expression of 5-lipoxygenase in human colorectal cancer.
Colorectal Neoplasms
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells.
Colorectal Neoplasms
Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer.
Colorectal Neoplasms
Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities.
Colorectal Neoplasms
Overexpression of 5-Lipoxygenase in Colon Polyps and Cancer and the Effect of 5-LOX Inhibitors In vitro and in a Murine Model.
Colorectal Neoplasms
Study of the polymorphisms of cyclooxygenase-2 (-765G>C) and 5-lipoxygenase (1708G>A) in patients with colorectal cancer.
Colorectal Neoplasms
TEMPORARY REMOVAL: Inhibition of COX-2 and 5-LOX regulates the progression of colorectal cancer by promoting PTEN and suppressing PI3K/AKT pathway.
Colorectal Neoplasms
The Co-regulatory Role of 5-Lipoxygenase and Cyclooxygenase-2 in the Carcinogenesis and their Promotion by Cigarette Smoking in Colons.
Conjunctivitis, Allergic
5-Lipoxygenase inhibitors and allergic conjunctivitis reactions in the guinea-pig.
Contracture
Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum.
Coronary Artery Disease
A new 5-lipoxygenase inhibitor seems to be safe and effective for the treatment of osteoarthritis.
Coronary Artery Disease
Association of ALOX5AP with ischemic stroke in eastern Chinese.
Coronary Artery Disease
Associations of genetic polymorphisms of arachidonate 5-lipoxygenase-activating protein with risk of coronary artery disease in a European-American population.
Coronary Artery Disease
Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.
Coronary Artery Disease
Promoter methylation and functional variants in arachidonate 5-lipoxygenase and forkhead box protein O1 genes associated with coronary artery disease.
Coronary Disease
5-Lipoxygenase Gene Variants Are Not Associated With Atherosclerosis or Incident Coronary Heart Disease in the Multi-Ethnic Study of Atherosclerosis Cohort.
Coronary Disease
The omega-6/omega-3 fatty acid ratio, genetic variation, and cardiovascular disease.
Coronary Occlusion
Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart.
Coronavirus Infections
Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy.
COVID-19
The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications.
Craniocerebral Trauma
The mixed lipoxygenase/cyclooxygenase inhibitor SK&F 105809 reduces cerebral edema after closed head injury in rat.
Crohn Disease
Regulated spatial distribution of cyclooxygenases and lipoxygenases in Crohn's ulcer.
Cystic Fibrosis
Eicosanoid mediator expression in mononuclear and polymorphonuclear cells in normal subjects and patients with atopic asthma and cystic fibrosis.
Cystic Fibrosis
Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis.
Cystic Fibrosis
Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis.
Cystic Fibrosis
[Eicosanoid metabolism in peripheral blood cells in patients with cystic fibrosis]
Cystitis
Lipoxygenase-5 Expression in Canine Urinary Bladder: Normal Urothelium, Cystitis and Transitional Cell Carcinoma.
Cytomegalovirus Infections
Evidence of human cytomegalovirus infection and expression of 5-lipoxygenase in borderline ovarian tumors.
Cytomegalovirus Infections
Human cytomegalovirus infection induces leukotriene B4 and 5-lipoxygenase expression in human placentae and umbilical vein endothelial cells.
Cytomegalovirus Infections
Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer.
Dehydration
Eosinophil 15-lipoxygenase is a leukotriene A4 synthase.
Demyelinating Diseases
Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damage.
Demyelinating Diseases
Toxic peripheral neuropathy with demyelination in Sprague-Dawley rats given CGS 21595--a 5-lipoxygenase inhibitor.
Dengue
Augmentation of 5-lipoxygenase activity and expression during dengue serotype-2 infection.
Dermatitis
Conjugated linoleic acid attenuates 2,4-dinitrofluorobenzene-induced atopic dermatitis in mice through dual inhibition of COX-2/5-LOX and TLR4/NF-?B signaling.
Dermatitis
Deficiency of n-6 polyunsaturated fatty acids is mainly responsible for atopic dermatitis-like pruritic skin inflammation in special diet-fed hairless mice.
Dermatitis, Atopic
Double-blinded, placebo-controlled, cross-over pilot study on the efficacy of zileuton for canine atopic dermatitis.
Dermatitis, Atopic
Inhibition of Experimental Atopic Dermatitis by Rhubarb (Rhizomes of Rheum tanguticum) and 5-Lipoxygenase Inhibition of its Major Constituent, Emodin.
Dermatitis, Atopic
Involvement of leukotriene B(4) in spontaneous itch-related behaviour in NC mice with atopic dermatitis-like skin lesions.
Dermatitis, Atopic
Leukotrienes in atopic eczema.
Dermatitis, Contact
Involvement of arachidonate-dependent lipid mediators and platelet-activating factor in experimental murine contact dermatitis.
Dermatitis, Contact
Leukotriene B?-leukotriene B? receptor axis promotes oxazolone-induced contact dermatitis by directing skin homing of neutrophils and CD8? T cells.
Dermatitis, Contact
Phytochemical and biological studies of bryophytes.
Dermatomyositis
The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis.
Diabetes Mellitus
Evaluation of the neuroprotective and antidiabetic potential of phenol-rich extracts from virgin olive oils by in vitro assays.
Diabetes Mellitus
Targeted deep resequencing of ALOX5 and ALOX5AP in patients with diabetes and association of rare variants with leukotriene pathways.
Diabetes Mellitus, Type 1
Impaired wound healing in type 1 diabetes is dependent on 5-lipoxygenase products.
Diabetes Mellitus, Type 2
5-Lipoxygenase (ALOX5): Genetic susceptibility to type 2 diabetes and vitamin D effects on monocytes.
Diabetes Mellitus, Type 2
Exploring N1-p-Fluorobenzyl-Cymserine as an Inhibitor of 5-Lipoxygenase as a Candidate for Type 2 Diabetes and Neurodegenerative Disorder Treatment.
Diabetes Mellitus, Type 2
Increased PUFA Content and 5-Lipoxygenase Pathway Expression Are Associated with Subcutaneous Adipose Tissue Inflammation in Obese Women with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Regulation of oxidative stress and inflammation by glycaemic control: evidence for reversible activation of the 5-lipoxygenase pathway in type 1, but not in type 2 diabetes.
Diabetes Mellitus, Type 2
Targeted deep resequencing of ALOX5 and ALOX5AP in patients with diabetes and association of rare variants with leukotriene pathways.
Diabetic Retinopathy
5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy.
Diabetic Retinopathy
Expression of bioactive lysophospholipids and processing enzymes in the vitreous from patients with proliferative diabetic retinopathy.
Dyspnea
Inhibition of allergen-induced bronchoconstriction in hyperreactive rats as a model for testing 5-lipoxygenase inhibitors and leukotriene D4 receptor antagonists.
Dyspnea
L-656,224 (7-chloro-2-[(4-methoxyphenyl)methyl]-3- methyl-5-propyl-4-benzofuranol): a novel, selective, orally active 5-lipoxygenase inhibitor.
Embolic Stroke
Early and Sustained Increases in Leukotriene B4 Levels Are Associated with Poor Clinical Outcome in Ischemic Stroke Patients.
Encephalitis
LTB4 and LTC4 are absent in the cerebrospinal fluid of human immunodeficiency virus type 1-seropositive persons with toxoplasmic encephalitis: evidence for inhibition of 5-lipoxygenase by Toxoplasma gondii.
Encephalitis
Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats.
Encephalitis
Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase.
Encephalitis
SAR-studies of ?-secretase modulators with PPAR?-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer's disease.
Encephalitis
Western blot expression of 5-lipoxygenase in the brain from striped dolphins (stenella coeruleoalba) and bottlenose dolphins (tursiops truncatus) with or without encephalitis/meningo-encephalitis of infectious nature.
Encephalomyelitis
Phenidone, a dual inhibitor of cyclooxygenases and lipoxygenases, ameliorates rat paralysis in experimental autoimmune encephalomyelitis by suppressing its target enzymes.
Encephalomyelitis
Suppression of active but not passive autoimmune encephalomyelitis by dual cyclo-oxygenase and 5-lipoxygenase inhibition.
Encephalomyelitis
Suppression of experimental autoimmune encephalomyelitis by dual cyclo-oxygenase and 5-lipoxygenase inhibition.
Encephalomyelitis
Suppression of experimental autoimmune encephalomyelitis by sulfasalazine.
Encephalomyelitis, Autoimmune, Experimental
Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase.
Encephalomyelitis, Autoimmune, Experimental
Phenidone, a dual inhibitor of cyclooxygenases and lipoxygenases, ameliorates rat paralysis in experimental autoimmune encephalomyelitis by suppressing its target enzymes.
Encephalomyelitis, Autoimmune, Experimental
Suppression of active but not passive autoimmune encephalomyelitis by dual cyclo-oxygenase and 5-lipoxygenase inhibition.
Encephalomyelitis, Autoimmune, Experimental
Suppression of experimental autoimmune encephalomyelitis by dual cyclo-oxygenase and 5-lipoxygenase inhibition.
Encephalomyelitis, Autoimmune, Experimental
Suppression of experimental autoimmune encephalomyelitis by sulfasalazine.
Endometrial Neoplasms
Integrated eicosanoid lipidomics and gene expression reveal decreased prostaglandin catabolism and increased 5-lipoxygenase expression in aggressive subtypes of endometrial cancer.
Endometrial Neoplasms
The Role of Eicosanoids in Gynecological Malignancies.
Endotoxemia
5-lipoxygenase inhibitor (AA-861) attenuates neutrophil-mediated oxidative stress on the venular endothelium in endotoxemia.
Endotoxemia
Attenuation of hypoxic pulmonary vasoconstriction by endotoxemia requires 5-lipoxygenase in mice.
Endotoxemia
Effect of 5-lipoxygenase inhibitor against lipopolysaccharide-induced hypothermia in mice.
Endotoxemia
Effect of a 5-lipoxygenase inhibitor on endotoxin-induced pulmonary dysfunction in awake sheep.
Endotoxemia
Effect of inhibition of 5-lipoxygenase metabolism of arachidonic acid on response to endotoxemia in sheep.
Endotoxemia
Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton.
Endotoxemia
Role of TLR-4 in liver macrophage and endothelial cell responsiveness during acute endotoxemia.
Eosinophilia
5-lipoxygenase- and Glucocorticoid-dependent eosinophilia in a novel surgical model in mice.
Eosinophilia
A 5-lipoxygenase inhibitor, FR110302, suppresses airway hyperresponsiveness and lung eosinophilia induced by Sephadex particles in rats.
Eosinophilia
Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice.
Eosinophilia
Comparison of 5- and 15-lipoxygenase activities in blood and alveolar leukocyte preparations from normal subjects and patients with eosinophilia.
Eosinophilia
Leukotriene enhanced allergic lung inflammation through induction of chemokine production.
Eosinophilia
Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13.
Epilepsy
Cysteinyl Leukotrienes and Their Receptors: Emerging Therapeutic Targets in Central Nervous System Disorders.
Erythema
Double-blinded, placebo-controlled, cross-over pilot study on the efficacy of zileuton for canine atopic dermatitis.
Esophageal Neoplasms
5-Lipoxygenase contributes to the progression of hepatocellular carcinoma.
Esophageal Neoplasms
Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention.
Esophageal Neoplasms
The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Association between 5-lipoxygenase expression, and malignant behaviors and poor prognosis in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Dual inhibition of 5-LOX and COX-2 suppresses esophageal squamous cell carcinoma.
Familial Primary Pulmonary Hypertension
5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
5-Lipoxygenase and human pulmonary artery endothelial cell proliferation.
Fatty Liver
Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice.
Fibrosarcoma
In vitro proliferation of fibrosarcoma cells depends on intact functions of lipoxygenases and cytochrome P-450-monooxygenase.
Gallstones
A novel 5-lipoxygenase inhibitor prevents gallstone formation in a lithogenic prairie dog model.
Gastritis
The long-term effect of Helicobacter pylori eradication on COX-1/2, 5-LOX and leukotriene receptors in patients with a risk gastritis phenotype--a link to gastric carcinogenesis.
Gastrointestinal Neoplasms
Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
Giant Cell Tumors
5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices.
Glioblastoma
Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis.
Glioblastoma
Down-regulation of vinculin upon MK886-induced apoptosis in LN18 glioblastoma cells.
Glioblastoma
Increased expression of 5-lipoxygenase in glioblastoma multiforme.
Glioblastoma
Kukoamine A inhibits human glioblastoma cell growth and migration through apoptosis induction and epithelial-mesenchymal transition attenuation.
Glioblastoma
NMR metabolomics analysis of the effects of 5-lipoxygenase inhibitors on metabolism in glioblastomas.
Glioblastoma
The 1,4 benzoquinone-featured 5-lipoxygenase inhibitor RF-Id induces apoptotic death through downregulation of IAPs in human glioblastoma cells.
Glioma
5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid.
Glioma
5-lipoxygenase pathway promotes cell proliferation in human glioma cell lines.
Glioma
A Hydroquinone-Based Derivative Elicits Apoptosis and Autophagy via Activating a ROS-Dependent Unfolded Protein Response in Human Glioblastoma.
Glioma
An Inhibitor of Arachidonate 5-Lipoxygenase, Nordy, Induces Differentiation and Inhibits Self-Renewal of Glioma Stem-Like Cells.
Glioma
Augmentation of chemotherapy-triggered glioma cell apoptosis by blockade of arachidonic acid metabolism-the potential role of ceramide accumulation.
Glioma
Effects of the 5-lipoxygenase inhibitors AA-863 and U-60,257 on human glioma cell lines.
Glioma
Leukotriene and 5-lipoxygenase inhibitor induced variations in thymidine uptake in a human glioma cell line cultured as monolayers or as multicellular spheroids.
Glioma
Modulation of glioma cell growth and 5-lipoxygenase expression by interferon.
Glomerulonephritis
Arachidonate and renal function.
Glomerulonephritis
Effect of thromboxane A2 inhibition and antagonism on prostaglandin and leukotriene synthesis in glomerular immune injury.
Glomerulonephritis
Expression of 5-lipoxygenase and 5-lipoxygenase activation protein in glomerulonephritis.
Glomerulonephritis
Five-lipoxygenase products in glomerular immune injury.
Glomerulonephritis
Gene expression of 5-lipoxygenase and LTA4 hydrolase in renal tissue of nephrotic syndrome patients.
Glomerulonephritis
Leukotrienes and lipoxins: lipoxygenase-derived modulators of leukocyte recruitment and vascular tone in glomerulonephritis.
Glomerulonephritis
Licofelone inhibits interleukin-18-induced pro-inflammatory cytokine release and cellular proliferation in human mesangial cells.
Glomerulonephritis
Role of leukotrienes and lipoxygenases in glomerular injury.
Glomerulonephritis
Selective inhibition of 5-lipoxygenase attenuates glomerulonephritis in the rat.
Glomerulonephritis, IGA
Expression of 5-lipoxygenase and 5-lipoxygenase activation protein in glomerulonephritis.
Gout
Drug-Mediated Intracellular Donation of Nitric Oxide Potently Inhibits 5-Lipoxygenase: A Possible Key to Future Antileukotriene Therapy.
Gout
NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout.
Gout
[Inhibiting cyclooxygenase and 5-lipoxygenase activities is an anti-inflammatory mechanism of Huzhang Gout Granule.]
Graft vs Host Disease
Inhibition of 5-lipoxygenase alleviates graft-versus-host disease.
Granuloma
5-lipoxygenase pathway is essential for the control of granuloma extension induced by Schistosoma mansoni eggs in lung.
Granuloma
Mice deficient for 5-lipoxygenase, but not leukocyte-type 12-lipoxygenase, display altered immune responses during infection with Schistosoma mansoni.
Granuloma
The role of platelet activating factor and other lipid mediators in inflammatory angiogenesis.
Granuloma Annulare
Treatment of disseminated granuloma annulare with a 5-lipoxygenase inhibitor and vitamin E.
Granulomatous Disease, Chronic
Toxoplasma gondii alters eicosanoid release by human mononuclear phagocytes: role of leukotrienes in interferon gamma-induced antitoxoplasma activity.
Head and Neck Neoplasms
The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.
Hepatitis B
A mutant of hepatitis B virus X protein (HBx Delta 127) enhances hepatoma cell migration via osteopontin involving 5-lipoxygenase.
Hepatitis B
A mutant of hepatitis B virus X protein (HBxDelta127) promotes cell growth through a positive feedback loop involving 5-lipoxygenase and fatty acid synthase.
Hepatitis B
Hepatitis B Virus X Protein Drives Multiple Cross-Talk Cascade Loops Involving NF-?B, 5-LOX, OPN and Capn4 to Promote Cell Migration.
Hepatitis C
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Histoplasmosis
5-Lipoxygenase deficiency impairs innate and adaptive immune responses during fungal infection.
Hyperalgesia
Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.
Hyperalgesia
Contribution of 5- and 12-lipoxygenase products to mechanical hyperalgesia induced by prostaglandin E(2) and epinephrine in the rat.
Hyperalgesia
Effect of a 5-lipoxygenase inhibitor on nerve growth factor-induced thermal hyperalgesia in the rat.
Hyperalgesia
Effect of licofelone against mechanical hyperalgesia and cold allodynia in the rat model of incisional pain.
Hyperalgesia
Effect of zileuton in radicular pain induced by herniated nucleus pulposus in rats.
Hyperalgesia
L-656,224 (7-chloro-2-[(4-methoxyphenyl)methyl]-3- methyl-5-propyl-4-benzofuranol): a novel, selective, orally active 5-lipoxygenase inhibitor.
Hyperalgesia
Nerve growth factor induced hyperalgesia in the rat hind paw is dependent on circulating neutrophils.
Hyperalgesia
Paulistine-The Functional Duality of a Wasp Venom Peptide Toxin.
Hyperalgesia
Pharmacological evidence for a role of lipoxygenase products in platelet-activating factor (PAF)-induced hyperalgesia.
Hyperalgesia
Pharmacological modulation of eicosanoid levels and hyperalgesia in yeast-induced inflammation.
Hyperalgesia
Spinal 12-lipoxygenase-derived hepoxilin A3 contributes to inflammatory hyperalgesia via activation of TRPV1 and TRPA1 receptors.
Hypercholesterolemia
Hypercholesterolemia increases the production of leukotriene B4 in neutrophils by enhancing the nuclear localization of 5-lipoxygenase.
Hypercholesterolemia
Pharmacological properties of marine macroalgae-associated heterotrophic bacteria.
Hyperlipoproteinemia Type II
5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia.
Hypersensitivity
5-lipoxygenase expression and activity in aorta from streptozotocin-induced diabetic rats.
Hypersensitivity
A Novel 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor AM679 Reduces Inflammation in the RSV-Infected Mouse Eye.
Hypersensitivity
Antileukotrienes in clinical development for asthma.
Hypersensitivity
Development and evaluation of ST-1829 based on 5-benzylidene-2-phenylthiazolones as promising agent for anti-leukotriene therapy.
Hypersensitivity
Development of 5-lipoxygenase inhibitors--lessons from cellular enzyme regulation.
Hypersensitivity
Effect of AA-861, a selective 5-lipoxygenase inhibitor, on models of allergy in several species.
Hypersensitivity
Enhanced production of LTB4 and free radicals in rat lung by exhaustive physical exercise.
Hypersensitivity
Lipoxygenase inhibitors from natural plant sources. Part 1: Medicinal plants with inhibitory activity on arachidonate 5-lipoxygenase and 5-lipoxygenase[sol ]cyclooxygenase.
Hypersensitivity
Membrane fluidity is a key modulator of membrane binding, insertion, and activity of 5-lipoxygenase.
Hypersensitivity
MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation.
Hypersensitivity
Molecular characterization of EP6--a novel imidazo[1,2-a]pyridine based direct 5-lipoxygenase inhibitor.
Hypersensitivity
Possible involvement of 5-lipoxygenase metabolite in itch-associated response of mosquito allergy in mice.
Hypersensitivity
Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005.
Hypersensitivity
Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor.
Hypersensitivity
Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors.
Hypersensitivity
TGF?/SMAD signalling modulates MLL and MLL-AF4 mediated 5-lipoxygenase promoter activation.
Hypersensitivity
The use of leukotriene D4 receptor antagonists and 5-lipoxygenase inhibitors to define a role for leukotrienes in allergic reactions.
Hypersensitivity
[Effects of alminoprofen on the allergic reactions]
Hypersensitivity, Delayed
Effects of cyclooxygenase and lipoxygenase inhibitors on inflammation associated with oxazolone-induced delayed hypersensitivity.
Hypersensitivity, Immediate
2,3-Dihydro-5-benzofuranols as antioxidant-based inhibitors of leukotriene biosynthesis.
Hypersensitivity, Immediate
5-Lipoxygenase inhibitors and allergic conjunctivitis reactions in the guinea-pig.
Hypersensitivity, Immediate
Antioxidant-based inhibitors of leukotriene biosynthesis. The discovery of 6-[1-[2-(hydroxymethyl)phenyl]-1-propen-3-yl]-2,3-dihydro-5- benzofuranol, a potent topical antiinflammatory agent.
Hypersensitivity, Immediate
Effects of a 5-lipoxygenase inhibitor (L-651,392) and leukotriene D4 antagonist (L-649,923) in two animal models of immediate hypersensitivity reactions.
Hypersensitivity, Immediate
Non steroidal anti-inflammatory and anti-allergy agents.
Hypertension
A new treatment for severe pulmonary arterial hypertension based on an old idea: inhibition of 5-lipoxygenase.
Hypertension
Effect of 5-lipoxygenase and cyclooxygenase blockade on porcine hemodynamics during continuous infusion of platelet-activating factor.
Hypertension
HIV X4 Variants Increase Arachidonate 5-Lipoxygenase in the Pulmonary Microenvironment and are associated with Pulmonary Arterial Hypertension.
Hypertension
Pharmacological properties of marine macroalgae-associated heterotrophic bacteria.
Hypertension, Pregnancy-Induced
Cyclooxygenase gene expression in human endometrium and decidua.
Hypertension, Pulmonary
Contractile actions of endothelin-1 in isolated helical strips from rat pulmonary artery: potentiation of serotonin-induced contraction.
Hypertension, Pulmonary
Delayed thromboxane or tumor necrosis factor-alpha, but not leukotriene inhibition, attenuates prolonged pulmonary hypertension in endotoxemia.
Hypertension, Pulmonary
Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats.
Hypertension, Pulmonary
Expression of 5-lipoxygenase in pulmonary artery endothelial cells.
Hypertension, Pulmonary
Prolonged pulmonary hypertension caused by platelet-activating factor and leukotriene C4 in the rat lung.
Hyperventilation
Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air.
Hyperventilation
The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air.
Hypotension
Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model.
Idiopathic Pulmonary Fibrosis
Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis.
Ileitis
The role of leukotriene B4 in Clostridium difficile toxin A-induced ileitis in rats.
Immune System Diseases
Characterization of the molecular mechanism of 5-lipoxygenase inhibition by 2-aminothiazoles.
Immune System Diseases
Functional variants of the human 5-lipoxygenase gene and their genetic diagnosis.
Immune System Diseases
Phosphorylation of serine 271 on 5-lipoxygenase and its role in nuclear export.
Immune System Diseases
Regulation of the 5-lipoxygenase pathway in human leucocytes.
Infarction, Middle Cerebral Artery
Lipoxin a(4) inhibits 5-lipoxygenase translocation and leukotrienes biosynthesis to exert a neuroprotective effect in cerebral ischemia/reperfusion injury.
Infarction, Middle Cerebral Artery
Metabolic changes of arachidonic acid after cerebral ischemia-reperfusion in diabetic rats.
Infarction, Middle Cerebral Artery
Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats.
Infections
5-Lipoxygenase Activity Increases Susceptibility to Experimental Paracoccidioides brasiliensis Infection.
Infections
5-Lipoxygenase deficiency impairs innate and adaptive immune responses during fungal infection.
Infections
5-Lipoxygenase is a key determinant of acute myocardial inflammation and mortality during Trypanosoma cruzi infection.
Infections
5-Lipoxygenase Negatively Regulates Th1 Response during Brucella abortus Infection in Mice.
Infections
5-Lipoxygenase plays a role in the control of parasite burden and contributes to oxidative damage of erythrocytes in murine Chagas' disease.
Infections
5-LOX inhibitor modulates the inflammatory responses provoked by Helicobacter pylori infection.
Infections
Augmentation of 5-lipoxygenase activity and expression during dengue serotype-2 infection.
Infections
Changes in Caenorhabditis elegans immunity and Staphylococcal virulence factors during their interactions.
Infections
Concurrent Control of KSHV Life Cycle through Chromatin Modulation and Host Hedgehog Signaling: A New Prospect to the Therapeutic Potential of Lipoxin A4.
Infections
Differences in cNOS/iNOS Activity during Resistance to Trypanosoma cruzi Infection in 5-Lipoxygenase Knockout Mice.
Infections
Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection.
Infections
Gliotoxin from Aspergillus fumigatus Abrogates Leukotriene B4 Formation through Inhibition of Leukotriene A4 Hydrolase.
Infections
Human CMV infection induces 5-lipoxygenase expression and leukotriene B4 production in vascular smooth muscle cells.
Infections
In vivo generation of 5-lipoxygenase products in frogs and toads.
Infections
Inhibitory activities and attenuated expressions of 5-LOX with red ginseng in Helicobacter pylori-infected gastric epithelial cells.
Infections
Leukotriene B4 enhances innate immune defense against the puerperal sepsis agent Streptococcus pyogenes.
Infections
Leukotriene B4 protects latently infected mice against murine cytomegalovirus reactivation following allogeneic transplantation.
Infections
Leukotriene B4 receptor BLT1 signaling is critical for neutrophil apoptosis and resolution of experimental Lyme arthritis.
Infections
Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities.
Infections
Leukotrienes play a role in the control of parasite burden in murine strongyloidiasis.
Infections
Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation.
Infections
Lipoxin A4 impairs effective bacterial control and potentiates joint inflammation and damage caused by Staphylococcus aureus infection.
Infections
Mice deficient for 5-lipoxygenase, but not leukocyte-type 12-lipoxygenase, display altered immune responses during infection with Schistosoma mansoni.
Infections
Pasteurella haemolytica leukotoxin enhances production of leukotriene B4 and 5-hydroxyeicosatetraenoic acid by bovine polymorphonuclear leukocytes.
Infections
Pivotal Role of 5-Lipoxygenase Pathway in Lung Injury After Experimental Sepsis.
Infections
Respiratory syncytial virus induces the expression of 5-lipoxygenase and endothelin-1 in bronchial epithelial cells.
Infections
Rhinovirus infection increases 5-lipoxygenase and cyclooxygenase-2 in bronchial biopsy specimens from nonatopic subjects.
Infections
Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology.
Infections
The Pivotal Role of 5-Lipoxygenase-Derived LTB4 in Controlling Pulmonary Paracoccidioidomycosis.
Infections
The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications.
Infections
Toxoplasma gondii Soluble Tachyzoite Antigen Triggers Protective Mechanisms against Fatal Intestinal Pathology in Oral Infection of C57BL/6 Mice.
Infections
Trypanosoma cruzi: Effect of the absence of 5-lipoxygenase (5-LO)-derived leukotrienes on levels of cytokines, nitric oxide and iNOS expression in cardiac tissue in the acute phase of infection in mice.
Inflammatory Bowel Diseases
5-Hydroxyeicosatetraenoic acid and leukotriene D4 increase intestinal epithelial paracellular permeability.
Inflammatory Bowel Diseases
5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.
Inflammatory Bowel Diseases
5-Lipoxygenase inhibitors in the treatment of inflammatory bowel disease.
Inflammatory Bowel Diseases
5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration.
Inflammatory Bowel Diseases
5-lipoxygenase modulates the alteration of paracellular barrier function in mice ileum during experimental colitis.
Inflammatory Bowel Diseases
Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase.
Inflammatory Bowel Diseases
Colonic expression of leukotriene-pathway enzymes in inflammatory bowel diseases.
Inflammatory Bowel Diseases
Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C.
Inflammatory Bowel Diseases
Effect of 5-lipoxygenase inhibition on events associated with inflammatory bowel disease in rats.
Inflammatory Bowel Diseases
Expression of 5-lipoxygenase mRNA is unchanged in the colon of patients with active inflammatory bowel disease.
Inflammatory Bowel Diseases
In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production.
Inflammatory Bowel Diseases
Possible mode of action of 5-aminosalicylic acid.
Inflammatory Bowel Diseases
Sulphasalazine fails to prevent development of mucosal ulceration and 5-lipoxygenase activity in guinea-pigs with chronic inflammatory bowel disease induced by combined bacterial immunization and oral carrageenin.
Inflammatory Bowel Diseases
The role of leukotriene antagonists and inhibitors in the treatment of airway disease.
Inflammatory Bowel Diseases
Treatment of inflammatory bowel disease from now to the millennium.
Inflammatory Bowel Diseases
Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
Inflammatory Bowel Diseases
[Benzoxazole Derivative B-98 Ameliorates Dextran Sulfate Sodium-induced Acute Murine Colitis and the Change of T Cell Profiles in Acute Murine Colitis Model].
Inflammatory Bowel Diseases
[Leukotrienes. A review of the significance for disease in man and the possibilities for therapeutic intervention]
Influenza, Human
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Influenza, Human
Induction of a 5-lipoxygenase product by daidzein is involved in the regulation of influenza virus replication.
Insulin Resistance
5-LO inhibition ameliorates palmitic acid-induced ER stress, oxidative stress and insulin resistance via AMPK activation in murine myotubes.
Insulin Resistance
A role for 5-lipoxygenase products in obesity-associated inflammation and insulin resistance.
Insulin Resistance
Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice.
Insulin Resistance
Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice.
Intestinal Polyposis
Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice.
Intestinal Polyposis
Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation.
Iron Overload
Iron-Dependent Trafficking of 5-Lipoxygenase and Impact on Human Macrophage Activation.
Irritable Bowel Syndrome
Frankincense--therapeutic properties.
Ischemic Stroke
Advances in the genetic basis of coronary artery disease.
Ischemic Stroke
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene rs4073259 polymorphism not associated with ischemic stroke in the Northeastern Chinese Han population(?).
Ischemic Stroke
Association of ALOX5, LTA4H and LTC4S gene polymorphisms with ischemic stroke risk in a cohort of Chinese in east China.
Ischemic Stroke
Association of ALOX5AP with ischemic stroke: a population-based case-control study.
Ischemic Stroke
Flavocoxid, dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, exhibits neuroprotection in rat model of ischaemic stroke.
Ischemic Stroke
Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: a replication study in two independent populations.
Ischemic Stroke
Genetics of ischemic stroke.
Ischemic Stroke
Ischaemic stroke in hypertensive patients is associated with variations in the PDE4D genome region.
Ischemic Stroke
Ischemic stroke risk in a southeastern Chinese population: Insights from 5-lipoxygenase activating protein and phosphodiesterase 4D single-nucleotide polymorphisms.
Ischemic Stroke
Phosphodiesterase 4D and 5-lipoxygenase activating protein genes and risk of ischemic stroke in Sardinians.
Ischemic Stroke
Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke.
Ischemic Stroke
The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia.
Ischemic Stroke
Three polymorphisms of ALOX5AP and risk of ischemic stroke in Chinese: evidence from a meta-analysis.
Ischemic Stroke
Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once?
Ischemic Stroke
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Joint Diseases
Lipoxygenase products in inflammatory synovial fluids and other exudates.
Kidney Diseases
Fish oil feeding modulates leukotriene production in murine lupus nephritis.
Kidney Failure, Chronic
5-Lipoxygenase-mediated mitochondrial damage and apoptosis of mononuclear cells in ESRD patients.
Kidney Failure, Chronic
N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity.
Kidney Neoplasms
Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells.
Leishmaniasis
Arachidonic acid metabolism in murine leishmaniasis (Donovani): ex-vivo evidence for increased cyclooxygenase and 5-lipoxygenase activity in spleen cells.
Leishmaniasis, Visceral
Parasitic load determination by differential expressions of 5-lipoxygenase and PGE2 synthases in visceral leishmaniasis.
Leukemia
1,3,4-Oxadiazole, 1,3,4-thiadiazole, and 1,2,4-triazole analogs of the fenamates: in vitro inhibition of cyclooxygenase and 5-lipoxygenase activities.
Leukemia
12-Lipoxygenase from rat basophilic leukemia cells, an oxygenase with leukotriene A4-synthase activity.
Leukemia
12-Lipoxygenase from rat basophilic leukemia cells: separation from 5-lipoxygenase and temperature-dependent inactivation by hydroperoxy fatty acid.
Leukemia
5-Lipoxygenase gene expression in HL60 cells during differentiation with DMSO.
Leukemia
5-Lipoxygenase inhibitors potentiate effects of TGF-beta 1 on the differentiation of human leukemia HL-60 cells.
Leukemia
A Calluna vulgaris extract 5-lipoxygenase inhibitor shows potent antiproliferative effects on human leukemia HL-60 cells.
Leukemia
Anti-inflammatory activity of pectolinarigenin and pectolinarin isolated from Cirsium chanroenicum.
Leukemia
Arachidonate 15-lipoxygenase (omega-6 lipoxygenase) from human leukocytes. Purification and structural homology to other mammalian lipoxygenases.
Leukemia
Arachidonate 5-lipoxygenase inhibitors show potent antiproliferative effects on human leukemia cell lines.
Leukemia
Biochemical and biological activities of 2,3-dihydro-6-[3-(2-hydroxymethyl)phenyl-2-propenyl]-5-benzofuranol (L-651,896), a novel topical anti-inflammatory agent.
Leukemia
Characterization of specific subcellular 15-hydroxyeicosatetraenoic acid (15-HETE) binding sites on rat basophilic leukemia cells.
Leukemia
Co-localization of leukotriene a4 hydrolase with 5-lipoxygenase in nuclei of alveolar macrophages and rat basophilic leukemia cells but not neutrophils.
Leukemia
Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells.
Leukemia
Effect of azelastine on the release and action of leukotriene C4 and D4.
Leukemia
Effects of the new 5-lipoxygenase inhibitor E6080 on leukotriene release in vitro.
Leukemia
Effects of the rhizomes of Atractylodes japonica and atractylenolide I on allergic response and experimental atopic dermatitis.
Leukemia
Experiments on the mode of action of piriprost (U-60,257), an inhibitor of leukotriene formation in cloned mouse mast cells and in rat basophil leukemia cells.
Leukemia
In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production.
Leukemia
Inhibition of Experimental Atopic Dermatitis by Rhubarb (Rhizomes of Rheum tanguticum) and 5-Lipoxygenase Inhibition of its Major Constituent, Emodin.
Leukemia
Inhibition of leukotriene synthesis by azelastine.
Leukemia
Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor.
Leukemia
Inhibitory effect of docosahexaenoic acid-containing phospholipids on 5-lipoxygenase in rat basophilic leukemia cells.
Leukemia
Interactions of 5-lipoxygenase with membranes: studies on the association of soluble enzyme with membranes and alterations in enzyme activity.
Leukemia
Isolation and characterization of a cDNA clone encoding rat 5-lipoxygenase.
Leukemia
Kinetic studies on arachidonate 5-lipoxygenase from rat basophilic leukemia cells.
Leukemia
Leukotriene C4 uses a probenecid-sensitive export carrier that does not recognize leukotriene B4.
Leukemia
Localization of 5-lipoxygenase to the nucleus of resting rat basophilic leukemia cells.
Leukemia
Localization of 5-lipoxygenase to the nucleus of unstimulated rat basophilic leukemia cells.
Leukemia
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.
Leukemia
Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis.
Leukemia
Mono (S) hydroxy fatty acids: novel ligands for cytosolic actin.
Leukemia
Novel 1,2,4-oxadiazoles and 1,2,4-thiadiazoles as dual 5-lipoxygenase and cyclooxygenase inhibitors.
Leukemia
Novel bishydroxamic acids as 5-lipoxygenase inhibitors.
Leukemia
Novel Combination Treatments Targeting Chronic Myeloid Leukemia Stem Cells.
Leukemia
Novel membrane target proteins for lipoxygenase-derived mono(S)hydroxy fatty acids.
Leukemia
Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells.
Leukemia
Oxygenation of phosphatidylcholine by human polymorphonuclear leukocyte 15-lipoxygenase.
Leukemia
Pharmacological properties of a new anti-inflammatory compound, alpha-(3,5-di-tert-butyl-4-hydroxybenzylidene)-gamma-butyrolacto ne (KME-4), and its inhibitory effects on prostaglandin synthetase and 5-lipoxygenase.
Leukemia
Purification of a mammalian 5-lipoxygenase from rat basophilic leukemia cells.
Leukemia
Purification, characterization, and structural properties of a single protein from rat basophilic leukemia (RBL-1) cells possessing 5-lipoxygenase and leukotriene A4 synthetase activities.
Leukemia
Regulation of lipoxygenase activity by polyunsaturated lysophosphatidylcholines or their oxygenation derivatives.
Leukemia
Saiboku-To, a herbal extract mixture, selectively inhibits 5-lipoxygenase activity in leukotriene synthesis in rat basophilic leukemia-1 cells.
Leukemia
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Leukemia
Stimulation of leukotriene production and membrane translocation of 5-lipoxygenase by cross-linking of the IgE receptors in RBL-2H3 cells.
Leukemia
Studies on arachidonate 5-lipoxygenase of rat basophilic leukemia cells.
Leukemia
Studies on lipoxygenase inhibitors. I. MY3-469 (3-methoxytropolone), a potent and selective inhibitor of 12-lipoxygenase, produced by Streptoverticillium hadanonense KY11449.
Leukemia
Studies on lipoxygenase inhibitors. II. KF8940 (2-n-heptyl-4-hydroxyquinoline-N-oxide), a potent and selective inhibitor of 5-lipoxygenase, produced by Pseudomonas methanica.
Leukemia
Styrylpyrazoles, styrylisoxazoles, and styrylisothiazoles. Novel 5-lipoxygenase and cyclooxygenase inhibitors.
Leukemia
Synthesis and 5-lipoxygenase inhibitory activity of 5-hydroperoxy-6,8,11,14-eicosatetraenoic acid analogues.
Leukemia
Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)- 4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity.
Leukemia
The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
Leukemia
The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor.
Leukemia
The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2.
Leukemia
The pharmacologic effects of 5-[3,5-bis(1,1-dimethylethyl)-4- hydroxyphenyl]-1,3,4-thiadiazole-2(3H)-thione, choline salt (CI-986), a novel inhibitor of arachidonic acid metabolism in models of inflammation, analgesia and gastric irritation.
Leukemia
The regulation of 5-lipoxygenase activity in rat basophilic leukemia cells.
Leukemia
The Rhizomes of Acorus gramineus and the Constituents Inhibit Allergic Response In vitro and In vivo.
Leukemia
The Rhizomes of Alisma orientale and Alisol Derivatives Inhibit Allergic Response and Experimental Atopic Dermatitis.
Leukemia
Translocation and leukotriene synthetic capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages.
Leukemia
Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model.
Leukemia
[Studies on 5-lipoxygenase inhibitors. Synthesis of and structure--activity relationship in p-hydroxyarylalkenylbenzoazoles]
Leukemia, Erythroblastic, Acute
Altered gravity modulates 5-lipoxygenase in human erythroleukemia K562 cells.
Leukemia, Erythroblastic, Acute
Lipoxygenase activity in altered gravity.
Leukemia, Monocytic, Acute
Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A 5-lipoxygenase inhibitor at micromolar concentration raises intracellular calcium in U937 cells prior to their physiologic cell death.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Morphologic changes of apoptosis induced in human chronic myelogenous leukemia "blast" cells by SC41661A (Searle), a selective inhibitor of 5-lipoxygenase.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Knockdown of Alox5 gene promotes apoptosis of K562/ADM cells].
Leukemia, Myeloid
Regulation of leukotriene-biosynthetic enzymes during differentiation of myelocytic HL-60 cells to eosinophilic or neutrophilic cells.
Leukemia, Myeloid
[Relationship between Polymorphism in ALOX5, ALOX5AP and Susceptibility to Myeloid Leukemia].
Leukemia, Myeloid, Acute
5-Lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Induction of apoptosis in blood cells from a patient with acute myelogenous leukemia by SC41661A, a selective inhibitor of 5-lipoxygenase.
Leukocytosis
Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation.
Leukopenia
Differential protective activities of site specific lipoxygenase inhibitors in endotoxic shock and production of tumor necrosis factor.
Leukopenia
Haemodynamic and haematologic effects of Acanthaster planci venom in dogs.
Leukopenia
Leukotriene B4 is involved in hemodialysis-associated neutropenia.
Leydig Cell Tumor
Induction of apoptosis in an estrogen-responsive mouse Leydig tumor cell by leukotriene.
Lipidoses
Lipidosis induced in the dog gallbladder by a direct 5-lipoxygenase inhibitor.
Liver Cirrhosis
5-Lipoxygenase (5-LO) is Involved in Kupffer Cell Survival. Possible Role of 5-LO Products in the Pathogenesis of Liver Fibrosis.
Liver Cirrhosis
A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Liver Cirrhosis
Differential effects of malotilate on 5-, 12- and 15-lipoxygenase in human ascites cells.
Liver Cirrhosis
Eicosanoid production by density-defined human peritoneal macrophages during inflammation.
Liver Cirrhosis
Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis.
Liver Cirrhosis
Inhibition of 5-Lipoxygenase in Hepatic Stellate Cells Alleviates Liver Fibrosis.
Liver Cirrhosis
Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis.
Liver Cirrhosis
Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells.
Liver Diseases
5-lipoxygenase activation is involved in the mechanisms of chronic hepatic injury in a rat model of chronic aluminum overload exposure.
Liver Diseases
Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.
Liver Diseases
Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis.
Liver Diseases
Inhibition of 5-lipoxygenase inhibitor zileuton in high-fat diet-induced nonalcoholic fatty liver disease progression model.
Liver Diseases
Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice.
Liver Diseases
[The roles of cyclooxygenase-2 and 5-lipoxygenase in liver disease]
Liver Failure, Acute
Inhibition of 5-lipoxygenase pathway attenuates acute liver failure by inhibiting macrophage activation.
Lung Diseases
Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators.
Lung Diseases
Fuscoside: an anti-inflammatory marine natural product which selectively inhibits 5-lipoxygenase. Part II: Biochemical studies in the human neutrophil.
Lung Diseases, Interstitial
The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study.
Lung Diseases, Obstructive
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
Lung Injury
5-Lipoxygenase knockout mice exhibit a resistance to pleurisy and lung injury caused by carrageenan.
Lung Injury
5-lipoxygenase pathway is essential for the control of granuloma extension induced by Schistosoma mansoni eggs in lung.
Lung Injury
Acute pancreatitis.
Lung Injury
Increase in filtration coefficient from actions of melittin on neutrophils in isolated rabbit lungs.
Lung Injury
Intrinsic 5-lipoxygenase activity is required for neutrophil responsivity.
Lung Injury
Leukotriene inhibitors attenuate rat lung injury induced by hydrogen peroxide.
Lung Injury
Oleic acid induces pulmonary injury independent of eicosanoids in the isolated, perfused rabbit lung.
Lung Injury
Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury.
Lung Injury
Pivotal Role of 5-Lipoxygenase Pathway in Lung Injury After Experimental Sepsis.
Lung Injury
Reduction of neutrophil influx diminishes lung injury and mortality following phosgene inhalation.
Lung Neoplasms
A genomic response of H-358 bronchiolar carcinoma cells to MK 886, an inhibitor of 5-lipoxygenase, assessed with a cDNA array.
Lung Neoplasms
Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment.
Lung Neoplasms
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Lung Neoplasms
Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling.
Lung Neoplasms
miR-146a suppresses 5-lipoxygenase activating protein (FLAP) expression and Leukotriene B4 production in lung cancer cells.
Lung Neoplasms
The future of cyclooxygenase-2 inhibitors and other inhibitors of the eicosanoid signal pathway in the prevention and therapy of lung cancer.
Lung Neoplasms
The mode of cell death in H-358 lung cancer cells cultured with inhibitors of 5-lipoxygenase or the free radical spin trap, NTBN.
Lupus Erythematosus, Systemic
A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Chemiluminescence is increased in a subgroup of PHA-stimulated lymphocytes from patients with systemic lupus erythematosus and inhibited by 5-lipoxygenase inhibitors.
Lyme Disease
Leukotriene B4 receptor BLT1 signaling is critical for neutrophil apoptosis and resolution of experimental Lyme arthritis.
Lyme Disease
Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of Lyme arthritis.
Lyme Disease
Macrophage LTB
Lymphatic Metastasis
5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage.
Lymphatic Metastasis
Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells.
Lymphedema
Leukotriene B4 antagonism ameliorates experimental lymphedema.
Lymphoma
5-Lipoxygenase and cysteinyl leukotriene receptor 1 regulate epidermal growth factor-induced cell migration through Tiam1 upregulation and Rac1 activation.
Lymphoma
Creating conditions similar to those that occur during exposure of cells to microgravity induces apoptosis in human lymphocytes by 5-lipoxygenase-mediated mitochondrial uncoupling and cytochrome c release.
Lymphoma
Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells.
Lymphoma
Involvement of 5-lipoxygenase in survival of Epstein-Barr virus (EBV)-converted B lymphoma cells.
Lymphoma, B-Cell
Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells.
Lymphoma, Mantle-Cell
Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells.
Lymphoma, T-Cell
5-Lipoxygenase and cysteinyl leukotriene receptor 1 regulate epidermal growth factor-induced cell migration through Tiam1 upregulation and Rac1 activation.
Malaria
Deoxyhypusine Hydroxylase from Plasmodium vivax, the Neglected Human Malaria Parasite: Molecular Cloning, Expression and Specific Inhibition by the 5-LOX Inhibitor Zileuton.
Malaria
The oxylipin and endocannabidome responses in acute phase Plasmodium falciparum malaria in children.
Malaria, Cerebral
Differences in the modulation of reactive species, lipid bodies, cyclooxygenase-2, 5-lipoxygenase and PPAR-? in cerebral malaria-susceptible and resistant mice.
Mastocytoma
A new 5-lipoxygenase selective inhibitor derived from Artocarpus communis strongly inhibits arachidonic acid-induced ear edema.
Mastocytoma
Enhancement of 5-lipoxygenase activity in mastocytoma P-815 cells by n-butyrate treatment.
Mastocytoma
L-656,224 (7-chloro-2-[(4-methoxyphenyl)methyl]-3- methyl-5-propyl-4-benzofuranol): a novel, selective, orally active 5-lipoxygenase inhibitor.
Mastocytoma
Predominant synthesis of 5-hydroxyeicosatetraenoic acid by a cloned mastocytoma P-815 line, 2-E-6 cells.
Mastocytoma
Selective inhibition of 5-lipoxygenase by natural compounds isolated from Chinese plants, Artemisia rubripes Nakai.
Medulloblastoma
Leukotriene Synthesis Is Critical for Medulloblastoma Progression.
Melanoma
A Mixture of Polyunsaturated Fatty Acids ?-3 and ?-6 Reduces Melanoma Growth by Inhibiting Inflammatory Mediators in the Murine Tumor Microenvironment.
Melanoma
Cytoplasmic phospholipase A2 metabolites play a critical role in pulmonary tumor metastasis in mice.
Melanoma
Inhibitors of 5-lipoxygenase inhibit expression of intercellular adhesion molecule-1 in human melanoma cells.
Melanoma
Ketoconazole: a thromboxane synthetase and 5-lipoxygenase inhibitor with antimetastatic activity in B16-F10 melanoma.
Melanoma
Leukotriene B4 creates a favorable microenvironment for murine melanoma growth.
Meningioma
Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
Mesothelioma
The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.
Metabolic Diseases
5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation.
Metabolic Syndrome
17? Estradiol Modulates Perfusion Pressure and Expression of 5-LOX and CYP450 4A in the Isolated Kidney of Metabolic Syndrome Female Rats.
Miosis
Effect of sodium naproxen on inflammatory response induced by anterior chamber paracentesis in the rabbit.
Mouth Neoplasms
Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch carcinogenesis by a 5-lipoxygenase inhibitor, garcinol.
Mouth Neoplasms
Ethanol promotes chemically induced oral cancer in mice through activation of the 5-lipoxygenase pathway of arachidonic acid metabolism.
Mouth Neoplasms
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Mouth Neoplasms
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.
Multiple Sclerosis
A Systematic Review on the Role of Arachidonic Acid Pathway in Multiple Sclerosis.
Multiple Sclerosis
Cysteinyl Leukotrienes and Their Receptors: Emerging Therapeutic Targets in Central Nervous System Disorders.
Multiple Sclerosis
Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions.
Multiple Sclerosis
Suppression of experimental autoimmune encephalomyelitis by sulfasalazine.
Muscular Atrophy
Genetic ablation of 12/15-lipoxygenase but not 5-lipoxygenase protects against denervation-induced muscle atrophy.
Mycoses
5-Lipoxygenase deficiency impairs innate and adaptive immune responses during fungal infection.
Mycoses
Leukotriene B4-loaded microspheres as a new approach to enhance antimicrobial responses in Histoplasma capsulatum-infected mice.
Myeloproliferative Disorders
Deficient induction of leukotriene synthesis in human neutrophils by lipoxygenase-deficient platelets.
Myocardial Infarction
5-Lipoxygenase facilitates healing after myocardial infarction.
Myocardial Infarction
A functional Sp1/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene is not associated with myocardial infarction.
Myocardial Infarction
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction.
Myocardial Infarction
Acrolein increases 5-lipoxygenase expression in murine macrophages through activation of ERK pathway.
Myocardial Infarction
Arachidonate 5-lipoxygenase (5-LO) promoter genotype and risk of myocardial infarction: a case-control study.
Myocardial Infarction
Association of ALOX5AP with ischemic stroke: a population-based case-control study.
Myocardial Infarction
Association of Sp1 tandem repeat polymorphism of ALOX5 with coronary artery disease in Indian subjects.
Myocardial Infarction
Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future.
Myocardial Infarction
Cardioprotective effect of 5-lipoxygenase gene (ALOX5) silencing in ischemia-reperfusion.
Myocardial Infarction
Common Polymorphisms in the 5-Lipoxygenase Pathway and Risk of Incident Myocardial Infarction: A Danish Case-Cohort Study.
Myocardial Infarction
Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction.
Myocardial Infarction
Genetic polymorphisms that predict outcome and need for treatment in cardiovascular disease.
Myocardial Infarction
Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.
Myocardial Infarction
Influence of atherosclerosis on the vascular reactivity of isolated human epicardial coronary arteries to leukotriene C4.
Myocardial Infarction
Inhibition of 5-lipoxygenase by zileuton in a rat model of myocardial infarction.
Myocardial Infarction
Inhibitory effects of a phosphate diester of alpha-tocopherol and ascorbic acid (EPC-K1) on myocardial infarction in rats.
Myocardial Infarction
Interactions between 5-Lipoxygenase Polymorphisms and Adipose Tissue Contents of Arachidonic and Eicosapentaenoic Acids Do Not Affect Risk of Myocardial Infarction in Middle-Aged Men and Women in a Danish Case-Cohort Study.
Myocardial Infarction
Leukotriene B4 production in healthy subjects carrying variants of the arachidonate 5-lipoxygenase-activating protein gene associated with a risk of myocardial infarction.
Myocardial Infarction
Monoclonal anti-CD18 antibody prevents transcellular biosynthesis of cysteinyl leukotrienes in vitro and in vivo and protects against leukotriene-dependent increase in coronary vascular resistance and myocardial stiffness.
Myocardial Infarction
Nutrigenetic association of the 5-lipoxygenase gene with myocardial infarction.
Myocardial Infarction
Reduction of myocardial infarct size in rats by a selective 5-lipoxygenase inhibitor (AA-861).
Myocardial Infarction
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke.
Myocardial Infarction
The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field.
Myocardial Infarction
Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population.
Myocardial Infarction
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Myocardial Infarction
Water-soluble quercetin modulates the choleresis and bile lipid ratio in rats.
Myocardial Infarction
[Study on mechanisms and myocardial protective effect of Qishen Yiqi dropping pills on rats with myocardial infarction].
Myocardial Ischemia
Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.
Myocardial Ischemia
Modulation of coronary flow rate and cardiac contractility by the divalent cation ionophore A23187 and inhibitors of the cyclooxygenase and 5-lipoxygenase pathways: development of heterogeneous patterns of myocardial ischemia.
Myocardial Ischemia
Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice.
Myocardial Ischemia
The selective 5-LOX inhibitor 11-keto-?-boswellic acid protects against myocardial ischemia reperfusion injury in rats: involvement of redox and inflammatory cascades.
Myositis
The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis.
nad(p)h oxidase (h2o2-forming) deficiency
Novel effect of oxidized low-density lipoprotein: cellular ATP depletion via downregulation of glyceraldehyde-3-phosphate dehydrogenase.
nadph dehydrogenase (quinone) deficiency
NADPH oxidase deficiency results in reduced alveolar macrophage 5-lipoxygenase expression and decreased leukotriene synthesis.
Nasal Obstruction
[Studies on the experimental allergic rhinitis induced by Japanese cedar pollen--role of cysteinyl leukotrienes in nasal allergic symptoms]
Nasal Polyps
Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma.
Nasal Polyps
Expression of Arachidonate Metabolism Enzymes and Receptors in Nasal Polyps of Aspirin-Hypersensitive Asthmatics.
Nasal Polyps
Expression of COX-1, COX-2, 5-LOX and
CysLT
2
in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease.
Nasal Polyps
Expression of cyclooxygenase-2 and 5-lipoxygenase in nasal polyps associated with interleukin-4 promoter polymorphism -590.
Neoplasm Metastasis
15-Lipoxygenase-2 is differentially expressed in normal and neoplastic ovary.
Neoplasm Metastasis
5-Lipoxygenase Antagonist therapy: a new approach towards targeted cancer chemotherapy.
Neoplasm Metastasis
5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage.
Neoplasm Metastasis
5-Lipoxygenase promotes epithelial-mesenchymal transition through the ERK signaling pathway in gastric cancer.
Neoplasm Metastasis
5-Lipoxygenase: Its involvement in gastrointestinal malignancies.
Neoplasm Metastasis
Anti-Cancer Activity of 2,4-Disubstituted Thiophene Derivatives: Dual Inhibitors of Lipoxygenase and Cyclooxygenase.
Neoplasm Metastasis
Cytoplasmic phospholipase A2 metabolites play a critical role in pulmonary tumor metastasis in mice.
Neoplasm Metastasis
Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment.
Neoplasm Metastasis
Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.
Neoplasm Metastasis
Enhanced metastatic ability of TNF-alpha-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides.
Neoplasm Metastasis
Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells.
Neoplasm Metastasis
Inhibitor of 5-lipoxygenase, zileuton, suppresses prostate cancer metastasis by upregulating E-cadherin and paxillin.
Neoplasm Metastasis
Inhibitors of 5-lipoxygenase inhibit expression of intercellular adhesion molecule-1 in human melanoma cells.
Neoplasm Metastasis
Multifaceted link between cancer and inflammation.
Neoplasm Metastasis
Neutrophils support lung colonization of metastasis-initiating breast cancer cells.
Neoplasm Metastasis
Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer.
Neoplasm Metastasis
The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis.
Neoplasms
1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 & tubulin: Their anti-proliferative & anti-inflammatory activity.
Neoplasms
15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth.
Neoplasms
5,7-dihydroxy-2-(3-hydroxy-4, 5-dimethoxy-phenyl)-chromen-4-one-a flavone from Bruguiera gymnorrhiza displaying anti-inflammatory properties.
Neoplasms
5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid.
Neoplasms
5-Lipoxygenase and Cyclooxygenase inhibitory Dammarane triterpenoid 1 from Borassus flabellifer seed coat, inhibits Tumor Necrosis Factor-? secretion in LPS induced THP-1 human monocytes and induces apoptosis in MIA PaCa-2 Pancreatic cancer cells.
Neoplasms
5-Lipoxygenase and endotoxin-induced microvascular albumin exchanges and leucocyte recruitment in guinea-pig lungs.
Neoplasms
5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue.
Neoplasms
5-Lipoxygenase Antagonist therapy: a new approach towards targeted cancer chemotherapy.
Neoplasms
5-lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking.
Neoplasms
5-Lipoxygenase contributes to the progression of hepatocellular carcinoma.
Neoplasms
5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice.
Neoplasms
5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9.
Neoplasms
5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity.
Neoplasms
5-Lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia.
Neoplasms
5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage.
Neoplasms
5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices.
Neoplasms
5-Lipoxygenase promotes epithelial-mesenchymal transition through the ERK signaling pathway in gastric cancer.
Neoplasms
5-Lipoxygenase: Its involvement in gastrointestinal malignancies.
Neoplasms
A Cell-based Assay for Screening Lipoxygenase Inhibitors.
Neoplasms
A Mixture of Polyunsaturated Fatty Acids ?-3 and ?-6 Reduces Melanoma Growth by Inhibiting Inflammatory Mediators in the Murine Tumor Microenvironment.
Neoplasms
A novel anti-pancreatic cancer agent, LY293111.
Neoplasms
A novel hydroxamic acid derivative, MHY218, induces apoptosis and cell cycle arrest through downregulation of NF-?B in HCT116 human colon cancer cells.
Neoplasms
A Phase 1/2 Study of Flavocoxid, an Oral NF-?B Inhibitor, in Duchenne Muscular Dystrophy.
Neoplasms
A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Neoplasms
Absence of modulation of monokine production via endogenous cyclooxygenase or 5-lipoxygenase metabolites: MK-886 (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2- dimethylpropanoic acid), indomethacin, or arachidonate fail to alter immunoreactive interleukin-1 beta, or TNF-alpha production by human monocytes in vitro.
Neoplasms
Activation of 5-lipoxygenase is required for nicotine mediated epithelial-mesenchymal transition and tumor cell growth.
Neoplasms
Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor.
Neoplasms
Alpha-tocopherol decreases tumor necrosis factor-alpha mRNA and protein from activated human monocytes by inhibition of 5-lipoxygenase.
Neoplasms
Altered eicosanoid levels in human colon cancer.
Neoplasms
Altered oncogene, tumor suppressor and cell-cycle gene expression in PANC-1 cells cultured with the pleiotrophic 5-lipoxygenase inhibitor, MK886, assessed with a gene chip.
Neoplasms
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
Neoplasms
Analysis of proximal ALOX5 promoter binding proteins by quantitative proteomics.
Neoplasms
Anti-Cancer Activity of 2,4-Disubstituted Thiophene Derivatives: Dual Inhibitors of Lipoxygenase and Cyclooxygenase.
Neoplasms
Anti-inflammatory activity of four Bolivian Baccharis species (Compositae).
Neoplasms
Anti-inflammatory and analgesic potential of Tamarindus indica Linn. (Fabaceae): a narrative review.
Neoplasms
Anti-inflammatory effect of methoxyflavonoids from Chiliadenus montanus (Jasonia Montana) growing in Egypt.
Neoplasms
Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin in vitro.
Neoplasms
Anticancer effects of licofelone (ML-3000) in prostate cancer cells.
Neoplasms
Apoptotic Cancer Cells Suppress 5-Lipoxygenase in Tumor-Associated Macrophages.
Neoplasms
Arachidonate 5 lipoxygenase expression in papillary thyroid carcinoma promotes invasion via MMP-9 induction.
Neoplasms
Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
Neoplasms
Assessment of the expression of biomarkers of uremic inflammation in dogs with renal disease.
Neoplasms
Atypical lambda/iota PKC conveys 5-lipoxygenase/leukotriene B4-mediated cross-talk between phospholipase A2s regulating NF-kappa B activation in response to tumor necrosis factor-alpha and interleukin-1beta.
Neoplasms
Berberine Inhibits the Apoptosis-Induced Metastasis by Suppressing the iPLA2/LOX-5/LTB4 Pathway in Hepatocellular Carcinoma.
Neoplasms
Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas.
Neoplasms
Black Tea: Phytochemicals, Cancer Chemoprevention and Clinical Studies.
Neoplasms
CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
Neoplasms
Cancer chemoprevention by 7-prenyloxycoumarins: a role for 5-lipoxygenase inhibition?
Neoplasms
Cancer-Produced Metabolites of 5-Lipoxygenase Induce Tumor-Evoked Regulatory B Cells via Peroxisome Proliferator-Activated Receptor ?.
Neoplasms
CarbORev-5901: The First Carborane-Based Inhibitor of the 5-Lipoxygenase Pathway.
Neoplasms
Cassia sieberiana DC. leaves modulate LPS-induced inflammatory response in THP-1 cells and inhibit eicosanoid-metabolizing enzymes.
Neoplasms
Chemical Composition of Pterospermum heterophyllum Root and its Anti-Arthritis Effect on Adjuvant-Induced Arthritis in Rats via Modulation of Inflammatory Responses.
Neoplasms
Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch carcinogenesis by a 5-lipoxygenase inhibitor, garcinol.
Neoplasms
Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.
Neoplasms
Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.
Neoplasms
Chronic adventitial inflammation, vasa vasorum expansion, and 5-lipoxygenase up-regulation in irradiated arteries from cancer survivors.
Neoplasms
Composition and Mechanism of Antitumor Effects of Hericium erinaceus Mushroom Extracts in Tumor-Bearing Mice.
Neoplasms
Computer modeling in predicting the bioactivity of human 5-lipoxygenase inhibitors.
Neoplasms
Conjugated linoleic acid attenuates 2,4-dinitrofluorobenzene-induced atopic dermatitis in mice through dual inhibition of COX-2/5-LOX and TLR4/NF-?B signaling.
Neoplasms
Conjugated linoleic acid reduction of murine mammary tumor cell growth through 5-hydroxyeicosatetraenoic acid.
Neoplasms
Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway.
Neoplasms
Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.
Neoplasms
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Neoplasms
Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer.
Neoplasms
Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy.
Neoplasms
Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells.
Neoplasms
Cytoplasmic 5-Lipoxygenase Staining Is a Highly Sensitive Marker of Human Tumors of the Choroid Plexus.
Neoplasms
Deletion of 5-Lipoxygenase in the Tumor Microenvironment Promotes Lung Cancer Progression and Metastasis through Regulating T Cell Recruitment.
Neoplasms
Dendropanax dentiger (Harms) Merr. root and its major constituents exert therapeutic effect on adjuvant-induced arthritis in rats.
Neoplasms
Design and synthesis of novel 2-amino-5-hydroxyindole derivatives that inhibit human 5-lipoxygenase.
Neoplasms
Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents.
Neoplasms
Differential gene signatures in rat mammary tumors induced by DMBA and those induced by fractionated gamma radiation.
Neoplasms
Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
Neoplasms
Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes.
Neoplasms
Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription.
Neoplasms
Drug-Mediated Intracellular Donation of Nitric Oxide Potently Inhibits 5-Lipoxygenase: A Possible Key to Future Antileukotriene Therapy.
Neoplasms
Dual acting anti-inflammatory drugs.
Neoplasms
Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
Neoplasms
Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro.
Neoplasms
DuCLOX-2/5 Inhibition Attenuates Inflammatory Response and Induces Mitochondrial Apoptosis for Mammary Gland Chemoprevention.
Neoplasms
DuCLOX-2/5 inhibition: a promising target for cancer chemoprevention.
Neoplasms
Effects of D,L-2-difluoromethylornithine and indomethacin on mammary tumor promotion in rats fed high n-3 and/or n-6 fat diets.
Neoplasms
Effects of phenidone (DuCLOX-2/5 inhibitor) against N-methyl-N-nitrosourea induced mammary gland carcinoma in albino rats.
Neoplasms
Effects of tenuiorin and methyl orsellinate from the lichen Peltigera leucophlebia on 5-/15-lipoxygenases and proliferation of malignant cell lines in vitro.
Neoplasms
Eicosapentaenoic acid reduces the invasive and metastatic activities of malignant tumor cells.
Neoplasms
Emodin Rescued Hyperhomocysteinemia-Induced Dementia and Alzheimer's Disease-Like Features in Rats.
Neoplasms
Endogenous production of leukotriene D4 mediates autocrine survival and proliferation via CysLT1 receptor signalling in intestinal epithelial cells.
Neoplasms
Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.
Neoplasms
Ethanolic extract of Pyrus pashia buch ham ex. D. Don (Kainth): A bioaccessible source of polyphenols with anti-inflammatory activity in vitro and in vivo.
Neoplasms
Evaluation of Anti-Inflammatory Properties of Isoorientin Isolated from Tubers of Pueraria tuberosa.
Neoplasms
Evaluation of in vitro biological activities: antioxidant; anti-inflammatory; anti-cholinesterase; anti- xanthine oxidase, anti-superoxyde dismutase, anti-?-glucosidase and cytotoxic of 19 bioflavonoids.
Neoplasms
Evaluation of targeted arterial delivery of the branched chain fatty acid 12-methyltetradecanoic acid as a novel therapy for solid tumors.
Neoplasms
Evidence of human cytomegalovirus infection and expression of 5-lipoxygenase in borderline ovarian tumors.
Neoplasms
Evidence that interleukin-1 beta and tumor necrosis factor inhibit gastric fundus motility via the 5-lipoxygenase pathway.
Neoplasms
Expression of 5-lipoxygenase in human colorectal cancer.
Neoplasms
Five-lipoxygenase pathway of arachidonic acid metabolism in carcino-genesis and cancer chemoprevention.
Neoplasms
Five-lipoxygenase-activating protein inhibitor MK-886 induces apoptosis in gastric cancer through upregulation of p27kip1 and bax.
Neoplasms
Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: A comparison study with methylprednisolone.
Neoplasms
Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis.
Neoplasms
Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis.
Neoplasms
Gene expression alterations of human peripheral blood monocytes induced by medium-term treatment with the TH2-cytokines interleukin-4 and -13.
Neoplasms
Gene expression of immunologically important factors in blood cells, milk cells, and mammary tissue of cows.
Neoplasms
Genotoxic activity and induction of biotransformation enzymes in two human cell lines after treatment by Erika fuel extract.
Neoplasms
Grape seed and red wine polyphenol extracts inhibit cellular cholesterol uptake, cell proliferation, and 5-lipoxygenase activity.
Neoplasms
Human 5-, 12- and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer.
Neoplasms
Increased expression of the 5-lipoxygenase pathway and its cellular localization in Barrett's adenocarcinoma.
Neoplasms
Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration.
Neoplasms
Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in brain of HIV-1 transgenic rats.
Neoplasms
Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer.
Neoplasms
Induction of apoptosis in an estrogen-responsive mouse Leydig tumor cell by leukotriene.
Neoplasms
Inflammatory Process and Molecular Targets for Antiinflammatory Nutraceuticals.
Neoplasms
Influx of extracellular calcium is required for the membrane translocation of 5-lipoxygenase and leukotriene synthesis.
Neoplasms
Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells.
Neoplasms
Inhibition of 5-lipoxygenase downregulates stemness and kills prostate cancer stem cells by triggering apoptosis via activation of c-Jun N-terminal kinase.
Neoplasms
Inhibition of 5-lipoxygenase pathway suppresses the growth of bladder cancer cells.
Neoplasms
Inhibition of 5-lipoxygenase suppresses vascular endothelial growth factor-induced angiogenesis in endothelial cells.
Neoplasms
Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells.
Neoplasms
Inhibition of human 5-lipoxygenase and anti-neoplastic effects by 2-amino-1,4-benzoquinones.
Neoplasms
Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine.
Neoplasms
Inhibition of tumour growth by lipoxygenase inhibitors.
Neoplasms
Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents.
Neoplasms
Inhibitory effect of esculetin on 5-lipoxygenase and leukotriene biosynthesis.
Neoplasms
Inhibitory Effects of Panduratin A on Allergy-Related Mediator Production in Rat Basophilic Leukemia Mast Cells.
Neoplasms
Interactions between cytokines and eicosanoids: a study using human peritoneal macrophages.
Neoplasms
Intracellular Ca2+ mediates lipoxygenase-induced proliferation of U-373 MG human astrocytoma cells.
Neoplasms
Involvement of 5-lipoxygenase in programmed cell death of cancer cells.
Neoplasms
Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.
Neoplasms
Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors.
Neoplasms
Iron-Dependent Trafficking of 5-Lipoxygenase and Impact on Human Macrophage Activation.
Neoplasms
Isoflavone-rich extracts from wooly glycine Glycine tomentella inhibits LPS-induced TNF-alpha expression in a macrophage cell line of Atlantic salmon (Salmo salar L.).
Neoplasms
Kukoamine A inhibits human glioblastoma cell growth and migration through apoptosis induction and epithelial-mesenchymal transition attenuation.
Neoplasms
Leukotriene B4 creates a favorable microenvironment for murine melanoma growth.
Neoplasms
Leukotriene B4.
Neoplasms
Leukotriene C4 is an essential 5-lipoxygenase intermediate in A23187-induced macrophage cytostatic activity against P815 tumor cells.
Neoplasms
Leukotriene D4-induced Caco-2 cell proliferation is mediated by prostaglandin E2 synthesis.
Neoplasms
Leukotriene Synthesis Is Critical for Medulloblastoma Progression.
Neoplasms
Lipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention.
Neoplasms
Lipoxygenase directed anti-inflammatory and anti-cancerous secondary metabolites: ADMET-based screening, molecular docking and dynamics simulation.
Neoplasms
Lipoxygenase inhibitors but not site specific 5-lipoxygenase blockers protect against endotoxic shock and inhibit production of tumor necrosis factor.
Neoplasms
Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras(G12D/+) mice.
Neoplasms
LTB4 is present in exudative pleural effusions and contributes actively to neutrophil recruitment in the inflamed pleural space.
Neoplasms
Lycopodine triggers apoptosis by modulating 5-lipoxygenase, and depolarizing mitochondrial membrane potential in androgen sensitive and refractory prostate cancer cells without modulating p53 activity: signaling cascade and drug-DNA interaction.
Neoplasms
Macelignan inhibits histamine release and inflammatory mediator production in activated rat basophilic leukemia mast cells.
Neoplasms
Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice.
Neoplasms
Mechanism of the anti-tumour effect of 2,3,5-trimethyl-6-(3-pyridylmethyl) 1,4-benzoquinone (CV-6504).
Neoplasms
Mechanisms of induction of cytosolic and microsomal glutathione transferase (GST) genes by xenobiotics and pro-inflammatory agents.
Neoplasms
Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells.
Neoplasms
Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis.
Neoplasms
Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer.
Neoplasms
MK-886 enhances tumour necrosis factor-alpha-induced differentiation and apoptosis.
Neoplasms
MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation.
Neoplasms
MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase.
Neoplasms
Molecular chaperones stimulate bone resorption.
Neoplasms
Monocytic differentiation of leukemic HL-60 cells induced by co-treatment with TNF-alpha and MK886 requires activation of pro-apoptotic machinery.
Neoplasms
Multifaceted link between cancer and inflammation.
Neoplasms
N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity.
Neoplasms
Neurogenesis and neuroprotection in the adult brain. A putative role for 5-lipoxygenase?
Neoplasms
Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation.
Neoplasms
New pyridone, thioxopyridine, pyrazolopyridine and pyridine derivatives that modulate inflammatory mediators in stimulated RAW 264.7 murine macrophage.
Neoplasms
Nicotine inhibits cytokine synthesis by mouse colonic mucosa.
Neoplasms
Nicotine promoted colon cancer growth via epidermal growth factor receptor, c-Src, and 5-lipoxygenase-mediated signal pathway.
Neoplasms
Nordihydroguaiaretic acid inhibition of NFATc1 suppresses osteoclastogenesis and arthritis bone destruction in rats.
Neoplasms
Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC).
Neoplasms
Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells.
Neoplasms
Omega-3 fatty acid regulates inflammatory cytokine/mediator messenger RNA expression in Porphyromonas gingivalis-induced experimental periodontal disease.
Neoplasms
On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.
Neoplasms
Overexpression of 5-lipoxygenase and its relation with cell proliferation and angiogenesis in 7,12-dimethylbenz(?)anthracene-induced rat mammary carcinogenesis.
Neoplasms
Overexpression of 5-Lipoxygenase in Colon Polyps and Cancer and the Effect of 5-LOX Inhibitors In vitro and in a Murine Model.
Neoplasms
Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis.
Neoplasms
Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n-3 fatty acids.
Neoplasms
Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse.
Neoplasms
Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer.
Neoplasms
Photodynamic Therapeutic Role of Indocyanine Green in Tumor-Associated Inflammation in Skin Cancer.
Neoplasms
Photothermal therapeutic effect of PEGylated gold nano-semicubes in chemically-induced skin cancer in mice.
Neoplasms
Polymorphisms in candidate asthma genes.
Neoplasms
Polyunsaturated Fatty Acid Diet and Upregulation of Lipoxin A4 Reduce the Inflammatory Response of Preeclampsia.
Neoplasms
Predominant synthesis of 5-hydroxyeicosatetraenoic acid by a cloned mastocytoma P-815 line, 2-E-6 cells.
Neoplasms
Prevalence of 5-Lipoxygenase Expression in Canine Osteosarcoma and the Effects of a Dual 5-Lipoxygenase/Cyclooxygenase Inhibitor on Osteosarcoma Cells In Vitro and In Vivo.
Neoplasms
Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids.
Neoplasms
Priming for the synthesis of 5-lipoxygenase products in human blood ex vivo by human granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha.
Neoplasms
Proliferation of estrogen-responsive mouse tumor cell line B-1F stimulated by Saiboku-to, but inhibited by Scutellaria baicalensis, a component of Saiboku-to.
Neoplasms
Protective effect of (+)-catechin against lipopolysaccharide-induced inflammatory response in RAW 264.7 cells through downregulation of NF-?B and p38 MAPK.
Neoplasms
Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas.
Neoplasms
Reduced release of leukotrienes B4 and C4 from alveolar macrophages of rats with silicosis.
Neoplasms
Regulation of the eicosanoid pathway by tumour necrosis factor alpha and leukotriene D4 in intestinal epithelial cells.
Neoplasms
Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells?
Neoplasms
Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.
Neoplasms
Research Article Flavocoxid Protects Against Cadmium-Induced Disruption of the Blood-Testis Barrier and Improves Testicular Damage and Germ Cell Impairment in Mice.
Neoplasms
Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice.
Neoplasms
Role of eicosanoids in prostate cancer progression.
Neoplasms
Salix tetrasperma Roxb. Extract Alleviates Neuropathic Pain in Rats via Modulation of the NF-?B/TNF-?/NOX/iNOS Pathway.
Neoplasms
SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase.
Neoplasms
Serum 5-LOX: a progressive protein marker for breast cancer and new approach for therapeutic target.
Neoplasms
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Neoplasms
Short-term intensive atorvastatin therapy improves endothelial function partly via attenuating perivascular adipose tissue inflammation through 5-lipoxygenase pathway in hyperlipidemic rabbits.
Neoplasms
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Neoplasms
Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice.
Neoplasms
Sterols and triterpenoids as potential anti-inflammatories: Molecular docking studies for binding to some enzymes involved in inflammatory pathways.
Neoplasms
Study of the polymorphisms of cyclooxygenase-2 (-765G>C) and 5-lipoxygenase (1708G>A) in patients with colorectal cancer.
Neoplasms
Study on antitumor activities of the chrysin-chromene-spirooxindole on Lewis lung carcinoma C57BL/6 mice in vivo.
Neoplasms
Suppression of 5-lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor cell lines.
Neoplasms
Synthesis and biological evaluation of novel myrtucommulones and structural analogues that target mPGES-1 and 5-lipoxygenase.
Neoplasms
Synthesis and evaluation of 5-lipoxygenase translocation inhibitors from acylnitroso hetero-Diels-Alder cycloadducts.
Neoplasms
Synthesis of new anticancer and anti-inflammatory isoxazolines and aziridines from the natural (-)-deltoin.
Neoplasms
Synthesis of New Harmine Isoxazoles and Evaluation of their Potential Anti-Alzheimer, Anti-inflammatory, and Anticancer Activities.
Neoplasms
Synthesis of new isoxazoline derivatives from harmine and evaluation of their anti-Alzheimer, anti-cancer and anti-inflammatory activities.
Neoplasms
Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX.
Neoplasms
Tagitinin F has anti-inflammatory, anti-nociceptive and anti-matrix metalloproteinase properties: An in silico, in vitro and in vivo study.
Neoplasms
Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer.
Neoplasms
Targeting Lipid Peroxidation for Cancer Treatment.
Neoplasms
Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression.
Neoplasms
Tepoxalin a dual 5-LOX-COX inhibitor and erlotinib an EGFR inhibitor halts progression of gastric cancer in tumor xenograft mice.
Neoplasms
TGF?/SMAD signalling modulates MLL and MLL-AF4 mediated 5-lipoxygenase promoter activation.
Neoplasms
The 5-lipoxygenase inhibitor tepoxalin induces oxidative damage and altered PTEN status prior to apoptosis in canine osteosarcoma cell lines.
Neoplasms
The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
Neoplasms
The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice.
Neoplasms
The arachidonic acid-LTB4-BLT2 pathway enhances human B-CLL aggressiveness.
Neoplasms
The effect of 5-lipoxygenase inhibition on blood-brain barrier permeability in experimental brain tumors.
Neoplasms
The emerging role of targeting cancer metabolism for cancer therapy.
Neoplasms
The expression of cytosolic phospholipase A2 and biosynthesis of leukotriene B4 in acute myeloid leukemia cells.
Neoplasms
The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target.
Neoplasms
The future of cyclooxygenase-2 inhibitors and other inhibitors of the eicosanoid signal pathway in the prevention and therapy of lung cancer.
Neoplasms
The inhibitory activity of cocoa phenolic extract against pro-inflammatory mediators secretion induced by lipopolysaccharide in RAW 264.7 cells.
Neoplasms
The involvement of protein kinase C, calcium, and 5-lipoxygenase in the production of tumor necrosis factor by a cloned interleukin-3 dependent cell line with natural cytotoxic activity.
Neoplasms
The mRNA overexpression of inflammatory enzymes, phospholipase A2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1-hydroxyanthraquinone.
Neoplasms
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
Neoplasms
The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications.
Neoplasms
The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.
Neoplasms
Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model.
Neoplasms
Vitamin E metabolite 13'-carboxychromanols inhibit pro-inflammatory enzymes, induce apoptosis and autophagy in human cancer cells by modulating sphingolipids and suppress colon tumor development in mice.
Neoplasms
Zinc and iron complexes of oleanolic acid, (OA) attenuate allergic airway inflammation in rats.
Neoplasms
[Study on mechanisms and myocardial protective effect of Qishen Yiqi dropping pills on rats with myocardial infarction].
Nephritis
Increased 5-lipoxygenase activating protein in immune-mediated experimental nephritis.
Nephrotic Syndrome
5-Lipoxygenase and leukotriene A4 hydrolase expression in primary nephrotic syndrome.
Nephrotic Syndrome
Gene expression of 5-lipoxygenase and LTA4 hydrolase in renal tissue of nephrotic syndrome patients.
Nephrotic Syndrome
Nephrotic syndrome associated with N-hydroxyureas, inhibitors of 5-lipoxygenase.
Neuroblastoma
5-LOX in Alzheimer's Disease: Potential Serum Marker and In Vitro Evidences for Rescue of Neurotoxicity by Its Inhibitor YWCS.
Neuroblastoma
Involvement of 5-lipoxygenase in programmed cell death of cancer cells.
Neuroblastoma
Toxicity of human monocytic THP-1 cells and microglia toward SH-SY5Y neuroblastoma cells is reduced by inhibitors of 5-lipoxygenase and its activating protein FLAP.
Neurodegenerative Diseases
Evidence for using a dual COX 1/2 and 5-LOX inhibitor in neurodegenerative diseases.
Neurodegenerative Diseases
Exploring N1-p-Fluorobenzyl-Cymserine as an Inhibitor of 5-Lipoxygenase as a Candidate for Type 2 Diabetes and Neurodegenerative Disorder Treatment.
Neurodegenerative Diseases
Inflammatory 5-LOX mRNA and protein are increased in brain of aging rats.
Neurodegenerative Diseases
Iron-Dependent Trafficking of 5-Lipoxygenase and Impact on Human Macrophage Activation.
Neurodegenerative Diseases
Neuroprotection of (+)-2-(1-Hydroxyl-4-Oxocyclohexyl) Ethyl Caffeate Against Hydrogen Peroxide and Lipopolysaccharide Induced Injury via Modulating Arachidonic Acid Network and p38-MAPK Signaling.
Neurodegenerative Diseases
New anti-inflammatory treatment strategy in Alzheimer's disease.
Neurodegenerative Diseases
Phosphorylation of 5-LOX: The Potential Set-point of Inflammation.
Neurodegenerative Diseases
Protection of dopaminergic neurons by 5-lipoxygenase inhibitor.
Neurodegenerative Diseases
The 5-Lipoxygenase Inhibitor Zileuton Confers Neuroprotection against Glutamate Oxidative Damage by Inhibiting Ferroptosis.
Neuroinflammatory Diseases
Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damage.
Neuroinflammatory Diseases
Modulation of lipopolysaccharide-induced memory insult, ?-secretase, and neuroinflammation in triple transgenic mice by 5-lipoxygenase.
Neuroinflammatory Diseases
Naja sputatrix Venom Preconditioning Attenuates Neuroinflammation in a Rat Model of Surgical Brain Injury via PLA2/5-LOX/LTB4 Cascade Activation.
Neuroinflammatory Diseases
Neuroprotection of (+)-2-(1-Hydroxyl-4-Oxocyclohexyl) Ethyl Caffeate Against Hydrogen Peroxide and Lipopolysaccharide Induced Injury via Modulating Arachidonic Acid Network and p38-MAPK Signaling.
Neuroinflammatory Diseases
The natural dual cyclooxygenase and 5-lipoxygenase inhibitor flavocoxid is protective in EAE through effects on Th1/Th17 differentiation and macrophage/microglia activation.
Neuroinflammatory Diseases
Toxicity of human monocytic THP-1 cells and microglia toward SH-SY5Y neuroblastoma cells is reduced by inhibitors of 5-lipoxygenase and its activating protein FLAP.
Neuroinflammatory Diseases
Western blot expression of 5-lipoxygenase in the brain from striped dolphins (stenella coeruleoalba) and bottlenose dolphins (tursiops truncatus) with or without encephalitis/meningo-encephalitis of infectious nature.
Neuroinflammatory Diseases
Zileuton ameliorates depressive-like behaviors, hippocampal neuroinflammation, apoptosis and synapse dysfunction in mice exposed to chronic mild stress.
Neutropenia
The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma.
Non-alcoholic Fatty Liver Disease
Inhibition of 5-lipoxygenase inhibitor zileuton in high-fat diet-induced nonalcoholic fatty liver disease progression model.
Obesity
5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity.
Obesity
A high-fat diet induces bone loss in mice lacking the Alox5 gene.
Obesity
Arachidonate 5-lipoxygenase variants in atherosclerosis, obesity, and bone traits.
Obesity
Cysteinyl Leukotrienes (CysLTs): Role in Obesity-Induced Asthma.
Obesity
Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits.
Obesity
Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice.
Obesity
Response to arachidonate 5-lipoxygenase variants in atherosclerosis, obesity, and bone traits.
Obesity
The 5-lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease.
Osteoarthritis
5-Lipoxygenase Metabolic Contributions to NSAID-Induced Organ Toxicity.
Osteoarthritis
A new 5-lipoxygenase inhibitor seems to be safe and effective for the treatment of osteoarthritis.
Osteoarthritis
A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA.
Osteoarthritis
Anticonvulsive Effects of Licofelone on Status Epilepticus Induced by Lithium-pilocarpine in Wistar Rats: a Role for Inducible Nitric Oxide Synthase.
Osteoarthritis
Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial.
Osteoarthritis
Efficacy and safety of flavocoxid compared with naproxen in subjects with osteoarthritis of the knee- a subset analysis.
Osteoarthritis
Efficacy of licofelone in dogs with clinical osteoarthritis.
Osteoarthritis
Expression and activity of COX-1 and 2 and 5-LOX in joint tissues from dogs with naturally occurring coxofemoral joint osteoarthritis.
Osteoarthritis
In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase.
Osteoarthritis
In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis.
Osteoarthritis
Licofelone (Merckle).
Osteoarthritis
Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors.
Osteoarthritis
Licofelone inhibits interleukin-18-induced pro-inflammatory cytokine release and cellular proliferation in human mesangial cells.
Osteoarthritis
Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity.
Osteoarthritis
Licofelone, a potent COX/5-LOX inhibitor and a novel option for treatment of neurological disorders.
Osteoarthritis
Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
Osteoarthritis
Licofelone: the answer to unmet needs in osteoarthritis therapy?
Osteoarthritis
Lipoxygenase products and expression of 5-lipoxygenase and 5-lipoxygenase-activating protein in human cultured synovial cells.
Osteoarthritis
Role of eicosanoids in structural degradation in osteoarthritis.
Osteoarthritis
Safety of anti-inflammatory treatment--new ways of thinking.
Osteoarthritis
Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition.
Osteoarthritis
The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases.
Osteoarthritis
The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway.
Osteoarthritis
Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis.
Osteoarthritis, Knee
Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first Multi-Centre Clinical Trial using quantitative MRI.
Osteosarcoma
A23187-induced translocation of 5-lipoxygenase in osteosarcoma cells.
Osteosarcoma
Characterization of cloned human leukocyte 5-lipoxygenase expressed in mammalian cells.
Osteosarcoma
Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis.
Osteosarcoma
Prevalence of 5-Lipoxygenase Expression in Canine Osteosarcoma and the Effects of a Dual 5-Lipoxygenase/Cyclooxygenase Inhibitor on Osteosarcoma Cells In Vitro and In Vivo.
Osteosarcoma
The 5-lipoxygenase inhibitor tepoxalin induces oxidative damage and altered PTEN status prior to apoptosis in canine osteosarcoma cell lines.
Ovarian Neoplasms
Acquired cisplatin resistance in human ovarian A2780 cancer cells correlates with shift in taurine homeostasis and ability to volume regulate.
Ovarian Neoplasms
Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration.
Ovarian Neoplasms
Lipoxygenase pathway receptor expression in ovarian cancer.
Ovarian Neoplasms
TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling.
Overweight
The effect of low-dose marine n-3 fatty acids on the biosynthesis of pro-inflammatory 5-lipoxygenase pathway metabolites in overweight subjects: A randomized controlled trial.
Pancreatic Neoplasms
5-Lipoxygenase and Cyclooxygenase inhibitory Dammarane triterpenoid 1 from Borassus flabellifer seed coat, inhibits Tumor Necrosis Factor-? secretion in LPS induced THP-1 human monocytes and induces apoptosis in MIA PaCa-2 Pancreatic cancer cells.
Pancreatic Neoplasms
5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue.
Pancreatic Neoplasms
5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions.
Pancreatic Neoplasms
A novel anti-pancreatic cancer agent, LY293111.
Pancreatic Neoplasms
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints.
Pancreatic Neoplasms
Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor.
Pancreatic Neoplasms
Altered oncogene, tumor suppressor and cell-cycle gene expression in PANC-1 cells cultured with the pleiotrophic 5-lipoxygenase inhibitor, MK886, assessed with a gene chip.
Pancreatic Neoplasms
Caspase-dependent and -independent panc-1 cell death due to actinomycin D and MK 886 are additive but increase clonogenic survival.
Pancreatic Neoplasms
Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer.
Pancreatic Neoplasms
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
Pancreatic Neoplasms
Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.
Pancreatic Neoplasms
Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase.
Pancreatic Neoplasms
Five-lipoxygenase inhibitors reduce Panc-1 survival: the mode of cell death and synergism of MK886 with gamma linolenic acid.
Pancreatic Neoplasms
Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells.
Pancreatic Neoplasms
Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.
Pancreatic Neoplasms
Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells.
Pancreatic Neoplasms
Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells.
Pancreatic Neoplasms
Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway.
Pancreatic Neoplasms
Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer.
Pancreatic Neoplasms
Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model.
Pancreatitis
5-lipoxygenase knockout mice exhibit a resistance to acute pancreatitis induced by cerulein.
Pancreatitis
Acute pancreatitis.
Pancreatitis
Effects of dual inhibitor of cyclooxygenase and 5-lipoxygenase on acute necrotizing pancreatitis in rats.
Pancreatitis
Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis.
Pancreatitis
Inhibition of 5-lipoxygenase represses neutrophils activation and activates apoptosis in pancreatic tissues during acute necrotizing pancreatitis.
Pancreatitis
Leukotriene generation and neutrophil infiltration after experimental acute pancreatitis.
Pancreatitis
Protective effect of AA-861 (5-lipoxygenase inhibitor) on experimental acute necrotizing pancreatitis in rats.
Pancreatitis, Acute Necrotizing
Effects of dual inhibitor of cyclooxygenase and 5-lipoxygenase on acute necrotizing pancreatitis in rats.
Pancreatitis, Acute Necrotizing
Inhibition of 5-lipoxygenase represses neutrophils activation and activates apoptosis in pancreatic tissues during acute necrotizing pancreatitis.
Pancreatitis, Acute Necrotizing
Protective effect of AA-861 (5-lipoxygenase inhibitor) on experimental acute necrotizing pancreatitis in rats.
Paracoccidioidomycosis
5-Lipoxygenase Activity Increases Susceptibility to Experimental Paracoccidioides brasiliensis Infection.
Parasitemia
5-Lipoxygenase is a key determinant of acute myocardial inflammation and mortality during Trypanosoma cruzi infection.
Parkinson Disease
Cysteinyl Leukotrienes and Their Receptors: Emerging Therapeutic Targets in Central Nervous System Disorders.
Parkinson Disease
Evaluation of the neuroprotective and antidiabetic potential of phenol-rich extracts from virgin olive oils by in vitro assays.
Parkinson Disease
Nutraceutical Potential of Phenolics from 'Brava' and 'Mansa' Extra-Virgin Olive Oils on the Inhibition of Enzymes Associated to Neurodegenerative Disorders in Comparison with Those of 'Picual' and 'Cornicabra'.
Parkinson Disease
Protection of dopaminergic neurons by 5-lipoxygenase inhibitor.
Parkinson Disease
[5-lipoxygenase is involved in rotenone-induced injury in PC12 cells].
Pemphigoid, Bullous
Increased levels of immunoreactive leukotriene B4 in blister fluids of bullous pemphigoid patients and effects of a selective 5-lipoxygenase inhibitor on experimental skin lesions.
Periapical Periodontitis
5-Lipoxygenase Knockout Aggravated Apical Periodontitis in a Murine Model.
Periapical Periodontitis
Dual Role of 5-Lipoxygenase in Osteoclastogenesis in Bacterial-induced Apical Periodontitis.
Periapical Periodontitis
Effects of 5-lipoxygenase gene disruption on inflammation, osteoclastogenesis and bone resorption in polymicrobial apical periodontitis.
Periodontal Diseases
Inhibition of 5-Lipoxygenase (5-Lo) Attenuates Inflammation and Bone Resorption in Lipopolysaccharide (Lps)-Induced Periodontal Disease.
Periodontal Diseases
Inhibition of 5-lipoxygenase attenuates inflammation and BONE resorption in lipopolysaccharide-induced periodontal disease.
Peripheral Nervous System Diseases
Toxic peripheral neuropathy with demyelination in Sprague-Dawley rats given CGS 21595--a 5-lipoxygenase inhibitor.
Peritonitis
Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid.
Peritonitis
Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice.
Peritonitis
Endogenous metabolites of vitamin E limit inflammation by targeting 5-lipoxygenase.
Peritonitis
Molecular modeling of the non-covalent binding of the dietary tomato carotenoids lycopene and lycophyll, and selected oxidative metabolites with 5-lipoxygenase.
Peritonitis
Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation.
Peritonitis
[Effects of anti-toxic agents in septic shock]
Pharyngitis
Yan-Hou-Qing formula attenuates ammonia-induced acute pharyngitis in rats via inhibition of NF-?B and COX-2.
Pleural Effusion
LTB4 is present in exudative pleural effusions and contributes actively to neutrophil recruitment in the inflamed pleural space.
Pleural Effusion
Possible involvement of eicosanoids in alpha-naphthylthiourea-induced pulmonary oedema and alteration of angiotensin-converting enzyme activity.
Pleurisy
5-Lipoxygenase knockout mice exhibit a resistance to pleurisy and lung injury caused by carrageenan.
Pleurisy
Anti-inflammatory profile of N-phenylpyrazole arylhydrazone derivatives in rats.
Pleurisy
Arachidonic acid-induced pleurisy (ARIP): an in vivo model for testing 5-lipoxygenase inhibition.
Pleurisy
Comparison of several new 5-lipoxygenase inhibitors in a rat Arthus pleurisy model.
Pleurisy
Effects of TZI-41127, a novel selective 5-lipoxygenase inhibitor, on A23187-induced pleurisy in rats.
Pleurisy
Inhibition of LTB4 biosynthesis in situ by CGS 23885, a potent 5-lipoxygenase inhibitor, correlates with its pleural fluid concentrations in an experimentally induced rat pleurisy model.
Pleurisy
Involvement of leukotriene B4 in zymosan-induced rat pleurisy: inhibition of leukocyte infiltration by the 5-lipoxygenase inhibitor T-0757.
Pleurisy
Role of leukotrienes in rat reversed passive Arthus pleurisy and the effect of AA-861, a 5-lipoxygenase inhibitor.
Pleurisy
Roles of leukotrienes in two rat allergic inflammatory models; IgE-mediated and IgG-antigen complex-induced pleurisies.
Pleuropneumonia
5-Lipoxygenase and cyclooxygenase-2 in the lungs of pigs naturally affected by enzootic pneumonia and porcine pleuropneumonia.
Pneumonia
5-Lipoxygenase and cyclooxygenase-2 in the lungs of pigs naturally affected by enzootic pneumonia and porcine pleuropneumonia.
Pneumonia
A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings.
Pneumonia
Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice.
Pneumonia
Electrophilic Fatty Acid Species Inhibit 5-Lipoxygenase and Attenuate Sepsis-Induced Pulmonary Inflammation.
Pneumonia
Inhibition by methylprednisolone of zymosan-induced leukotriene synthesis in alveolar macrophages.
Pneumonia
Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor.
Pneumonia
Leukotriene B4 receptors contribute to house dust mite-induced eosinophilic airway inflammation via TH2 cytokine production.
Pneumonia
Leukotrienes in pulmonary arterial hypertension.
Pneumonia
Phenotypically-Silent Bone Morphogenetic Protein Receptor 2 (Bmpr2) Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing The Risk for Neointimal Transformation.
Pneumonia
Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.
Pneumonia
Role of 5-lipoxygenase in IL-13-induced pulmonary inflammation and remodeling.
Pneumonia
The importance of leukotrienes in airway inflammation in a mouse model of asthma.
Pneumonia
The peroxisome proliferator-activated receptor agonist pioglitazone and 5-lipoxygenase inhibitor zileuton have no effect on lung inflammation in healthy volunteers by positron emission tomography in a single-blind placebo-controlled cohort study.
Polycythemia Vera
A drug targeting 5-lipoxygenase enhances the activity of a JAK2 inhibitor in CD34+ bone marrow cells from patients with JAK2V617F-positive polycythemia vera in vitro.
Polymyositis
The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis.
Pouchitis
Increased leukotriene B4 release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis.
Pre-Eclampsia
Cyclooxygenase gene expression in human endometrium and decidua.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Diverse expression of cytosolic phospholipase A2, 5-lipoxygenase and prostaglandin H synthase 2 in acute pre-B-lymphocytic leukaemia cells.
Premature Birth
Plasma oxylipins and unesterified precursor fatty acids are altered by DHA supplementation in pregnancy: Can they help predict risk of preterm birth?
Prostatic Hyperplasia
Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.
Prostatic Neoplasms
15-Lipoxygenase-1-mediated metabolism of docosahexaenoic acid is required for syndecan-1 signaling and apoptosis in prostate cancer cells.
Prostatic Neoplasms
5-Lipoxygenase expression in benign and malignant canine prostate tissues.
Prostatic Neoplasms
Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase.
Prostatic Neoplasms
Anticancer effects of licofelone (ML-3000) in prostate cancer cells.
Prostatic Neoplasms
Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase.
Prostatic Neoplasms
Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells.
Prostatic Neoplasms
Chemistry and biology for the small molecules targeting characteristics of cancer cells.
Prostatic Neoplasms
Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription.
Prostatic Neoplasms
Enhanced formation of 5-oxo-6,8,11,14-eicosatetraenoic acid by cancer cells in response to oxidative stress, docosahexaenoic acid, and neutrophil-derived 5-hydroxy-6,8,11,14-eicosatetraenoic acid.
Prostatic Neoplasms
Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival.
Prostatic Neoplasms
Fatty acid oxidation and signaling in apoptosis.
Prostatic Neoplasms
Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk.
Prostatic Neoplasms
Inhibition of 5-lipoxygenase downregulates stemness and kills prostate cancer stem cells by triggering apoptosis via activation of c-Jun N-terminal kinase.
Prostatic Neoplasms
Inhibition of 5-Lipoxygenase Selectively Triggers Disruption of c-Myc Signaling in Prostate Cancer Cells.
Prostatic Neoplasms
Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon.
Prostatic Neoplasms
Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells.
Prostatic Neoplasms
Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase.
Prostatic Neoplasms
Inhibitor of 5-lipoxygenase, zileuton, suppresses prostate cancer metastasis by upregulating E-cadherin and paxillin.
Prostatic Neoplasms
Lycopodine triggers apoptosis by modulating 5-lipoxygenase, and depolarizing mitochondrial membrane potential in androgen sensitive and refractory prostate cancer cells without modulating p53 activity: signaling cascade and drug-DNA interaction.
Prostatic Neoplasms
MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase.
Prostatic Neoplasms
MK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: implications for the treatment of castration-resistant, bone-metastatic prostate cancer.
Prostatic Neoplasms
Molecular mechanisms of prostate cancer cell death triggered by inhibition of arachidonate 5-lipoxygenase: involvement of Fas death receptor-mediated signals.
Prostatic Neoplasms
OXER1, a G protein-coupled oxoeicosatetraenoid receptor, mediates the survival-promoting effects of arachidonate 5-lipoxygenase in prostate cancer cells.
Prostatic Neoplasms
Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis.
Prostatic Neoplasms
Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase.
Prostatic Neoplasms
Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.
Prostatic Neoplasms
The effects of oral Cardax (disodium disuccinate astaxanthin) on multiple independent oxidative stress markers in a mouse peritoneal inflammation model: influence on 5-lipoxygenase in vitro and in vivo.
Prostatic Neoplasms
Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKC? without inhibiting Akt.
Proteinuria
Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species. Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives.
Proteinuria
Effects of celecoxib and nordihydroguaiaretic acid on puromycin aminonucleoside-induced nephrosis in the rat.
Proteinuria
Functional significance of leukotriene B4 in normal and glomerulonephritic kidneys.
Proteinuria
Inhibition of 5-lipoxygenase activating protein decreases proteinuria in diabetic rats.
Proteinuria
Involvement of lipid mediators in the pathogenesis of experimental nephrosis in rats: its pharmacological modulation.
Proteinuria
Involvement of thromboxane A2, leukotrienes and free radicals in puromycin nephrosis in rats.
Pruritus
Double-blinded, placebo-controlled, cross-over pilot study on the efficacy of zileuton for canine atopic dermatitis.
Pruritus
Possible involvement of 5-lipoxygenase metabolite in itch-associated response of mosquito allergy in mice.
Pruritus
Potential new therapeutic targets for pathological pruritus.
Psoriasis
5-Lipoxygenase activation in psoriasis: a dead issue?
Psoriasis
A double-blind vehicle-controlled study of R 68 151 in psoriasis: a topical 5-lipoxygenase inhibitor.
Psoriasis
Arachidonic acid metabolism by polymorphonuclear leukocytes in psoriasis.
Psoriasis
Chemotactic lipoxygenase products in sera from patients with psoriasis.
Psoriasis
Current status and recent developments in anthracenone antipsoriatics.
Psoriasis
Effect of 5-lipoxygenase inhibition on events associated with inflammatory bowel disease in rats.
Psoriasis
Fuscoside: an anti-inflammatory marine natural product which selectively inhibits 5-lipoxygenase. Part II: Biochemical studies in the human neutrophil.
Psoriasis
In vitro inhibition of leukotriene B4 formation by exogeneous 5-lipoxygenase inhibitors is associated with enhanced generation of 15-hydroxy-eicosatetraenoic acid (15-HETE) by human neutrophils.
Psoriasis
Influence of traditional Chinese anti-inflammatory medicinal plants on leukocyte and platelet functions.
Psoriasis
Inhibition of ionophore-stimulated leukotriene B4 production in human leucocytes by monohydroxy fatty acids.
Psoriasis
Modulation of epidermal cell division and growth by oxygenation products of arachidonic acid.
Psoriasis
n-3 fatty acids in psoriasis.
Psoriasis
Non steroidal anti-inflammatory and anti-allergy agents.
Psoriasis
Percutaneous absorption and metabolism of lonapalene in psoriatic skin.
Psoriasis
Pharmacologic and clinical effects of lonapalene (RS 43179), a 5-lipoxygenase inhibitor, in psoriasis.
Psoriasis
Polymorphonuclear leukocyte 5-lipoxygenase activity in psoriasis.
Psoriasis
Potent antagonism of calmodulin activity in vitro, but lack of antiproliferative effects on keratinocytes by the novel leukotriene biosynthesis inhibitor MK-886.
Psoriasis
Selective decrease of 15-hydroxyeicosatetraenoic acid (15-HETE) formation in uninvolved psoriatic dermis.
Psoriasis
Significance of leukotriene-A4 hydrolase in the pathogenesis of psoriasis.
Psoriasis
Sulfasalazine in treatment of psoriasis.
Psoriasis
The inflammatory response of rabbit skin to topical arachidonic acid and its pharmacological modulation.
Psoriasis
Topical nonsteroidal antipsoriatic agents. 2. 2,3-(Alkylidenedioxy)naphthalene analogues of lonapalene.
Psoriasis
Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis.
Psoriasis
[Leukotrienes. A review of the significance for disease in man and the possibilities for therapeutic intervention]
Psoriasis
[Partially hydrogenated aryl-1,2/1,4-anthraquinone derivatives, 5-lipoxygenase inhibitors with arotinoid structure]
Pulmonary Arterial Hypertension
A new treatment for severe pulmonary arterial hypertension based on an old idea: inhibition of 5-lipoxygenase.
Pulmonary Arterial Hypertension
HIV X4 Variants Increase Arachidonate 5-Lipoxygenase in the Pulmonary Microenvironment and are associated with Pulmonary Arterial Hypertension.
Pulmonary Atelectasis
Antagonism of leukotriene receptors and administration of a 5-lipoxygenase inhibitor do not affect hypoxic vasoconstriction.
Pulmonary Disease, Chronic Obstructive
5-lipoxygenase inhibitors for the treatment of COPD.
Pulmonary Disease, Chronic Obstructive
A turn on and a turn off: BLT1 and BLT2 mechanisms in the lung.
Pulmonary Disease, Chronic Obstructive
Effect of the 5-lipoxygenase inhibitor, fenleuton, on antigen-induced neutrophil accumulation and lung function changes in horses with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Leukotrienes in respiratory disease.
Pulmonary Disease, Chronic Obstructive
Lipid peroxidation and 5-lipoxygenase activity in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Phytochemical study, molecular docking, genotoxicity and therapeutic efficacy of the aqueous extract of the stem bark of Ximenia americana L. in the treatment of experimental COPD in rats.
Pulmonary Disease, Chronic Obstructive
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
Pulmonary Eosinophilia
A semisynthetic diterpenoid lactone inhibits NF-?B signalling to ameliorate inflammation and airway hyperresponsiveness in a mouse asthma model.
Pulmonary Eosinophilia
Eotaxin and RANTES enhance 5-oxo-6,8,11,14-eicosatetraenoic acid-induced eosinophil chemotaxis.
Pulmonary Eosinophilia
Suppressive effects of F-1322 on the antigen-induced late asthmatic response and pulmonary eosinophilia in guinea pigs.
Pulmonary Fibrosis
Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice.
Pulmonary Fibrosis
Protection from pulmonary fibrosis in leukotriene-deficient mice.
Pulmonary Fibrosis
The 5-lipoxygenase pathway: a new therapeutic target for the treatment of pulmonary fibrosis.
Renal Insufficiency
Protective effect of peptide leukotriene antagonist on renal failure induced by a tourniquet in rabbits.
Renal Insufficiency, Chronic
Inhibition of 5-Lipoxygenase Decreases Renal Fibrosis and Progression of Chronic Kidney Disease.
Reperfusion Injury
Characterization of LY233569 on 5-lipoxygenase and reperfusion injury of ischemic myocardium.
Reperfusion Injury
Effect of nordihydroguaiaretic acid on behavioral impairment and neuronal cell death after forebrain ischemia.
Reperfusion Injury
Effects of the arachidonate 5-lipoxygenase synthesis inhibitor A-64077 in intestinal ischemia-reperfusion injury.
Reperfusion Injury
In vivo correlation of neutrophil receptor expression, ischemia-reperfusion injury, and selective 5-lipoxygenase inhibition in guinea pigs.
Reperfusion Injury
Ischemia-reperfusion injury in myocutaneous flaps: role of leukocytes and leukotrienes.
Reperfusion Injury
Protective effect of the 5-lipoxygenase inhibitor ardisiaquinone A on hepatic ischemia-reperfusion injury in rats.
Reperfusion Injury
Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton.
Reperfusion Injury
Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice.
Reperfusion Injury
Systemic neutrophil intrinsic 5-lipoxygenase activity and CD18 receptor expression linked to reperfusion injury.
Reperfusion Injury
The role of 5-lipoxygenase and leukotrienes in shock and ischemia-reperfusion injury.
Reperfusion Injury
The selective 5-LOX inhibitor 11-keto-?-boswellic acid protects against myocardial ischemia reperfusion injury in rats: involvement of redox and inflammatory cascades.
Reperfusion Injury
[Mechanism of Musk and Borneol on Inflammatory of Cerebral Ischemia and Reperfusion Injury at Different Time Points of Acute Phase in Rats].
Respiratory Distress Syndrome
Functional variants of the human 5-lipoxygenase gene and their genetic diagnosis.
Respiratory Distress Syndrome
Therapeutic intervention in a rat model of adult respiratory distress syndrome: II. Lipoxygenase pathway inhibition.
Respiratory Distress Syndrome
Therapeutic intervention in a rat model of ARDS: I. Dual inhibition of arachidonic acid metabolism.
Respiratory Hypersensitivity
Leukotriene enhanced allergic lung inflammation through induction of chemokine production.
Respiratory Insufficiency
5-Lipoxygenase deficiency prevents respiratory failure during ventilator-induced lung injury.
Rhinitis, Allergic
Allergen-stimulated leukotriene B4 and interleukin-8 levels in patients with asthma and allergic rhinitis-modulation by a lipid pathway inhibitor.
Rhinitis, Allergic
Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005.
Rhinitis, Allergic
Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor.
Rhinitis, Allergic
The effects of anti-PAF and other agents on the nasal symptoms in sensitized guinea pigs.
Rhinitis, Allergic
The influence of 5-lipoxygenase inhibition in allergic rhinitis.
Rhinitis, Allergic
The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).
Rhinitis, Allergic
[Studies on the experimental allergic rhinitis induced by Japanese cedar pollen--role of cysteinyl leukotrienes in nasal allergic symptoms]
Rhinitis, Allergic, Seasonal
Leukotrienes as mediators of nasal inflammation.
Rhinitis, Allergic, Seasonal
Randomized double-blind, placebo-controlled clinical trial of a selective 5-lipoxygenase inhibitor (AA-861) for the prevention of seasonal allergic rhinitis.
Schistosomiasis
Mice deficient for 5-lipoxygenase, but not leukocyte-type 12-lipoxygenase, display altered immune responses during infection with Schistosoma mansoni.
Scleroderma, Systemic
Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis.
Seizures
Are leukotrienes or PAF involved in hyperbaric oxygen toxicity?
Seizures
On the relation between cerebral cysteinyl-leukotriene formation and epileptic seizures.
Sepsis
5-Lipoxygenase activating protein (FLAP) dependent leukotriene biosynthesis inhibition (MK591) attenuates Lipid A endotoxin-induced inflammation.
Sepsis
Colonic microvascular integrity in acute endotoxaemia: interactions between constitutive nitric oxide and 5-lipoxygenase products.
Sepsis
Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis.
Sepsis
In silico system pharmacology for the potential bioactive ingredients contained in Xingnaojing Injection () and Its material basis for sepsis treatment.
Sepsis
Induction of inducible nitric oxide synthase by lipopolysaccharide/interferon gamma and sepsis down-regulates 5-lipoxygenase metabolism in murine alveolar macrophages.
Sepsis
Inhibition of 5-lipoxygenase is associated with downregulation of the leukotriene B4 receptor 1/ Interleukin-12p35 pathway and ameliorates sepsis-induced myocardial injury.
Sepsis
Leukotriene B4-mediated sterile inflammation promotes susceptibility to sepsis in a mouse model of type 1 diabetes.
Sepsis
Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis.
Sepsis
Pivotal Role of 5-Lipoxygenase Pathway in Lung Injury After Experimental Sepsis.
Sinusitis
Advances in upper airway diseases and allergen immunotherapy.
Sinusitis
Frankincense--therapeutic properties.
Sjogren-Larsson Syndrome
5-Lipoxygenase inhibition: a new treatment strategy for Sjögren-Larsson syndrome.
Skin Diseases
Cellular and biochemical characterization of the anti-inflammatory effects of DuP 654 in the arachidonic acid murine skin inflammation model.
Skin Diseases
Identification of 4-[4-(4-fluoro-phenyl)-thiazol-2-ylamino]-2,6-dimethyl-phenol (KR-33749) as an inhibitor of 5-lipoxygenase with potent antiinflammatory activity.
Skin Diseases
In vitro 5-Lipoxygenase and Anti-Oxidant Activities of South African Medicinal Plants Commonly Used Topically for Skin Diseases.
Skin Diseases
Inhibition of ionophore-stimulated leukotriene B4 production in human leucocytes by monohydroxy fatty acids.
Skin Diseases
The lipoxygenase inhibitor 2-phenylmethyl-1-naphthol (DuP 654) is a 12(S)-hydroxyeicosatetraenoic acid receptor antagonist in the human epidermal cell line SCL-II.
Skin Diseases
Treatment of hyperkeratotic skin diseases with R 68151, a topical 5-lipoxygenase inhibitor: four case reports.
Skin Neoplasms
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.
Sleep Apnea, Obstructive
Urine Concentrations of Cysteinyl Leukotrienes in Children With Obstructive Sleep-Disordered Breathing.
Spasm
Influence of atherosclerosis on the vascular reactivity of isolated human epicardial coronary arteries to leukotriene C4.
Spinal Cord Injuries
Involvement of 5-lipoxygenase in spinal cord injury.
Spinal Cord Injuries
Thromboxane and 5-HETE increase after experimental spinal cord injury in rabbits.
Squamous Cell Carcinoma of Head and Neck
5-lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats.
Squamous Cell Carcinoma of Head and Neck
5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells.
ST Elevation Myocardial Infarction
Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction.
Staphylococcal Infections
Reconstitution of Staphylococcus aureus Lipoteichoic Acid Synthase Activity Identifies Congo Red as a Selective Inhibitor.
Stomach Neoplasms
15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer.
Stomach Neoplasms
5-Lipoxygenase promotes epithelial-mesenchymal transition through the ERK signaling pathway in gastric cancer.
Stomach Neoplasms
Activation of 5-lipoxygenase is required for nicotine mediated epithelial-mesenchymal transition and tumor cell growth.
Stomach Neoplasms
CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer.
Stomach Neoplasms
The role of transient receptor potential channel blockers in human gastric cancer cell viability.
Stomach Neoplasms
Upregulation of leukotriene receptors in gastric cancer.
Stomach Ulcer
5-Lipoxygenase products: their biosynthesis in human gastric mucosa and possible involvement in inflammatory response and oxygen saturation index reduction in gastric ulcer patients.
Stomach Ulcer
Antiulcer Potential of Olea europea L. cv. Arbequina Leaf Extract Supported by Metabolic Profiling and Molecular Docking.
Stroke
5-Lipoxygenase activating protein (ALOX5AP): association with cardiovascular infarction and stroke.
Stroke
Advances in the genetic basis of coronary artery disease.
Stroke
ALOX5AP gene and the PDE4D gene in a central European population of stroke patients.
Stroke
Association of 5-lipoxygenase activating protein gene polymorphism and stroke: A study from north east of Iran.
Stroke
Association of ALOX5AP with ischemic stroke in eastern Chinese.
Stroke
Association of ALOX5AP1 SG13S114T/A variant with ischemic stroke, stroke subtypes and aspirin resistance.
Stroke
Genetic polymorphisms that predict outcome and need for treatment in cardiovascular disease.
Stroke
Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: a replication study in two independent populations.
Stroke
Inhibition of NF-kappaB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia.
Stroke
Interaction between ALOX5AP and CYP3A5 gene variants significantly increases the risk for cerebral infarctions in Chinese.
Stroke
Interaction of genetic risk factors confers higher risk for thrombotic stroke in male Chinese: a multicenter case-control study.
Stroke
Phosphodiesterase 4D and 5-lipoxygenase activating protein genes and risk of ischemic stroke in Sardinians.
Stroke
Polymorphism of SG13S114T/A in the ALOX5AP gene and the risk for stroke in a large Chinese cohort.
Stroke
Synergistic effect of ALOX5AP polymorphisms and cigarette smoking on the risk of atherosclerotic cerebral infarction in a Northern Han Chinese population.
Stroke
Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke.
Stroke
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke.
Stroke
The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field.
Stroke
Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population.
Stroke
[Polymorphic variants of ALOX5AP gene and the risk of acute stroke development in the Russian population].
Subarachnoid Hemorrhage
5-Lipoxygenase inhibition reduces inflammation and neuronal apoptosis via AKT signaling after subarachnoid hemorrhage in rats.
Subarachnoid Hemorrhage
Effect of leukotrienes, 12-HETE, histamine, bradykinin, and 5-hydroxytryptamine on in vivo rabbit cerebral arteriolar diameter.
Subarachnoid Hemorrhage
The novel 5-lipoxygenase inhibitor ABT-761 attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage.
Tauopathies
Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice.
Tauopathies
Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase.
Tauopathies
Overexpression of 5-Lipoxygenase Worsens the Phenotype of a Mouse Model of Tauopathy.
Tauopathies
Pharmacologic Inhibition of 5-Lipoxygenase Improves Memory, Rescues Synaptic Dysfunction, and Ameliorates Tau Pathology in a Transgenic Model of Tauopathy.
Tauopathies
The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy.
Testicular Neoplasms
Relationship between lipoxygenase and human testicular cancer.
Thrombocytopenia
Haemodynamic and haematologic effects of Acanthaster planci venom in dogs.
Thrombosis
Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus.
Thrombosis
Impact of Aspirin Eugenol Ester on Cyclooxygenase-1, Cyclooxygenase-2, C-Reactive Protein, Prothrombin and Arachidonate 5-Lipoxygenase in Healthy Rats.
Thrombosis
Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors.
Thrombosis
[Prevention of thrombosis and vascular inflammation: importance of combined cyclooxygenase and 5-lipoxygenase inhibitors]
Thyroid Cancer, Papillary
Arachidonate 5 lipoxygenase expression in papillary thyroid carcinoma promotes invasion via MMP-9 induction.
Toxic Optic Neuropathy
Optimization of imidazole 5-lipoxygenase inhibitors and selection and synthesis of a development candidate.
Toxoplasmosis
Lipoxin A? and 15-epi-lipoxin A? protect against experimental cerebral malaria by inhibiting IL-12/IFN-? in the brain.
Trypanosomiasis
Biological activities of xanthatin from Xanthium strumarium leaves.
Tuberculosis
ALOX5 variants associated with susceptibility to human pulmonary tuberculosis.
Tuberculosis
Chemokine secretion by human polymorphonuclear granulocytes after stimulation with Mycobacterium tuberculosis and lipoarabinomannan.
Tuberculosis
Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis.
Tularemia
Lipoxin A4, a 5-lipoxygenase pathway metabolite, modulates immune response during acute respiratory tularemia.
Ureteral Obstruction
Increases in glomerular eicosanoid production in rats with bilateral ureteral obstruction are mediated by enhanced enzyme activities of both the cyclooxygenase and 5-lipoxygenase pathways.
Urinary Bladder Neoplasms
Antitumor effects of lipoxygenase inhibitors on murine bladder cancer cell line (MBT-2).
Urinary Bladder Neoplasms
Inhibition of 5-lipoxygenase pathway suppresses the growth of bladder cancer cells.
Urinary Bladder Neoplasms
Inhibition of human 5-lipoxygenase and anti-neoplastic effects by 2-amino-1,4-benzoquinones.
Urinary Bladder Neoplasms
Lipoxygenase Protein Expression and Its Effect on Oxidative Stress Caused by Benzidine in Normal Human Urothelial Cell Lines.
Urologic Neoplasms
Lipoxygenase inhibitors prevent urological cancer cell growth.
Urticaria
NSAID-induced urticaria and angioedema: a reappraisal of its clinical management.
Uterine Cervical Neoplasms
Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells.
Uveitis
Concomitant treatment with a 5-lipoxygenase inhibitor improves the anti-inflammatory effect of the inhibition of nitric oxide synthase during the early phase of endotoxin-induced uveitis in the rabbit.
Uveitis
Steroidal and nonsteroidal drugs in endotoxin-induced uveitis.
Uveitis
The role of arachidonate metabolites in ocular inflammation.
Vascular Diseases
5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9.
Vascular Ring
Variable effects of human and canine polymorphonuclear leucocytes on vascular smooth muscle tone.
Vascular System Injuries
Leukocyte mediated vein injury and thrombosis is reduced by a lipoxygenase inhibitor.
Vascular System Injuries
Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury.
Vasospasm, Intracranial
Cysteinyl leukotrienes and leukotriene B mediate vasoconstriction to arginine vasopressin in rat basilar artery.
Vasospasm, Intracranial
Effect of 5-lipoxygenase inhibitor on experimental delayed cerebral vasospasm.
Vasospasm, Intracranial
Participation of vasopressin in the development of cerebral vasospasm in a rat model of subarachnoid haemorrhage.
Vasospasm, Intracranial
The novel 5-lipoxygenase inhibitor ABT-761 attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage.
Ventilator-Induced Lung Injury
5-Lipoxygenase deficiency prevents respiratory failure during ventilator-induced lung injury.
Virus Diseases
The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications.
Whooping Cough
15-Hydroxyeicosatetraenoic acid (15-HETE) receptors. Involvement in the 15-HETE-induced stimulation of the cryptic 5-lipoxygenase in PT-18 mast/basophil cells.
Whooping Cough
Activation of the human neutrophil 5-lipoxygenase by exogenous arachidonic acid: involvement of pertussis toxin-sensitive guanine nucleotide-binding proteins.
Whooping Cough
Arachidonic acid metabolites as intracellular modulators of the G protein-gated cardiac K+ channel.
Whooping Cough
Integrin-dependent homotypic adhesion of neutrophils. Arachidonic acid activates Raf-1/Mek/Erk via a 5-lipoxygenase- dependent pathway.
Whooping Cough
Regulation of the human leukocyte 5-lipoxygenase: stimulation by micromolar Ca2+ levels and phosphatidylcholine vesicles.
Xanthomatosis
5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00051
(1E)-1-(2,5-dihydroxyphenyl)-5-phenylpent-1-en-3-one
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
-
0.00052
(1E)-1-(3,4-dihydroxyphenyl)-6-phenylhex-1-en-3-one
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
-
0.00041
(1E)-1-(4-hydroxy-3,5-dimethoxyphenyl)-5-phenylpent-1-en-3-one
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
-
0.000572
(2E,6E,10E)-13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)-N-(4-methoxybenzyl)-2,6,10-trimethyltrideca-2,6,10-trienamide
Homo sapiens
pH 7.4, 37°C
-
0.000094
(2E,6E,10E)-13-((R)-6-hydroxy-2,8-dimethylchroman-2-yl)-N-(4-methoxybenzyl)-2,6,10-trimethyltrideca-2,6,10-trienamide
Homo sapiens
pH 7.4, 37°C
-
0.000077
(2E,6E,10E)-13-(6-hydroxy-2,8-dimethylchroman-2-yl)-2,6,10-trimethyl-N-(pyridin-3-ylmethyl)trideca-2,6,10-trienamide
Homo sapiens
pH 7.4, 37°C
-
0.000595
(2E,6E,10E)-N-benzyl-13-((R)-6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)-2,6,10-trimethyltrideca-2,6,10-trienamide
Homo sapiens
pH 7.4, 37°C
-
0.00005
(2E,6E,10E)-N-benzyl-13-((R)-6-hydroxy-2,8-dimethylchroman-2-yl)-2,6,10-trimethyltrideca-2,6,10-trienamide
Homo sapiens
pH 7.4, 37°C
-
0.0019
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl) methyl)-N-hydroxyheptanamide
Homo sapiens
pH 7.5, 25°C
-
0.0016
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl) methyl)-N-hydroxyoctanamide
Homo sapiens
pH 7.5, 25°C
-
0.0033
(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)-N-hydroxypentanamide
Homo sapiens
pH 7.5, 25°C
-
0.00011
(R)-N-(2-(diphenylamino)ethyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide, (R)-N-(3,3-bis(4-fluorophenyl)propyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide
Homo sapiens
pH 7.4, 37°C
-
0.00011
(R)-N-(3,3-bis(4-fluorophenyl)propyl)-3-(3-(1-hydroxyureido)but-1-yn-1-yl)benzamide
Homo sapiens
-
pH 7.4, 37°C
-
0.0013
1-(3-[5-(hydroxyureido)methyl-2-methoxyphenoxy]propyl)-3-[4-(trifluoromethoxy)phenyl]urea
Homo sapiens
pH 7.4, 37°C
0.0006
10-nitro-oleic acid
Homo sapiens
pH 7.4, 37°C
-
0.05
2,3-dichlorophenyl 3,5-dinitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.00026
2,5-dimethoxy-3-tridecylbenzene-1,4-diol
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00032 - 0.00033
2-phenylethyl (2E)-3-(2,5-dihydroxyphenyl)prop-2-enoate
-
0.00029
2-phenylethyl (2E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoate
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
-
0.00031
3,4,6-trimethoxy-5-undecylcyclohexa-2,4-dien-1-one
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.05
3-((naphthalene-1-yloxy)carbonyl)benzoic acid
Homo sapiens
pH 7.4, 37°C
0.00146
3-(1,10-dihydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00049
3-(1-acetoxy-10-hydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00175
3-(10-hydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00108
3-(10-hydroxydecyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00151
3-(11-hydroxyundecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00196
3-(11-hydroxyundecyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0007
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
Homo sapiens
pH 7.4, 37°C
-
0.00011
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(3-phenyl-3-(4-(trifluoromethoxy)phenyl)propyl)benzamide
Homo sapiens
pH 7.4, 37°C
-
0.0017
3-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(4-methoxy-2-(trifluoromethyl)benzyl)-benzamide
Homo sapiens
pH 7.4, 37°C
-
0.0003
3-(3-(1-hydroxyureido)hex-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
Homo sapiens
pH 7.4, 37°C
-
0.00184
3-(8-hydroxyoctyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00022
3-(8-hydroxyoctyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.05
3-(benzyloxycarbonyl)benzoic acid
Homo sapiens
pH 7.4, 37°C
0.05
3-(naphhthalen-1-ylcarbmoyl)benzoic acid
Homo sapiens
pH 7.4, 37°C
0.05
3-(phenylcarbamoyl)benzoic acid
Homo sapiens
pH 7.4, 37°C
0.00024
3-dodecyl-4,5-dimethoxybenzene-1,2-diol
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00013
3-dodecyl-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00274
3-n-pentadecylcatechol
Homo sapiens
pH 7.5, temperature not specified in the publication
-
0.0065
3-propylphenyl 3,5-dinitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.0005
3-tolyl 3,5-dinitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.00006
3-tridecyl-4,5-dimethoxybenzene-1,2-diol
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0001
3-undecyl-4,5-dimethoxybenzene-1,2-diol
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00116
3-[(10E)-pentadec-10'-en-1-yl]-catechol
Homo sapiens
i.e. a catechol mixture from Lithrea caustica containing 65% of the compound, pH 7.5, temperature not specified in the publication
-
0.00209
3-[(10Z)-pentadec-10'-en-1-yl]-catechol
Homo sapiens
pH 7.5, temperature not specified in the publication
-
0.00008
4,5-dimethoxy-3-tridecylcyclohexa-3,5-diene-1,2-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00009
4,5-dimethoxy-3-undecylcyclohexa-3,5-diene-1,2-dione
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.001
4-(3-(1-hydroxyureido)but-1-yn-1-yl)-N-(2-(trifluoromethyl)-benzyl)benzamide
Homo sapiens
pH 7.4, 37°C
-
0.00004
4-(4-(4-chlorophenyl)thiazol-2-ylimino)cyclohexa-2,5-dienone
Homo sapiens
pH 7.4, 37°C, recombinant enzyme
0.00003
4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol
Homo sapiens
pH 7.4, 37°C, recombinant enzyme
0.00029
5-methoxy-3-tridecylbenzene-1,2,4-triol
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.00092
6-hydroxy-3,4-dimethoxy-5-undecylcyclohexa-2,4-dien-1-one
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0038
AA-861
Homo sapiens
pH 7.4, 37°C
0.00029
baicalein
Homo sapiens
pH 7.4, 37°C
0.038
biphenyl-3-yl 3,5-dinitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.05
biphenyl-4-yl 3,5-dinitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.0048
BRP-7
Homo sapiens
pH 7.4, 37°C
0.0002
BWA4C
Homo sapiens
pH 7.4, 37°C
0.00097
caffeic acid phenethyl ester
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
0.0007
chalcone
Homo sapiens
pH 7.4, 37°C
0.0014
curcumin
Homo sapiens
pH 7.4, 37°C
0.05
cyrhetrenyl carboxylic acid
Homo sapiens
above 0.050 mM, pH 7.5, 23°C
-
0.000057
delta-garcinoic acid
Homo sapiens
pH 7.4, 37°C
-
0.00023
embelin
Homo sapiens
pH 7.4, 37°C
0.0032
ethyl 2-((2,4-difluorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0008
ethyl 2-((2,6-dichlorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0008
ethyl 2-((2,6-dimethylphenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0018
ethyl 2-((3,5-dimethylphenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0038
ethyl 2-((3-chlorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.005
ethyl 2-((4-fluorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0003
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0008
ethyl 5-hydroxy-1-methyl-2-((2-(trifluoromethyl)phenylthio)methyl)-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0009
ethyl 5-hydroxy-1-methyl-2-((4-(trifluoromethoxy)phenylthio)methyl)-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0042
ethyl 5-hydroxy-1-methyl-2-((4-(trifluoromethyl)phenylthio)methyl)-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0057
ethyl 5-hydroxy-1-methyl-2-(phenylthiomethyl)-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0029
ethyl 5-hydroxy-2-((2-methoxyphenylthio)methyl)-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0023
ethyl 5-hydroxy-2-((4-methoxyphenylthio)methyl)-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0007
ethyl 5-hydroxy-2-(mesitylthiomethyl)-1-methyl-1H-indole-3-carboxylate
Homo sapiens
pH 7.4, 37°C, cell-free enzyme extract
0.0025
ferrocenyl carboxylic acid
Homo sapiens
pH 7.5, 23°C
-
0.00006
luteolin
Homo sapiens
pH 7.4, 37°C
0.0011
MK886
Homo sapiens
pH 7.4, 37°C
0.05
N-(3,4-dimethoxyphenyl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.00012
N-(3-(4-chlorophenyl)-3-phenylpropyl)-3-(3-(1-hydroxyureido)-but-1-yn-1-yl)benzamide
Homo sapiens
pH 7.4, 37°C
-
0.0144
N-(3-bromobenzyl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.05
N-(3-bromophenyl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.05
N-(3-chlorophenyl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.0027
N-(4-methoxyphenyl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.05
N-(biphenyl-3-yl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.05
N-(naphthalene-1-yl)-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.0039
N-([(5R)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)-N-hydroxy-2-methylpropanamide
Homo sapiens
pH 7.5, 25°C
-
0.0035
N-([(5R)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)-N-hydroxycyclopropanecarboxamide
Homo sapiens
pH 7.5, 25°C
-
0.05
N-3-tolyl-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.0152
N-phenyl-3,5-dinitrobenzamide
Homo sapiens
pH 7.4, 37°C
0.0246
naphthalene-1-yl 3-nitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.003
NAPQI
Homo sapiens
pH 7.4, 37°C
-
0.0158
phenyl 3,5-dinitrobenzoate
Homo sapiens
pH 7.4, 37°C
0.00143
Plumbagin
Homo sapiens
pH 7.4, 37°C
0.0006
primin
Homo sapiens
pH 7.4, 37°C
-
0.0005
shikonin
Homo sapiens
pH 7.4, 37°C
0.0006
shogaol
Homo sapiens
pH 7.4, 37°C
0.00017
U73122
Homo sapiens
pH 7.4, 37°C
0.00066 - 0.00246
(2E,2'E)-(1,1'-(2,2-bis((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
0.00079 - 0.00237
(2E,2'E)-(1,1'-(2-((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
0.03
(2E,5E)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-3-phenyl-2-(phenylimino)-1,3-thiazolidin-4-one
0.00013 - 0.00038
(5E)-2-(3-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00012 - 0.00024
(5E)-2-(3-fluorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00011 - 0.00055
(5E)-2-(4-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00063 - 0.00193
(5E)-2-(4-aminophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00011 - 0.0004
(5E)-2-(4-chlorophenyl)-5-(4-hydroxybenzylidene)-1,3-thiazol-4(5H)-one
0.00009 - 0.00028
(5E)-2-(4-chlorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00065 - 0.00169
(5E)-2-(4-hydroxyphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.0004 - 0.00245
(5E)-2-(4-methylphenyl)-5-(3,4,5-trimethoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00098 - 0.00202
(5E)-5-(2,4-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.0008 - 0.0013
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.00048 - 0.00054
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00013 - 0.00035
(5E)-5-(3,5-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.0027 - 0.01
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.003 - 0.0095
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00125 - 0.0029
(5E)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.0003 - 0.00058
(5E)-5-(3-chlorobenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.003 - 0.0044
(5E)-5-(4-hydroxy-3-methoxy-5-nitrobenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00032 - 0.004
(5E)-5-(4-methoxybenzylidene)-2-(4-methoxyphenyl)-1,3-thiazol-4(5H)-one
0.0003 - 0.00066
(5E)-5-(4-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.00015 - 0.002
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.0003 - 0.00091
(5E)-5-(4-tert-butylbenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00019 - 0.00211
(5E)-5-(4-[(methylperoxy)acetyl]benzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.0003 - 0.00065
(5E)-5-(5-chloro-2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.0003 - 0.004
(5E)-5-(anthracen-9-ylmethylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00035 - 0.00073
(5E)-5-benzylidene-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.02 - 0.03
(5E)-5-[4-(dimethylamino)benzylidene]-2-(piperidin-1-yl)-1,3-thiazol-4(5H)-one
0.012 - 0.014
(5Z)-2-(cyclohexylamino)-5-(4-propoxybenzylidene)-1,3-thiazol-4(5H)-one
0.03
(5Z)-5-(4-methoxybenzylidene)-2-(pyrrolidin-1-yl)-1,3-thiazol-4(5H)-one
0.03
(5Z)-5-(4-methylbenzylidene)-2-(naphthalen-2-ylamino)-1,3-thiazol-4(5H)-one
0.03
(5Z)-5-benzylidene-2-(phenylamino)-1,3-thiazol-4(5H)-one
0.005
([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)(naphthalen-1-yl)acetic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.0006 - 0.007
1-(2,4-difluorophenyl)-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
0.0068 - 0.01
1-(2,4-dihydroxyphenyl)-2-(naphthalen-2-yl)ethanone
0.003 - 0.01
1-benzyl-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
0.005
1-O-dodecyl 2,3-O-isopropylidene-5,6-dideoxy-5-N-[4-(2-hydroxy-2-oxoethyl) phenylaminocarbonyl] amino-beta-L-gulofuranoside sodium salt
Homo sapiens
-
competitive inhibitor, IC50: 0.0035 mM with recombinant enzyme, IC50: 0.005 mM with native enzyme
0.001 - 0.004
1-[3-(methylsulfanyl)phenyl]-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
0.017
10,17(S)-dihydroxydocosahexaenoic acid
Homo sapiens
-
IC50: 0.017 mM
0.0048
15-hydroperoxy-6,8,11,13-eicosatetraenoic acid
Homo sapiens
-
IC50: 0.0048 mM
0.0015
2-(2,2-dimethyl-6-(4-nitrophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
Homo sapiens
-
-
0.00031
2-(2,2-dimethyl-7-phenyl-6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
Homo sapiens
-
-
0.004 - 0.01
2-(2-methoxyphenyl)-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)acetamide
0.0007 - 0.0015
2-(4-(biphenyl-4-ylamino)-6-chloropyrimidine-2-ylthio)octanoic acid
0.001 - 0.002
2-(4-(biphenyl-4-ylmethylamino)-6-chloropyrimidin-2-ylthio)octanoic acid
0.0004 - 0.0015
2-(4-chloro-6-(4'-cyanobiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
0.0005 - 0.002
2-(4-chloro-6-(5-methoxy-2-methylbiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
0.00023 - 0.0004
2-(4-methylphenyl)-5-(2-phenylethenylidene)-1,3-thiazol-4(5H)-one
0.0008 - 0.001
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(5-methyl-1,3-thiazol-2-yl)propanamide
0.0008 - 0.001
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
0.0009 - 0.006
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
0.003 - 0.008
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-thiophen-3-ylpropanamide
0.00023
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-(methylsulfonyl)acetamide
Homo sapiens
-
-
0.00025
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-(phenylsulfonyl)acetamide
Homo sapiens
-
-
0.00026
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-tosylacetamide
Homo sapiens
-
-
0.0016
2-(6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
Homo sapiens
-
-
0.00018
2-(6-(4-tert-butylphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
Homo sapiens
-
-
0.008 - 0.01
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(thiophen-2-ylmethyl)propanamide
0.0008 - 0.005
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
0.0008 - 0.01
2-(dibenzo[b,d]furan-3-yl)-5-hydroxycyclohexa-2,5-diene-1,4-dione
0.0041 - 0.0065
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)octanoic acid
0.01
2-benzyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
0.0014 - 0.003
2-hexyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
0.0046 - 0.01
2-hydroxy-5-(3-nitrophenyl)cyclohexa-2,5-diene-1,4-dione
0.00078 - 0.0023
2-hydroxy-5-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
0.01
2-hydroxy-5-methoxy-3-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
0.00028 - 0.0067
2-methoxy-5-(naphthalen-2-yloxy)cyclohexa-2,5-diene-1,4-dione
0.0015 - 0.003
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
0.006
2-[4'-(iso-propylphenyl)-amino]-5,6-dimethyl-1,4-benzoquinone
Homo sapiens
-
potent inhibitor, IC50: 0.006 mM
0.00068
2-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
0.00018
2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl]acetic acid
Homo sapiens
-
-
0.001 - 0.01
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
0.01
3'-nitrobiphenyl-2,4-diol
0.0009 - 0.01
3,4,5-trimethoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
0.01
3-(cyclohexylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
0.00058 - 0.011
3-(decahydronaphthalen-2-ylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
0.01
3-benzyl-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione
0.01
4-(1-benzothiophen-3-yl)benzene-1,3-diol
0.00018
4-(4-chlorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-2H-chromen-2-one
Homo sapiens
-
IC50: 180 nM
0.000055
4-(4-fluorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenoxy]methyl)-2H-chromen-2-one
Homo sapiens
-
IC50: 55 nM
0.000027
4-(4-fluorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-2H-chromen-2-one
Homo sapiens
-
IC50: 27 nM
0.0063 - 0.01
4-(dibenzo[b,d]furan-3-yl)benzene-1,3-diol
0.0023 - 0.0074
4-(naphthalen-2-ylmethyl)benzene-1,3-diol
0.0021 - 0.0032
4-(thianthren-2-yl)benzene-1,3-diol
0.009 - 0.01
4-benzylbenzene-1,3-diol
0.00042
4-chloro-N-([4-[(2E)-3-(2,4-dichlorophenyl)prop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
Homo sapiens
-
IC50: 0.00042 mM
0.00083
4-chloro-N-([4-[(2E)-3-phenylprop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
Homo sapiens
-
IC50: 0.00083 mM
0.0028 - 0.0046
4-hexylbenzene-1,3-diol
0.006 - 0.01
4-methoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
0.01
4-methyl-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,2,3-thiadiazole-5-carboxamide
0.00045
4-methyl-N-([4-[(2E)-3-(2,3,4-trimethylphenyl)prop-2 enoyl]phenyl]carbamoyl)benzenesulfonamide
Homo sapiens
-
IC50: 0.00045 mM
0.00089
4-methyl-N-([4-[(2E)-3-phenylprop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
Homo sapiens
-
IC50: 0.00089 mM
0.009 - 0.01
6-[(4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)methyl]naphthalene-2-carboxylic acid
0.007
7,17(S)-dihydroxydocosahexaenoic acid
Homo sapiens
-
IC50: 0.007 mM
0.000175
7-([3-fluoro-5-[(1R)-1-hydroxy-1-pyridin-2-ylpropyl]phenoxy]methyl)-4-furan-3-yl-2H-chromen-2-one
Homo sapiens
-
IC50: 175 nM
0.0002
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-furan-3-yl-2H-chromen-2-one
Homo sapiens
-
IC50: 200 nM
0.0003
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-phenyl-2H-chromen-2-one
Homo sapiens
-
IC50: 300 nM
0.000175
7-([3-fluoro-5-[(1S)-1-hydroxy-1-(1,3-thiazol-2-yl)propyl]phenoxy]methyl)-4-(4-fluorophenyl)-2H-chromen-2-one
Homo sapiens
-
IC50: 175 nM
0.000009
7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-4-furan-3-yl-2H-chromen-2-one
Homo sapiens
-
IC50: 9 nM
0.000026
7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-4-phenyl-2H-chromen-2-one
Homo sapiens
-
IC50: 26 nM
0.000015
7-[[3-(1-ethyl-1-hydroxypropyl)-5-fluorophenoxy]methyl]-4-furan-3-yl-2H-chromen-2-one
Homo sapiens
-
IC50: 15 nM
0.00013 - 0.00035
benzyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.00017 - 0.00048
benzyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0028 - 0.0042
biphenyl-2,4-diol
0.013
BW755C
Homo sapiens
-
i.e. 3-amino-1-[3-(trifluoromethyl)phenyl]-2-pyrazoline, IC50: 0.013 mM
0.025
caffeic acid
Homo sapiens
-
-
0.0195
celecoxib
Homo sapiens
-
37°C, whole blood assay
0.00115 - 0.00155
CJ-13610
Homo sapiens
-
pH 7.5, 37°C, dependent on assay method via fluorescence or UV measurement, kinetics, overview
0.157
daidzein
Homo sapiens
-
pH 7.4, 27°C
0.0069
delphinidin 3-O-galactoside
Homo sapiens
-
-
0.00215
delphinidin 3-O-glucoside
Homo sapiens
-
-
0.00065 - 0.0018
ethyl 1-benzyl-2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000097 - 0.0012
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0016 - 0.0017
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
0.00015 - 0.00045
ethyl 2-(3-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000086 - 0.00023
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0017 - 0.002
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
0.00058 - 0.0043
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-pyrrolo[2,3-f]quinoline-3-carboxylate
0.0012 - 0.0057
ethyl 2-(3-chlorobenzyl)-5-hydroxy-6-phenyl-1H-indole-3-carboxylate
0.01 - 0.03
ethyl 2-(3-chlorobenzyl)-5-methoxy-1-methyl-1H-benzo[g]-indole-3-carboxylate
0.03
ethyl 2-(3-chlorobenzyl)-5-phenyl-1H-benzo[g]indole-3-carboxylate
0.007 - 0.01
ethyl 2-(3-chlorobenzyl)-7,8-dimethoxy-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000045 - 0.00052
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0033 - 0.0048
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
0.00014 - 0.00034
ethyl 2-(3-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.00013 - 0.00052
ethyl 2-(3-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000095 - 0.0006
ethyl 2-(4-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000084 - 0.0012
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0007 - 0.0012
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
0.000067 - 0.00032
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.002 - 0.0021
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
0.000096 - 0.0005
ethyl 2-(4-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.00015 - 0.00065
ethyl 2-(4-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.00025 - 0.0017
ethyl 2-(4-trifluoromethylbenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0003 - 0.0024
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
0.000031 - 0.00049
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0017 - 0.0028
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
0.000049 - 0.0028
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0007 - 0.0039
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
0.0006 - 0.019
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]octanoate
0.0034 - 0.01
ethyl 5-benzoyloxy-2-(3-chlorobenzyl)-1H-benzo[g]indole-3-carboxylate
0.0055 - 0.0073
ethyl 5-hydroxy-2-phenylethyl-1H-indole-3-carboxylate
0.00013 - 0.00044
ethyl 5-hydroxy-2-phenylpropyl-1H-benzo[g]indole-3-carboxylate
0.00033 - 0.0028
ethyl 6-biphenyl-4-yl-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
0.026
eugenol
Homo sapiens
-
non-competitive, reversible inhibitor, IC50: 0.026 mM
0.125
genistein
Homo sapiens
-
pH 7.4, 27°C
0.0008
L-656,224
Homo sapiens
-
i.e. 7-chloro-2-[(4-methoxyphenyl)-methyl]-3-methyl-5-propyl-4-benzofuranol, IC50: 0.0008 mM
0.0004
L-670,630
Homo sapiens
-
IC50: 0.0004 mM
0.0003
L-689,065
Homo sapiens
-
IC50: 0.0003 mM
0.00002
L-697,198
Homo sapiens
-
IC50: 0.00002 mM
0.0015
L-702,701
Homo sapiens
-
IC50: 0.0015 mM
0.000027
L-746,530
Homo sapiens
-
IC50: 27 nM
0.00002
L705,302
Homo sapiens
-
IC50: 0.00002 mM
0.00058 - 0.00086
methyl (4-[(5E)-5-(4-methoxybenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]phenoxy)acetate
0.03
methyl 2-(allylamino)-1H-indole-3-carboxylate
0.0034 - 0.004
methyl 2-(benzylamino)-1H-indole-3-carboxylate
0.0069 - 0.0125
methyl 2-(diallylamino)-1H-indole-3-carboxylate
0.0098 - 0.0102
methyl 2-[(2-chlorophenyl)amino]-1H-indole-3-carboxylate
0.0035 - 0.0083
methyl 2-[(3-bromophenyl)amino]-1H-indole-3-carboxylate
0.0065 - 0.0081
methyl 2-[(3-chlorophenyl)amino]-1H-indole-3-carboxylate
0.0035 - 0.0055
methyl 2-[(3-chlorophenyl)amino]-5-chloro-1H-indole-3-carboxylate
0.0079 - 0.0134
methyl 2-[(3-fluorophenyl)amino]-1H-indole-3-carboxylate
0.0072 - 0.0098
methyl 2-[(4-chlorophenyl)amino]-1H-indole-3-carboxylate
0.004
miogadial
Homo sapiens
-
potent inhibitor, IC50: 0.004 mM
0.0075
miogatrial
Homo sapiens
-
potent inhibitor, IC50: 0.0075 mM
0.0032
MK-886
Homo sapiens
-
37°C, whole blood assay
0.1
ML-3000
Homo sapiens
-
above, 37°C, whole blood assay
0.002 - 0.01
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,3-benzodioxole-5-carboxamide
0.008 - 0.01
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)cyclopentanecarboxamide
0.000038 - 0.00016
N-(3-phenoxycinnamyl)-acetohydroxamic acid
0.0001
N-(4-chlorophenyl)-N-hydroxy-N'-(3-chlorophenyl)urea
Homo sapiens
-
IC50: 0.0001 mM
0.0009 - 0.01
N-(furan-2-ylmethyl)-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
0.00045
N-([4-[(2E)-3-(2,4-dichlorophenyl)prop-2-enoyl]phenyl]carbamoyl)-4-methylbenzenesulfonamide
Homo sapiens
-
IC50: 0.00045 mM
0.01
N-cyclopentyl-2-[7-(2-methoxyethoxy)-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]propanamide
0.00005 - 0.00016
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
0.004 - 0.01
N-tert-butyl-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
0.00009
nordihydroguaiaretic acid
Homo sapiens
-
pH 7.5, 37°C, assay method via fluorescence measurement
0.0086
polygodial
Homo sapiens
-
strong inhibitory activity, IC50: 0.0086 mM
0.00013
SC-756
Homo sapiens
-
pH 7.5, 37°C, assay method via fluorescence measurement
0.02
sulindac sulfide
Homo sapiens
-
pH and temperature not specified in the publication
0.0003
ZD 2138
Homo sapiens
-
i.e. CAS: 140841-32-3, IC50: 0.0003 mM
0.00011 - 0.00012
ZD-2138
Homo sapiens
-
pH 7.5, 37°C, dependent on assay method via fluorescence or UV measurement
0.00009
ZM 230,486
Homo sapiens
-
IC50: 0.00009 mM
0.00074 - 0.00148
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
additional information
additional information
-
0.00032
2-phenylethyl (2E)-3-(2,5-dihydroxyphenyl)prop-2-enoate
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
-
0.00033
2-phenylethyl (2E)-3-(2,5-dihydroxyphenyl)prop-2-enoate
Homo sapiens
5-Lox products biosynthesis assay, 37°C, pH not specified in the publication
-
0.0008
zileuton
Homo sapiens
pH 7.5, 25°C
0.0023
zileuton
Homo sapiens
inhibition of 5-Lox product biosynthesis in polymorphonuclear leukocyte, 37°C, pH not specified in the publication
0.00066
(2E,2'E)-(1,1'-(2,2-bis((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
Homo sapiens
-
-
0.00246
(2E,2'E)-(1,1'-(2,2-bis((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
Homo sapiens
-
per number of caffeic acid moieties
0.00079
(2E,2'E)-(1,1'-(2-((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
Homo sapiens
-
-
0.00237
(2E,2'E)-(1,1'-(2-((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
Homo sapiens
-
per number of caffeic acid moieties
0.03
(2E,5E)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-3-phenyl-2-(phenylimino)-1,3-thiazolidin-4-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.03
(2E,5E)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-3-phenyl-2-(phenylimino)-1,3-thiazolidin-4-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00013
(5E)-2-(3-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00038
(5E)-2-(3-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00012
(5E)-2-(3-fluorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00024
(5E)-2-(3-fluorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00011
(5E)-2-(4-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00055
(5E)-2-(4-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00063
(5E)-2-(4-aminophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00193
(5E)-2-(4-aminophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00011
(5E)-2-(4-chlorophenyl)-5-(4-hydroxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0004
(5E)-2-(4-chlorophenyl)-5-(4-hydroxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00009
(5E)-2-(4-chlorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00028
(5E)-2-(4-chlorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00065
(5E)-2-(4-hydroxyphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00169
(5E)-2-(4-hydroxyphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0004
(5E)-2-(4-methylphenyl)-5-(3,4,5-trimethoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00245
(5E)-2-(4-methylphenyl)-5-(3,4,5-trimethoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00098
(5E)-5-(2,4-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00202
(5E)-5-(2,4-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0008
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0013
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00048
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00054
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00013
(5E)-5-(3,5-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00035
(5E)-5-(3,5-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0027
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.01
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.003
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0095
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00125
(5E)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0029
(5E)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0003
(5E)-5-(3-chlorobenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00058
(5E)-5-(3-chlorobenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.003
(5E)-5-(4-hydroxy-3-methoxy-5-nitrobenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0044
(5E)-5-(4-hydroxy-3-methoxy-5-nitrobenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00032
(5E)-5-(4-methoxybenzylidene)-2-(4-methoxyphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.004
(5E)-5-(4-methoxybenzylidene)-2-(4-methoxyphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0003
(5E)-5-(4-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00066
(5E)-5-(4-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00015
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0005
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00053
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.002
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0003
(5E)-5-(4-tert-butylbenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00091
(5E)-5-(4-tert-butylbenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00019
(5E)-5-(4-[(methylperoxy)acetyl]benzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00211
(5E)-5-(4-[(methylperoxy)acetyl]benzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0003
(5E)-5-(5-chloro-2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00065
(5E)-5-(5-chloro-2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0003
(5E)-5-(anthracen-9-ylmethylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.004
(5E)-5-(anthracen-9-ylmethylidene)-2-phenyl-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00035
(5E)-5-benzylidene-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00073
(5E)-5-benzylidene-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.02
(5E)-5-[4-(dimethylamino)benzylidene]-2-(piperidin-1-yl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.03
(5E)-5-[4-(dimethylamino)benzylidene]-2-(piperidin-1-yl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.012
(5Z)-2-(cyclohexylamino)-5-(4-propoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.014
(5Z)-2-(cyclohexylamino)-5-(4-propoxybenzylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-(4-methoxybenzylidene)-2-(pyrrolidin-1-yl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-(4-methoxybenzylidene)-2-(pyrrolidin-1-yl)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-(4-methylbenzylidene)-2-(naphthalen-2-ylamino)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-(4-methylbenzylidene)-2-(naphthalen-2-ylamino)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-benzylidene-2-(phenylamino)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-benzylidene-2-(phenylamino)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0006
1-(2,4-difluorophenyl)-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
Homo sapiens
-
37°C, partially purified enzyme
0.007
1-(2,4-difluorophenyl)-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.0068
1-(2,4-dihydroxyphenyl)-2-(naphthalen-2-yl)ethanone
Homo sapiens
-
pH not specified in the publication, 37°C, cell-based test system
0.01
1-(2,4-dihydroxyphenyl)-2-(naphthalen-2-yl)ethanone
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.003
1-benzyl-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
1-benzyl-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
Homo sapiens
-
above, 37°C, partially purified enzyme
0.001
1-[3-(methylsulfanyl)phenyl]-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
Homo sapiens
-
37°C, partially purified enzyme
0.004
1-[3-(methylsulfanyl)phenyl]-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.004
2-(2-methoxyphenyl)-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)acetamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
2-(2-methoxyphenyl)-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)acetamide
Homo sapiens
-
above, 37°C, partially purified enzyme
0.0007
2-(4-(biphenyl-4-ylamino)-6-chloropyrimidine-2-ylthio)octanoic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.0015
2-(4-(biphenyl-4-ylamino)-6-chloropyrimidine-2-ylthio)octanoic acid
Homo sapiens
-
purified 5-lipoxygenase
0.001
2-(4-(biphenyl-4-ylmethylamino)-6-chloropyrimidin-2-ylthio)octanoic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.002
2-(4-(biphenyl-4-ylmethylamino)-6-chloropyrimidin-2-ylthio)octanoic acid
Homo sapiens
-
purified 5-lipoxygenase
0.0004
2-(4-chloro-6-(4'-cyanobiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.0015
2-(4-chloro-6-(4'-cyanobiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
Homo sapiens
-
purified 5-lipoxygenase
0.0005
2-(4-chloro-6-(5-methoxy-2-methylbiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.002
2-(4-chloro-6-(5-methoxy-2-methylbiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
Homo sapiens
-
purified 5-lipoxygenase
0.00023
2-(4-methylphenyl)-5-(2-phenylethenylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.0004
2-(4-methylphenyl)-5-(2-phenylethenylidene)-1,3-thiazol-4(5H)-one
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.0008
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(5-methyl-1,3-thiazol-2-yl)propanamide
Homo sapiens
-
37°C, partially purified enzyme
0.001
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(5-methyl-1,3-thiazol-2-yl)propanamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.0008
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
Homo sapiens
-
37°C, in intact polymorphonuclear leukocytes
0.001
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
Homo sapiens
-
37°C, partially purified enzyme
0.0009
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.006
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
Homo sapiens
-
37°C, partially purified enzyme
0.003
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-thiophen-3-ylpropanamide
Homo sapiens
-
37°C, partially purified enzyme
0.008
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-thiophen-3-ylpropanamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.008
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(thiophen-2-ylmethyl)propanamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(thiophen-2-ylmethyl)propanamide
Homo sapiens
-
37°C, partially purified enzyme
0.0008
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
Homo sapiens
-
37°C, partially purified enzyme
0.005
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.0008
2-(dibenzo[b,d]furan-3-yl)-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.01
2-(dibenzo[b,d]furan-3-yl)-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.0041
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)octanoic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.0065
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)octanoic acid
Homo sapiens
-
purified 5-lipoxygenase
0.01
2-benzyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.01
2-benzyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.0014
2-hexyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.003
2-hexyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-based test system
0.0046
2-hydroxy-5-(3-nitrophenyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.01
2-hydroxy-5-(3-nitrophenyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.00078
2-hydroxy-5-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.0023
2-hydroxy-5-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.01
2-hydroxy-5-methoxy-3-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.01
2-hydroxy-5-methoxy-3-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.00028
2-methoxy-5-(naphthalen-2-yloxy)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.0067
2-methoxy-5-(naphthalen-2-yloxy)cyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-based test system
0.0015
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.003
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
Homo sapiens
-
purified 5-lipoxygenase
0.00068
2-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Homo sapiens
-
-
0.00068
2-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Homo sapiens
-
per number of caffeic acid moieties
0.001
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
Homo sapiens
-
37°C, partially purified enzyme
0.01
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
Homo sapiens
-
above, 37°C, intact polymorphonuclear leukocytes
0.01
3'-nitrobiphenyl-2,4-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.01
3'-nitrobiphenyl-2,4-diol
Homo sapiens
-
value above,pH not specified in the publication, 37°C, cell-based test system
0.0009
3,4,5-trimethoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
Homo sapiens
-
37°C, in intact polymorphonuclear leukocytes
0.01
3,4,5-trimethoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
Homo sapiens
-
above, 37°C, partially purified enzyme
0.01
3-(cyclohexylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.01
3-(cyclohexylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.00058
3-(decahydronaphthalen-2-ylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-based test system
0.011
3-(decahydronaphthalen-2-ylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.01
3-benzyl-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.01
3-benzyl-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.01
4-(1-benzothiophen-3-yl)benzene-1,3-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.01
4-(1-benzothiophen-3-yl)benzene-1,3-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-free based test system
0.0063
4-(dibenzo[b,d]furan-3-yl)benzene-1,3-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.01
4-(dibenzo[b,d]furan-3-yl)benzene-1,3-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.0023
4-(naphthalen-2-ylmethyl)benzene-1,3-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.0074
4-(naphthalen-2-ylmethyl)benzene-1,3-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.0021
4-(thianthren-2-yl)benzene-1,3-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-based test system
0.0032
4-(thianthren-2-yl)benzene-1,3-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.009
4-benzylbenzene-1,3-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.01
4-benzylbenzene-1,3-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.0028
4-hexylbenzene-1,3-diol
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.0046
4-hexylbenzene-1,3-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.006
4-methoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
4-methoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
Homo sapiens
-
above, 37°C, partially purified enzyme
0.01
4-methyl-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,2,3-thiadiazole-5-carboxamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
4-methyl-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,2,3-thiadiazole-5-carboxamide
Homo sapiens
-
above, 37°C, partially purified enzyme
0.009
6-[(4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)methyl]naphthalene-2-carboxylic acid
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.01
6-[(4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)methyl]naphthalene-2-carboxylic acid
Homo sapiens
-
value above, pH not specified in the publication, 37°C, cell-based test system
0.00013
benzyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00035
benzyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00017
benzyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00048
benzyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0028
biphenyl-2,4-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-free based test system
0.0042
biphenyl-2,4-diol
Homo sapiens
-
pH not specified in the publication, 37°C, cell-based test system
0.00065
ethyl 1-benzyl-2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0018
ethyl 1-benzyl-2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.000097
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0012
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0016
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0017
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00015
ethyl 2-(3-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00045
ethyl 2-(3-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.000086
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00023
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0017
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.002
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00058
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-pyrrolo[2,3-f]quinoline-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0043
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-pyrrolo[2,3-f]quinoline-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0012
ethyl 2-(3-chlorobenzyl)-5-hydroxy-6-phenyl-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0057
ethyl 2-(3-chlorobenzyl)-5-hydroxy-6-phenyl-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.01
ethyl 2-(3-chlorobenzyl)-5-methoxy-1-methyl-1H-benzo[g]-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.03
ethyl 2-(3-chlorobenzyl)-5-methoxy-1-methyl-1H-benzo[g]-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.03
ethyl 2-(3-chlorobenzyl)-5-phenyl-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.03
ethyl 2-(3-chlorobenzyl)-5-phenyl-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.007
ethyl 2-(3-chlorobenzyl)-7,8-dimethoxy-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.01
ethyl 2-(3-chlorobenzyl)-7,8-dimethoxy-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.000045
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00052
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0033
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0048
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00014
ethyl 2-(3-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00034
ethyl 2-(3-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00013
ethyl 2-(3-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00052
ethyl 2-(3-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.000095
ethyl 2-(4-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0006
ethyl 2-(4-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.000084
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0012
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0007
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0012
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.000067
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00032
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.002
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0021
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.000096
ethyl 2-(4-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0005
ethyl 2-(4-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00015
ethyl 2-(4-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00065
ethyl 2-(4-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00025
ethyl 2-(4-trifluoromethylbenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0017
ethyl 2-(4-trifluoromethylbenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0003
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0024
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.000031
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00049
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0017
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0028
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.000049
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0028
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0007
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0039
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0006
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]octanoate
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.019
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]octanoate
Homo sapiens
-
purified 5-lipoxygenase
0.0034
ethyl 5-benzoyloxy-2-(3-chlorobenzyl)-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.01
ethyl 5-benzoyloxy-2-(3-chlorobenzyl)-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0055
ethyl 5-hydroxy-2-phenylethyl-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0073
ethyl 5-hydroxy-2-phenylethyl-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00013
ethyl 5-hydroxy-2-phenylpropyl-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.00044
ethyl 5-hydroxy-2-phenylpropyl-1H-benzo[g]indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00033
ethyl 6-biphenyl-4-yl-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0028
ethyl 6-biphenyl-4-yl-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.00058
methyl (4-[(5E)-5-(4-methoxybenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]phenoxy)acetate
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00086
methyl (4-[(5E)-5-(4-methoxybenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]phenoxy)acetate
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.03
methyl 2-(allylamino)-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.03
methyl 2-(allylamino)-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0034
methyl 2-(benzylamino)-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.004
methyl 2-(benzylamino)-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0069
methyl 2-(diallylamino)-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0125
methyl 2-(diallylamino)-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0098
methyl 2-[(2-chlorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0102
methyl 2-[(2-chlorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0035
methyl 2-[(3-bromophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0083
methyl 2-[(3-bromophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0065
methyl 2-[(3-chlorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0081
methyl 2-[(3-chlorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0035
methyl 2-[(3-chlorophenyl)amino]-5-chloro-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0055
methyl 2-[(3-chlorophenyl)amino]-5-chloro-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0079
methyl 2-[(3-fluorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0134
methyl 2-[(3-fluorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.0072
methyl 2-[(4-chlorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0098
methyl 2-[(4-chlorophenyl)amino]-1H-indole-3-carboxylate
Homo sapiens
-
recombinant 5-lipoxygenase
0.002
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,3-benzodioxole-5-carboxamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,3-benzodioxole-5-carboxamide
Homo sapiens
-
above, 37°C, partially purified enzyme
0.008
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)cyclopentanecarboxamide
Homo sapiens
-
37°C, intact polymorphonuclear leukocytes
0.01
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)cyclopentanecarboxamide
Homo sapiens
-
37°C, partially purified enzyme
0.000038
N-(3-phenoxycinnamyl)-acetohydroxamic acid
Homo sapiens
-
recombinant 5-lipoxygenase
0.00016
N-(3-phenoxycinnamyl)-acetohydroxamic acid
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0009
N-(furan-2-ylmethyl)-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
Homo sapiens
-
37°C, partially purified enzyme
0.01
N-(furan-2-ylmethyl)-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
Homo sapiens
-
above, 37°C, intact polymorphonuclear leukocytes
0.01
N-cyclopentyl-2-[7-(2-methoxyethoxy)-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]propanamide
Homo sapiens
-
above, 37°C, intact polymorphonuclear leukocytes
0.01
N-cyclopentyl-2-[7-(2-methoxyethoxy)-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]propanamide
Homo sapiens
-
above, 37°C, partially purified enzyme
0.00005
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
Homo sapiens
-
a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00008
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
Homo sapiens
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication
0.00011
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
Homo sapiens
-
in intact polymorphonuclear leukocytes
0.00016
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
Homo sapiens
-
purified 5-lipoxygenase
0.004
N-tert-butyl-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
Homo sapiens
-
37°C, partially purified enzyme
0.01
N-tert-butyl-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
Homo sapiens
-
above, 37°C, intact polymorphonuclear leukocytes
0.00012 - 0.00092
zileuton
Homo sapiens
-
pH 7.5, 37°C, dependent on assay method via fluorescence or UV measurement
0.0008
zileuton
Homo sapiens
-
recombinant 5-lipoxygenase
0.0009
zileuton
Homo sapiens
-
5-lipoxygenase inhibited in neutrophils
0.0011
zileuton
Homo sapiens
-
IC50: 0.0038 mM with recombinant enzyme, IC50: 0.0011 mM with native enzyme
0.01
zileuton
Homo sapiens
-
IC50: 0.01 mM
0.00074
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Homo sapiens
-
-
0.00148
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Homo sapiens
-
per number of caffeic acid moieties
additional information
additional information
Homo sapiens
-
enzyme inhibition in presence of inhibitor and glutathione peroxidase, overview
-
additional information
additional information
Homo sapiens
-
inhibitory activity in polymorphonuclear leukocytes, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DeWolf, W.E.
Enzymatic studies on purified 5-lipoxygenase
Lipoxygenases and Their Products (Crooke, S. T. ed. ) Academic Press
105-135
1991
Cavia porcellus, Homo sapiens, Rattus norvegicus, Sus scrofa
-
brenda
Denis, D.; Falgueyret, J.P.; Riendeau, D.; Abramovitz, M.
Characterization of the activity of purified recombinant human 5-lipoxygenase in the absence and presence of leukocyte factors
J. Biol. Chem.
266
5072-5079
1991
Homo sapiens
brenda
Rouzer, C.A.; Samuelsson, B.
Leukocyte arachidonate 5-lipoxygenase: isolation and characterization
Methods Enzymol.
187
312-319
1990
Homo sapiens
brenda
Cashman, J.R.; Lambert, C.; Sigal, E.
Inhibition of human leukocyte 5-lipoxygenase by 15-HPETE and related eicosanoids
Biochem. Biophys. Res. Commun.
155
38-44
1988
Homo sapiens
brenda
Rouzer, C.A.; Rands, E.; Kargman, S.; Jones, R.E.; Register, R.B.; Dixon, R.A.F.
Characterization of cloned human leukocyte 5-lipoxygenase expressed in mammalian cells
J. Biol. Chem.
263
10135-10140
1988
Homo sapiens
brenda
Soberman, R.J.
5- and 15(omega-6)-lipoxygenases from human polymorphonuclear leukocytes
Methods Enzymol.
163
344-349
1988
Homo sapiens
brenda
Rouzer, C.A.; Shimizu, T.; Samuelsson, B.
On the nature of the 5-lipoxygenase reaction in human leukocytes: characterization of a membrane-associated stimulatory factor
Proc. Natl. Acad. Sci. USA
82
7505-7509
1985
Homo sapiens
brenda
Falgueyret, J.P.; Denis, D.; MacDonald, D.; Hutchinson, J.H.; Riendeau, D.
Characterization of the arachidonate and ATP binding sites of human 5-lipoxygenase using photoaffinity labeling and enzyme immobilization
Biochemistry
34
13603-13611
1995
Homo sapiens
brenda
Colamorea, T.; Di Paola, R.; Macchia, F.; Guerrese, M.C.; Tursi, A.; Butterfield, J.H.; Caiaffa, M.F.; Haeggstrom, J.Z.; Macchia, L.
5-Lipoxygenase Upregulation by Dexamethasone in Human Mast Cells
Biochem. Biophys. Res. Commun.
265
617-624
1999
Homo sapiens
brenda
Brock, T.G.; McNish, R.W.; Peters-Golden, M.
Translocation and leukotriene synthetic capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages
J. Biol. Chem.
270
21652-21658
1995
Homo sapiens, Rattus norvegicus
brenda
Ghosh, J.; Myers, C.E.
Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells
Proc. Natl. Acad. Sci. USA
95
13182-13187
1998
Homo sapiens
brenda
Janssen-Timmen, U.; Vickers, P.J.; Wittig, U.; Lehmann, W.D.; Stark, H.J.; Fusenig, N.E.; Rosenbach, T.; Raedmark, O.; Samuelsson, B.; Habenicht, A.J.R.
Expression of 5-lipoxygenase in differentiating human skin keratinocytes
Proc. Natl. Acad. Sci. USA
92
6966-6970
1995
Homo sapiens
brenda
Bell, R.L.; Harris, R.R.
The enzymology and pharmacology of 5-lipoxygenase and 5-lipoxygenase activating protein
Clin. Rev. Allergy Immunol.
17
91-109
1999
Cavia porcellus, Oryctolagus cuniculus, Homo sapiens, Rattus norvegicus, Sus scrofa
brenda
Walther, M.; Ivanov, I.; Myagkova, G.; Kuhn, H.
Alterations of lipoxygenase specificity by targeted substrate modification and site-directed mutagenesis
Chem. Biol.
8
779-790
2001
Homo sapiens
brenda
Schwarz, K.; Gerth, C.; Anton, M.; Kuhn, H.
Alterations in Leukotriene Synthase Activity of the Human 5-Lipoxygenase by Site-Directed Mutagenesis Affecting Its Positional Specificity
Biochemistry
39
14515-14521
2000
Homo sapiens
brenda
Young, R.N.
Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized?
Eur. J. Med. Chem.
34
671-685
1999
Homo sapiens
-
brenda
Wetterholm, A.; Macchia, L.; Haeggstrom, J.Z.
Zinc and other divalent cations inhibit purified leukotriene A4 hydrolase and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes
Arch. Biochem. Biophys.
311
253-271
1994
Homo sapiens
-
brenda
Zhang, Y.Y.; Lind, B.; Raadmark, O.; Samuelsson, B.
Iron content of human 5-lipoxygenase. Effects of mutations regarding conserved histidine residues
J. Biol. Chem.
268
2535-2541
1993
Homo sapiens
brenda
Radmark, O.
Arachidonate 5-lipoxygenase
Prostaglandins
68-69
211-234
2002
Oryctolagus cuniculus, Homo sapiens, Mus musculus, Rattus norvegicus, Solanum tuberosum, Sus scrofa
brenda
Ghosh, J.
Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase
Biochem. Biophys. Res. Commun.
315
624-635
2004
Homo sapiens
brenda
Pande, A.H.; Moe, D.; Nemec, K.N.; Qin, S.; Tan, S.; Tatulian, S.A.
Modulation of human 5-lipoxygenase activity by membrane lipids
Biochemistry
43
14653-14666
2004
Homo sapiens
brenda
Brkert, E.; Szellas, D.; Radmark, O.; Steinhilber, D.; Werz, O.
Cell type-dependent activation of 5-lipoxygenase by arachidonic acid
J. Leukocyte Biol.
73
191-200
2003
Homo sapiens, Rattus norvegicus
brenda
Schneider, I.; Bucar, F.
Lipoxygenase inhibitors from natural plant sources. Part 1: Medicinal plants with inhibitory activity on arachidonate 5-lipoxygenase and 5-lipoxygenase/cyclooxygenase
Phytother. Res.
19
81-102
2005
Bos taurus, Cavia porcellus, Glycine max, Helianthus tuberosus, Homo sapiens, Mus musculus, Rattus norvegicus, Sus scrofa
brenda
Grimm, E.L.; Brideau, C.; Chauret, N.; Chan, C.C.; Delorme, D.; Ducharme, Y.; Ethier, D.; Falgueyret, J.P.; Friesen, R.W.; Guay, J.; Hamel, P.; Riendeau, D.; Soucy-Breau, C.; Tagari, P.; Girard, Y.
Substituted coumarins as potent 5-lipoxygenase inhibitors
Bioorg. Med. Chem. Lett.
16
2528-2531
2006
Homo sapiens
brenda
Abe, M.; Ozawa, Y.; Uda, Y.; Morimitsu, Y.; Nakamura, Y.; Osawa, T.
A novel labdane-type trialdehyde from myoga (Zingiber mioga Roscoe) that potently inhibits human platelet aggregation and human 5-lipoxygenase
Biosci. Biotechnol. Biochem.
70
2494-2500
2006
Homo sapiens
brenda
Shirumalla R. , S.R.; Naruganahalli K. , N.K.; Dastidar S. , D.S.; Sattigeri , S.V.; Kaur , K.G.; Deb , D.C.; Gupta J. , G.J.; Salman , S.M.; Ray , R.A.
RBx 7796: A novel inhibitor of 5-lipoxygenase
Inflamm. Res.
55
517-527
2006
Homo sapiens
brenda
Butovich, I.A.; Lukyanova, S.M.; Bachmann, C.
Dihydroxydocosahexaenoic acids of the neuroprotectin D family: synthesis, structure, and inhibition of human 5-lipoxygenase
J. Lipid Res.
47
2462-2474
2006
Homo sapiens
brenda
Araico, A.; Terencio, M.C.; Alcaraz, M.J.; Dominguez, J.N.; Leon, C.; Ferrandiz, M.L.
Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase
Life Sci.
78
2911-2918
2006
Homo sapiens
brenda
Poeckel, D.; Niedermeyer, T.H.; Pham, H.T.; Mikolasch, A.; Mundt, S.; Lindequist, U.; Lalk, M.; Werz, O.
Inhibition of human 5-lipoxygenase and anti-neoplastic effects by 2-amino-1,4-benzoquinones
Med. Chem.
2
591-595
2006
Homo sapiens
brenda
Rakonjac, M.; Fischer, L.; Provost, P.; Werz, O.; Steinhilber, D.; Samuelsson, B.; Radmark, O.
Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production
Proc. Natl. Acad. Sci. USA
103
13150-13155
2006
Homo sapiens
brenda
Raghavenra, H.; Diwakr, B.T.; Lokesh, B.R.; Naidu, K.A.
Eugenol--the active principle from cloves inhibits 5-lipoxygenase activity and leukotriene-C4 in human PMNL cells
Prostaglandins Leukot. Essent. Fatty Acids
74
23-27
2006
Homo sapiens
brenda
Frum, Y.; Viljoen, A.M.
In vitro 5-lipoxygenase and anti-oxidant activities of South African medicinal plants commonly used topically for skin diseases
Skin Pharmacol. Physiol.
19
329-335
2006
Homo sapiens
brenda
Pufahl, R.A.; Kasten, T.P.; Hills, R.; Gierse, J.K.; Reitz, B.A.; Weinberg, R.A.; Masferrer, J.L.
Development of a fluorescence-based enzyme assay of human 5-lipoxygenase
Anal. Biochem.
364
204-212
2007
Homo sapiens
brenda
Mahesha, H.G.; Singh, S.A.; Rao, A.G.
Inhibition of lipoxygenase by soy isoflavones: evidence of isoflavones as redox inhibitors
Arch. Biochem. Biophys.
461
176-185
2007
Homo sapiens
brenda
Belfiore, M.C.; Natoni, A.; Barzellotti, R.; Merendino, N.; Pessina, G.; Ghibelli, L.; Gualandi, G.
Involvement of 5-lipoxygenase in survival of Epstein-Barr virus (EBV)-converted B lymphoma cells
Cancer Lett.
254
236-243
2007
Homo sapiens
brenda
Gonzalez-Periz, A.; Claria, J.
New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways
Curr. Top. Med. Chem.
7
297-309
2007
Homo sapiens
brenda
Herb, F.; Thye, T.; Niemann, S.; Browne, E.N.; Chinbuah, M.A.; Gyapong, J.; Osei, I.; Owusu-Dabo, E.; Werz, O.; Ruesch-Gerdes, S.; Horstmann, R.D.; Meyer, C.G.
ALOX5 variants associated with susceptibility to human pulmonary tuberculosis
Hum. Mol. Genet.
17
1052-1060
2008
Homo sapiens
brenda
Cook-Moreau, J.M.; El-Makhour Hojeij, Y.; Barriere, G.; Rabinovitch-Chable, H.C.; Faucher, K.S.; Sturtz, F.G.; Rigaud, M.A.
Expression of 5-lipoxygenase (5-LOX) in T lymphocytes
Immunology
122
157-166
2007
Homo sapiens
brenda
Ezekwudo, D.E.; Wang, R.C.; Elegbede, J.A.
Methyl jasmonate induced apoptosis in human prostate carcinoma cells via 5-lipoxygenase dependent pathway
J. Exp. Ther. Oncol.
6
267-277
2007
Homo sapiens
brenda
Franke, L.; Schwarz, O.; Mueller-Kuhrt, L.; Hoernig, C.; Fischer, L.; George, S.; Tanrikulu, Y.; Schneider, P.; Werz, O.; Steinhilber, D.; Schneider, G.
Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening
J. Med. Chem.
50
2640-2646
2007
Homo sapiens
brenda
Massi, P.; Valenti, M.; Vaccani, A.; Gasperi, V.; Perletti, G.; Marras, E.; Fezza, F.; Maccarrone, M.; Parolaro, D.
5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid
J. Neurochem.
104
1091-1100
2008
Homo sapiens, Hordeum vulgare
brenda
Vincent, C.; Fiancette, R.; Donnard, M.; Bordessoule, D.; Turlure, P.; Trimoreau, F.; Denizot, Y.
5-LOX, 12-LOX and 15-LOX in immature forms of human leukemic blasts
Leuk. Res.
32
1756-1762
2008
Homo sapiens
brenda
Sudina, G.F.; Pushkareva, M.A.; Shephard, P.; Klein, T.
Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors
Prostaglandins Leukot. Essent. Fatty Acids
78
99-108
2008
Homo sapiens
brenda
Loetzer, K.; Jahn, S.; Kramer, C.; Hildner, M.; Nuesing, R.; Funk, C.D.; Habenicht, A.J.
5-Lipoxygenase/cyclooxygenase-2 cross-talk through cysteinyl leukotriene receptor 2 in endothelial cells
Prostaglandins Other Lipid Mediat.
84
108-115
2007
Homo sapiens
brenda
Michel, A.A.; Steinhilber, D.; Werz, O.
Development of a method for expression and purification of the regulatory C2-like domain of human 5-lipoxygenase
Protein Expr. Purif.
59
110-116
2008
Homo sapiens
brenda
Radmark, O.; Werz, O.; Steinhilber, D.; Samuelsson, B.
5-Lipoxygenase: regulation of expression and enzyme activity
Trends Biochem. Sci.
32
332-341
2007
Mus musculus, Rattus norvegicus, Homo sapiens (P09917)
brenda
Koeberle, A.; Zettl, H.; Greiner, C.; Wurglics, M.; Schubert-Zsilavecz, M.; Werz, O.
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase
J. Med. Chem.
51
8068-8076
2008
Homo sapiens
brenda
Strid, T.; Svartz, J.; Franck, N.; Hallin, E.; Ingelsson, B.; Soederstroem, M.; Hammarstroem, S.
Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein
Biochem. Biophys. Res. Commun.
381
518-522
2009
Homo sapiens
brenda
Macdonald, D.; Brideau, C.; Chan, C.C.; Falgueyret, J.P.; Frenette, R.; Guay, J.; Hutchinson, J.H.; Perrier, H.; Prasit, P.; Riendeau, D.; Tagari, P.; Therien, M.; Young, R.N.; Girard, Y.
Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein
Bioorg. Med. Chem. Lett.
18
2023-2027
2008
Homo sapiens
brenda
Doiron, J.; Boudreau, L.H.; Picot, N.; Villebonet, B.; Surette, M.E.; Touaibia, M.
Synthesis and 5-lipoxygenase inhibitory activity of new cinnamoyl and caffeoyl clusters
Bioorg. Med. Chem. Lett.
19
1118-1121
2009
Homo sapiens
brenda
Reddy, M.V.; Billa, V.K.; Pallela, V.R.; Mallireddigari, M.R.; Boominathan, R.; Gabriel, J.L.; Reddy, E.P.
Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors
Bioorg. Med. Chem.
16
3907-3916
2008
Oryctolagus cuniculus, Homo sapiens
brenda
Mahshid, Y.; Lisy, M.; Wang, X.; Spanbroek, R.; Flygare, J.; Christensson, B.; Bjoerkholm, M.; Sander, B.; Habenicht, A.; Claesson, H.
High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes
BMC Immunol.
10
2-2
2009
Homo sapiens
brenda
Jian, W.; Lee, S.H.; Williams, M.V.; Blair, I.A.
5-Lipoxygenase-mediated endogenous DNA damage
J. Biol. Chem.
284
16799-16807
2009
Homo sapiens
brenda
Radmark, O.; Samuelsson, B.
5-Lipoxygenase: mechanisms of regulation
J. Lipid Res.
50 Suppl
S40-S45
2009
Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Karg, E.M.; Luderer, S.; Pergola, C.; Buehring, U.; Rossi, A.; Northoff, H.; Sautebin, L.; Troschuetz, R.; Werz, O.
Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase
J. Med. Chem.
52
3474-3483
2009
Homo sapiens, Rattus norvegicus
brenda
Liedtke, A.J.; Keck, P.R.; Lehmann, F.; Koeberle, A.; Werz, O.; Laufer, S.A.
Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX)
J. Med. Chem.
52
4968-4972
2009
Homo sapiens
brenda
Knaup, B.; Oehme, A.; Valotis, A.; Schreier, P.
Anthocyanins as lipoxygenase inhibitors
Mol. Nutr. Food Res.
53
617-624
2009
Homo sapiens
brenda
Chen, S.H.; Fahmi, H.; Shi, Q.; Benderdour, M.
Regulation of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase-activating protein/5-lipoxygenase by 4-hydroxynonenal in human osteoarthritic chondrocytes
Arthritis Res. Ther.
12
R21
2010
Homo sapiens
brenda
Radmark, O.; Samuelsson, B.
Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis
Biochem. Biophys. Res. Commun.
396
105-110
2010
Homo sapiens
brenda
Esser, J.; Rakonjac, M.; Hofmann, B.; Fischer, L.; Provost, P.; Schneider, G.; Steinhilber, D.; Samuelsson, B.; Radmark, O.
Coactosin-like protein functions as a stabilizing chaperone for 5-lipoxygenase: Role of tryptophan 102
Biochem. J.
425
265-274
2010
Homo sapiens
brenda
Katryniok, C.; Schnur, N.; Gillis, A.; von Knethen, A.; Sorg, B.; Looijenga, L.; Radmark, O.; Steinhilber, D.
Role of DNA methylation and methyl-DNA binding proteins in the repression of 5-lipoxygenase promoter activity
Biochim. Biophys. Acta
1801
49-57
2010
Homo sapiens
brenda
Fischer, A.S.; Metzner, J.; Steinbrink, S.D.; Ulrich, S.; Angioni, C.; Geisslinger, G.; Steinhilber, D.; Maier, T.J.
5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity
Br. J. Pharmacol.
161
936-949
2010
Homo sapiens
brenda
Shin, V.Y.; Jin, H.C.; Ng, E.K.; Sung, J.J.; Chu, K.M.; Cho, C.H.
Activation of 5-lipoxygenase is required for nicotine mediated epithelial-mesenchymal transition and tumor cell growth
Cancer Lett.
292
237-245
2010
Homo sapiens
brenda
Steinbrink, S.D.; Pergola, C.; Buehring, U.; George, S.; Metzner, J.; Fischer, A.S.; Haefner, A.K.; Wisniewska, J.M.; Geisslinger, G.; Werz, O.; Steinhilber, D.; Maier, T.J.
Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations
Cell. Mol. Life Sci.
67
797-806
2010
Homo sapiens
brenda
Radmark, O.; Samuelsson, B.
Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer
J. Intern. Med.
268
5-14
2010
Homo sapiens
brenda
Filosa, R.; Peduto, A.; Aparoy, P.; Schaible, A.M.; Luderer, S.; Krauth, V.; Petronzi, C.; Massa, A.; de Rosa, M.; Reddanna, P.; Werz, O.
Discovery and biological evaluation of novel 1,4-benzoquinone and related resorcinol derivatives that inhibit 5-lipoxygenase
Eur. J. Med. Chem.
67
269-279
2013
Homo sapiens
brenda
Hofmann, B.; Barzen, S.; Roedl, C.B.; Kiehl, A.; Borig, J.; Zivkovic, A.; Stark, H.; Schneider, G.; Steinhilber, D.
A class of 5-benzylidene-2-phenylthiazolinones with high potency as direct 5-lipoxygenase inhibitors
J. Med. Chem.
54
1943-1947
2011
Homo sapiens
brenda
Kretschmer, S.B.M; Woltersdorf, S.; Vogt, D.; Lillich, F.F.; Ruehl, M.; Karas, M.; Maucher, I.V.; Roos, J.; Haefner, A.-K.; Kaiser, A.; Wurglics, M.; Schubert-Zsilavecz, M.; Angioni, C.; Geisslinger, G.; Stark, H.; Steinhilber, D.; Hofmann, B.
Characterization of the molecular mechanism of 5-lipoxygenase inhibition by 2-aminothiazoles
Biochem. Pharmacol.
123
52-62
2017
Homo sapiens (P09917), Homo sapiens
brenda
Khayrullina, V.R.; Taipov, I.A.; Veselovsky, A.V.; Shcherbinin, D.S.; Gerchikov, A.Y.
New inhibitors of 5-lipoxygenase catalytic activity based on 2-(3-methylphenyl)propanoic acid and 4-substituted morpholine derivatives
Biochemistry (Moscow)
79
376-384
2014
Homo sapiens (P09917)
brenda
Smyrniotis, C.J.; Barbour, S.R.; Xia, Z.; Hixon, M.S.; Holman, T.R.
ATP allosterically activates the human 5-lipoxygenase molecular mechanism of arachidonic acid and 5(S)-hydroperoxy-6(E),8(Z),11(Z),14(Z)-eicosatetraenoic acid
Biochemistry
53
4407-4419
2014
Homo sapiens (P09917), Homo sapiens
brenda
Mitra, S.; Bartlett, S.G.; Newcomer, M.E.
Identification of the substrate access portal of 5-lipoxygenase
Biochemistry
54
6333-6342
2015
Homo sapiens (P09917)
brenda
Schroeder, M.; Haefner, A.K.; Hofmann, B.; Radmark, O.; Tumulka, F.; Abele, R.; Doetsch, V.; Steinhilber, D.
Stabilisation and characterisation of the isolated regulatory domain of human 5-lipoxygenase
Biochim. Biophys. Acta
1842
1538-1547
2014
Homo sapiens (P09917), Homo sapiens
brenda
Haefner, A.K.; Gerstmeier, J.; Hoernig, M.; George, S.; Ball, A.K.; Schroeder, M.; Garscha, U.; Werz, O.; Steinhilber, D.
Characterization of the interaction of human 5-lipoxygenase with its activating protein FLAP
Biochim. Biophys. Acta
1851
1465-1472
2015
Homo sapiens (P09917), Homo sapiens
brenda
Ball, A.K.; Beilstein, K.; Wittmann, S.; Sueruen, D.; Saul, M.J.; Schnuetgen, F.; Flamand, N.; Capelo, R.; Kahnt, A.S.; Frey, H.; Schaefer, L.; Marschalek, R.; Haefner, A.K.; Steinhilber, D.
Characterization and cellular localization of human 5-lipoxygenase and its protein isoforms 5-LODELTA13, 5-LODELTA4 and 5-LOp12
Biochim. Biophys. Acta
1862
561-571
2017
Homo sapiens (P09917), Homo sapiens
brenda
Shang, E.; Liu, Y.; Wu, Y.; Zhu, W
; He, C.; Lai, L. Development of 3,5-dinitrobenzoate-based 5-lipoxygenase inhibitors
Bioorg. Med. Chem.
22
2396-2402
2014
Homo sapiens (P09917), Homo sapiens
brenda
Mittal, M.; Kumar, R.B.; Balagunaseelan, N.; Hamberg, M.; Jegerschoeld, C.; Radmark, O.; Haeggstroem, J.Z.; Rinaldo-Matthis, A.
Kinetic investigation of human 5-lipoxygenase with arachidonic acid
Bioorg. Med. Chem. Lett.
26
3547-3551
2016
Homo sapiens (P09917), Homo sapiens
brenda
Torras, J.; Maccarrone, M.; Dainese, E.
Molecular dynamics study on the apo- and holo-forms of 5-lipoxygenase
Biotechnol. Appl. Biochem.
65
54-61
2017
Homo sapiens (P09917)
brenda
Pergola, C.; Gerstmeier, J.; Moench, B.; Caliskan, B.; Luderer, S.; Weinigel, C.; Barz, D.; Maczewsky, J.; Pace, S.; Rossi, A.; Sautebin, L.; Banoglu, E.; Werz, O.
The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP)
Br. J. Pharmacol.
171
3051-3064
2014
Homo sapiens (P09917)
brenda
Peduto, A.; Scuotto, M.; Krauth, V.; Roviezzo, F.; Rossi, A.; Temml, V.; Esposito, V.; Stuppner, H.; Schuster, D.; D'Agostino, B.; Schiraldi, C.; de Rosa, M.; Werz, O.; Filosa, R.
Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase
Eur. J. Med. Chem.
127
715-726
2017
Homo sapiens (P09917), Homo sapiens
brenda
Peduto, A.; Bruno, F.; Dehm, F.; Krauth, V.; de Caprariis, P.; Weinigel, C.; Barz, D.; Massa, A.; De Rosa, M.; Werz, O.; Filosa, R.
Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase
Eur. J. Med. Chem.
81
492-498
2014
Homo sapiens (P09917), Homo sapiens
brenda
Ho, X.L.; Liu, J.J.; Loke, W.M.
Plant sterol-enriched soy milk consumption modulates 5-lipoxygenase, 12-lipoxygenase, and myeloperoxidase activities in healthy adults - a randomized-controlled trial
Free Radic. Res.
50
1396-1407
2016
Homo sapiens (P09917)
brenda
Schieferdecker, S.; Koenig, S.; Koeberle, A.; Dahse, H.-M.; Werz, O.; Nett, M.
Myxochelins target human 5-lipoxygenase
J. Nat. Prod.
78
335-338
2015
Homo sapiens (P09917), Homo sapiens
brenda
Meirer, K.; Glatzel, D.; Kretschmer, S.; Wittmann, S.K.; Hartmann, M.; Bloecher, R.; Angioni, C.; Geisslinger, G.; Steinhilber, D.; Hofmann, B.; Fuerst, R.; Proschak, E.
Design, synthesis and cellular characterization of a dual inhibitor of 5-lipoxygenase and soluble epoxide hydrolase
Molecules
22
45
2016
Homo sapiens (P09917)
brenda
Chagas-Paula, D.A.; Oliveira, T.B.; Faleiro, D.P.V.; Oliveira, R.B.; Da Costa, F.B.
Outstanding anti-inflammatory potential of selected Asteraceae species through the potent dual inhibition of cyclooxygenase-1 and 5-lipoxygenase
Planta Med.
81
1296-1307
2015
Homo sapiens (P09917)
brenda
Allain, E.P.; Boudreau, L.H.; Flamand, N.; Surette, M.E.
The Intracellular localisation and phosphorylation profile of the human 5-lipoxygenase DELTA13 isoform differs from that of its full length counterpart
PLoS ONE
10
e0132607
2015
Homo sapiens (P09917), Homo sapiens
brenda
Haefner, A.K.; Beilstein, K.; Graab, P.; Ball, A.K.; Saul, M.J.; Hofmann, B.; Steinhilber, D.
Identification and characterization of a new protein isoform of human 5-lipoxygenase
PLoS ONE
11
e0166591
2016
Homo sapiens (P09917), Homo sapiens
brenda
Maucher, I.V.; Ruehl, M.; Kretschmer, S.B.; Hofmann, B.; Kuehn, B.; Fettel, J.; Vogel, A.; Fluegel, K.T.; Manolikakes, G.; Hellmuth, N.; Haefner, A.K.; Golghalyani, V.; Ball, A.K.; Piesche, M.; Matrone, C.; Geisslinger, G.; Parnham, M.J.; Karas, M.; Steinhilber, D.; Roos, J.; Maier, T.J.
Michael acceptor containing drugs are a novel class of 5-lipoxygenase inhibitor targeting the surface cysteines C416 and C418
Biochem. Pharmacol.
125
55-74
2017
Homo sapiens (P09917), Homo sapiens
brenda
Green, A.R.; Freedman, C.; Tena, J.; Tourdot, B.E.; Liu, B.; Holinstat, M.; Holman, T.R.
5 S,15 S-Dihydroperoxyeicosatetraenoic Acid (5,15-diHpETE) as a lipoxin intermediate Reactivity and kinetics with human leukocyte 5-lipoxygenase, platelet 12-lipoxygenase, and reticulocyte 15-lipoxygenase-1
Biochemistry
57
6726-6734
2018
Homo sapiens (P09917), Homo sapiens
brenda
Perry, S.C.; Horn, T.; Tourdot, B.E.; Yamaguchi, A.; Kalyanaraman, C.; Conrad, W.S.; Akinkugbe, O.; Holinstat, M.; Jacobson, M.P.; Holman, T.R.
Role of human 15-lipoxygenase-2 in the biosynthesis of the lipoxin intermediate, 5S,15S-diHpETE, implicated with the altered positional specificity of human 15-lipoxygenase-1
Biochemistry
59
4118-4130
2020
Homo sapiens (P09917)
brenda
Doiron, J.A.; Leblanc, L.M.; Hebert, M.J.; Levesque, N.A.; Pare, A.F.; Jean-Francois, J.; Cormier, M.; Surette, M.E.; Touaibia, M.
Structure-activity relationship of caffeic acid phenethyl ester analogs as new 5-lipoxygenase inhibitors
Chem. Biol. Drug Des.
89
514-528
2017
Homo sapiens (P09917)
brenda
Selka, A.; Doiron, J.A.; Lyons, P.; Dastous, S.; Chiasson, A.; Cormier, M.; Turcotte, S.; Surette, M.E.; Touaibia, M.
Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells
Eur. J. Med. Chem.
179
347-357
2019
Homo sapiens (P09917)
brenda
Dinh, C.P.; Ville, A.; Neukirch, K.; Viault, G.; Temml, V.; Koeberle, A.; Werz, O.; Schuster, D.; Stuppner, H.; Richomme, P.; Helesbeux, J.J.; Seraphin, D.
Structure-based design, semi-synthesis and anti-inflammatory activity of tocotrienolic amides as 5-lipoxygenase inhibitors
Eur. J. Med. Chem.
202
112518
2020
Homo sapiens (P09917), Homo sapiens
brenda
Echeverria, J.; Urzua, A.
Inhibition of soybean 15-lipoxygenase and human 5-lipoxygenase by extracts of leaves, stem bark, phenols and catechols isolated from Lithraea caustica (Anacardiaceae)
Front. Pharmacol.
11
594257
2020
Homo sapiens (P09917), Homo sapiens
brenda
Roy, P.; Faye, D.; Blanchard, S.; Cormier, M.; Doiron, J.; Surette, M.; Touaibia, M.
New caffeic acid phenylethyl ester analogs bearing substituted triazole Synthesis and structure-activity relationship study towards 5-lipoxygenase inhibition
J. Chem.
2017
2380531
2017
Homo sapiens (P09917)
-
brenda
Phillips, O.A.; Bosso, M.A.; Ezeamuzie, C.I.
Synthesis and structure-activity relationships of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives as 5-lipoxygenase inhibitors
J. Enzyme Inhib. Med. Chem.
35
1471-1482
2020
Homo sapiens (P09917), Homo sapiens
brenda
Hiesinger, K.; Kramer, J.S.; Beyer, S.; Eckes, T.; Brunst, S.; Flauaus, C.; Wittmann, S.K.; Weizel, L.; Kaiser, A.; Kretschmer, S.B.M.; George, S.; Angioni, C.; Heering, J.; Geisslinger, G.; Schubert-Zsilavecz, M.; Schmidtko, A.; Pogoryelov, D.; Pfeilschifter, J.; Hofmann, B.; Steinhilber, D.; Sch, S.c.h.w.
Design, synthesis, and structure-activity relationship studies of dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase
J. Med. Chem.
63
11498-11521
2020
Homo sapiens (P09917), Homo sapiens
brenda
Park, N.Y.; Im, S.; Jiang, Q.
Different forms of vitamin E and metabolite 13-carboxychromanols inhibit cyclooxygenase-1 and its catalyzed thromboxane in platelets, and tocotrienols and 13-carboxychromanols are competitive inhibitors of 5-lipoxygenase
J. Nutr. Biochem.
100
108884
2022
Homo sapiens (P09917)
brenda
Gilbert, N.C.; Gerstmeier, J.; Schexnaydre, E.E.; Boerner, F.; Garscha, U.; Neau, D.B.; Werz, O.; Newcomer, M.E.
Structural and mechanistic insights into 5-lipoxygenase inhibition by natural products
Nat. Chem. Biol.
16
783-790
2020
Homo sapiens (P09917), Homo sapiens
brenda
Munoz-Osses, M.; Quiroz, J.; Vasquez-Martixadnez, Y.; Flores, E.; Navarrete, E.; Godoy, F.; Torrent, C.; Cortez-San Martin, M.; Gomez, A.; Mascayano, C.
Evaluation of cyrhetrenyl and ferrocenyl precursors as 5-lipoxygenase inhibitors - biological and computational studies
New J. Chem.
45
13360-13368
2021
Homo sapiens (P09917)
-
brenda
Mbarik, M.; Poirier, S.; Doiron, J.; Selka, A.; Barnett, D.; Cormier, M.; Touaibia, M.; Surette, M.
Phenolic acid phenethylesters and their corresponding ketones Inhibition of 5-lipoxygenase and stability in human blood and HepaRG cells
Pharmacol. Res. Perspect.
7
e00524
2019
Homo sapiens (P09917), Homo sapiens
brenda